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The most important prognostic indicator in early cancer is whether the disease 
has metastasised to regional lymph nodes. Pre-operative imaging is not 
sensitive enough to detect micrometastatic deposits therefore most patients 
judged to have more than 20% risk of disease spread will have elective surgical 
removal of the draining lymph node basins in order to reduce the risk of leaving 
tumour behind. Such operations can be lengthy and associated morbidity can 
reduce the patient’s quality of life. In the majority of these elective nodal 
clearances histopathological analysis is clear of disease in the majority 
suggesting that the surgery could be omitted without affecting the patient’s 
disease free survival.  
Sentinel node biopsy (SNB) is a surgical stating test in which the tumour 
draining lymph nodes can be thoroughly investigated for metastasis. If free of 
disease there is no indication to subject the patient to further surgery. SNB has 
been validated in oral cancer, but there is a false negative rate of up to 14%. 
Recent developments may improve the accuracy of the SNB test.  
This work evaluated new sentinel node technologies (navigation surgery, 
fluorescence imaging, and improved tracer formulations) in oral cancer, and 
opened up new applications for the test in other head and neck cancers 
(salivary, thyroid and larynx). These refinements in sentinel node process may 
allow many patients suffering with early cancer to benefit from personalised 
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Chapter 1 Introduction and Background 
 
 
1.1  Head and Neck cancer 
 
The medical field of “Head and Neck” describes a surgical subspecialty 
comprising oral and maxillofacial surgery (OMFS), ear nose and throat (ENT) 
and plastic surgeons who perform ablative and reconstructive surgery in a 
range of neoplasms located above thoracic inlet excluding primary intracranial 
tumours. Head and neck surgeons predominantly deal with malignant tumours 
as categorised according to the International Statistical Classification of Disease 
and Related Health Problems version 10 (ICD-10[1]).  Globally head and neck 
cancer is the sixth most common form of cancer, with annual worldwide 
incidence of 650,000 and causing 350,000 deaths per year[2]. Malignancies can 
develop in a variety of structures such as the upper aerodigestive tract, 
craniofacial skeleton, paranasal sinuses, salivary and thyroid glands as well as 
skin, soft tissue, haematological and metastatic tumours. This heterogeneous 
group treated under the umbrella of head and neck surgery can develop from a 
variety of cell types, each with a specific set of biological risk factors and natural 
history (Table 1. Head and Neck Cancer). The most prevalent malignancies 
(>90%) found the head and neck arise in epithelium exposed to carcinogens 
resulting in squamous cell carcinoma[3].  
 
Almost two-thirds of patients with head and neck squamous cell carcinoma 
(HNSCC) present with locally advanced disease and a further 10% with distant 
metastasis[4]. Such patients staged III and IV respectively by the TNM 
(American Joint Committee on Cancer[5]) classification system who are suitable 
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for active treatment will usually be offered a multimodal approach. Despite this 
the outlook is poor with a 35-52%[6-9] five year overall survival rate. Conversely 
the treatment for early HNSCC is usually single modality and 5 year survival is 
achieved in 90% of patients with stage I and 70% with stage II disease[3].  
 
Table 1.1 Overview of primary head and neck cancer 
 
 










2.UK age standardised 
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neck cancer survivors uniquely have to cope with facial disfigurement and 
functional impediments such as changes in speech and swallow. Furthermore 
surgery to the neck performed to remove metastatic or ‘at-risk’ lymph nodes is 
associated with long-term neck and shoulder pain, reduced shoulder mobility, 
weakness of facial muscles, and scarring. This treatment related morbidity 
significantly reduces patient’s quality of life[22, 23]. Treatment related morbidity 
can be reduced by tailoring the extent of surgery or radiotherapy to the clinically 
apparent disease however this requires an accurate patient-specific approach 
to ensure that those with occult metastatic disease are not disadvantaged. It is 
this health need that has led to the consideration of adopting novel staging 
techniques such as sentinel node biopsy (SNB) in the management of head and 
neck cancer.  
Each tumour has different controversies and neck management uncertainties 
that are further discussed below. 
 
1.2  Oral cancer 
 
Malignant tumours arising in the oral cavity are overwhelmingly epithelial in 
origin and are commonly referred to as oral squamous cell carcinoma (OSCC). 
It should be noted that although tumours of the lip are grouped with the oral 
cavity by ICD-10, the triggers and biological behaviour are more akin to skin 
SCC and thus they are managed differently to other oral tumours. 
 
 In western countries intraoral sites of predilection are the lateral/ventral tongue 
(40%) and the floor of mouth (30%) [24, 25]. In Asian populations there is a 




Although the development of OSCC is a multifactorial process, irreversible cell 
changes are triggered by a sustained and dose-dependent physical contact with 
carcinogens[26, 27]. The geographical anatomical variation relates to cultural 
preference for such substances. In western countries exposure with either 
alcohol and/or tobacco is found in over 90% of cases, and in countries where 
betel chewing is endemic (mainly the Indian subcontinent) it is implicated in up 
to 50% of cases [27]. 
Patients diagnosed with OSCC are clinically staged (by examination and 
imaging) pre-operatively according to the TMN classification (Table 1.2).  
 
Table 1.2. American Joint Committee on Cancer (AJCC) cancer staging manual 7th edition 
(2010)[28]. TNM classification for oral, salivary, and differentiated thyroid cancer 
T- Tumour 
 Oral Salivary Thyroid (differentiated) 
Tx No available information on the primary tumour 
 
T0 No evidence of primary tumour 
 
Tis Carcinoma in situ N/A  
T1 Tumour less than 2cm in 
greatest dimension 




T1b 1 2 
T2 Tumour 2-4 cm in 
greatest dimension  
2-4cm and no 
extraparenchymal 
spread 
2-4cm limited to thyroid 
T3 Tumour greater than 









Tumour invades adjacent 
structures (cortical bone, 
extrinsic muscles of the 
tongue, maxillary sinus, 
skin) 
Invades skin, 
mandible, ear canal, 
facial nerve 
Invades subcutaneous soft 
tissue, larynx, trachea, 






pterygoid plate, skull 
base and/or encases 
internal carotid artery 
Invades base of 
skull, pterygoid 




Invades prevertebral fascia 
or encases carotid  
Artery/vertebral vessels. 
N-Node 
Nx Regional nodes not assessed 
No region lymph node metastasis  N0 
N1 Metastasis in a single ipsilateral lymph node of 
3cm or less in maximum dimension 
N1a Metastasis to level VI 
N1b Metastasis 
unilateral/bilateral cervical 
nodes, or superior 
mediastinal nodes 
N2a Metastasis in a single ipsilateral lymph node N/A 
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more than 3cm but less than 6cm in maximum 
dimension 
N2b Metastasis in multiple ipsilateral lymph node 
more than 3cm but less than 6cm in maximum 
dimension 
N/A 
N2c Metastasis in bilateral or contralateral lymph 
node more than 3cm but less than 6cm in 
maximum dimension 
 
N3 Metastasis in a lymph node more than 6cm in 
greatest dimension 
 
M – Metastasis 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
In the UK surgery is the mainstay of treatment in all but palliative cases of 
OSCC. Adjuvant radiotherapy or chemoradiation are only indicated if there are 
adverse features that increase the chance of recurrence[29, 30]. The primary 
tumour is excised with a wide pathological margin (>5mm) necessitating 
reconstruction with pedicled or free flap in cases where primary closure is not 
possible. Surgical resection of regional lymph nodes (neck dissection) is 
performed at the same time as resection of the primary tumour with the 
additional benefit of access to neck vessels in patients requiring microvascular 
reconstruction. Patients with clinically diagnosed cervical metastasis undergo 
therapeutic neck dissection to remove all metastatic nodes plus other involved 
structures with a clear margin (Table 1.3. Classification of neck dissection), 





Table 1.3. Classification of neck dissection based on recommendations of American Head and 
Neck Society (AHNS)[31] 
 
Neck Dissection Structures dissected Neck Levels 







One or more neck levels 
dissected. E.g.  




(MRND) Type I 
Dissection of levels I-V with 
preservation of the spinal 
accessory nerve (XI) 
Modified radical 
neck dissection 
(MRND) Type II 
Dissection of levels I-V with 
preservation of XI and the 





(MRND) Type III 
Dissection of levels I-V with 




En bloc clearance of levels I-V, 









Inclusion of non-lymphatic 
structures e.g. carotid artery or 
additional lymphatic structures 
outside defined neck levels. 
 
Analysis has shown that despite clinical examination and multimodality imaging 
there is a limit of sensitivity for pre-operative diagnosis of small metastasis [33-
35]. Metanalysis looked at the sensitivity of occult metastasis detection by 
different imaging modalities in necks that had been classified N0 by clinical 
examination, finding pooled estimates of 52%, 65%, 66%, and 66%, for CT, 
MRI, PET and US, respectively[36].  
When occult neck metastasis are left untreated until they become clinically 
apparent (i.e. the patient undergoes a therapeutic rather than elective neck 
dissection) there is a significant detriment to outcome as demonstrated by a 
prospective randomised controlled trial comparing the two strategies in early 
(T1-T2) oral cancer[37]. In this trial the overall survival after elective neck 
dissection (END) was 80% compared to 67.5% in the therapeutic neck 
dissection arm (hazard ratio 0.64, p=0.01). However, neck metastasis 
developed in (108/253) 43% of patients randomized to the therapeutic surgery 
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arm. This would appear to represent the ‘true metastasis’ rate, and the cohort in 
whom resection of the cervical lymph nodes is indicated.  
 
Neck dissection is associated with complications such as chyle leak, wound 
infection, sensory disturbance, shoulder and neck dysfunction and scar[38, 39], 
and so ideally it should only be undertaken in patients for whom there will be a 
oncological benefit.  Furthermore, elective neck dissection may give false 
reassurance that all occult metastasis are removed reliably, leaving a disease 
free neck.  The combined results of two major cancer centres (Memorial Sloan-
Kettering, New York USA and Princess Margaret, Toronto Canada) reported 
that in a cohort of 164 patients with tongue tumours staged pT1-T2 N0 by 
elective neck dissection, 18% developed isolated recurrence in the neck[40].  
Over one-third of the recurrences (39%) were in the contralateral neck and 
when a subset of the neck dissections (52/164) were investigated by 
immunohistochemistry and serial sectioning previously undetected metastasis 
were identified in 15% of cases. These data suggest that blanket ipsilateral 
END will still miss metastasis in a small but significant group of patients. 
 
 In contrast, sentinel node biopsy (SNB) is a diagnostic test designed to detect 
occult metastasis. It provides accurate staging and identifies those patients with 
early metastatic disease that will benefit from lymphadenectomy and/or 
adjuvant treatment. 
 
The Sentinel European Node Trial (SENT[41]) showed that sentinel node 
biopsy (SNB) is a reliable staging tool in the cN0 neck in early oral cancer. The 
sensitivity for detection of metastasis was 88%, but there was a false negative 
rate (FNR) of 14%. SNB is an operator sensitive procedure but the merit of the 
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test has been appreciated by National Institute for Health and Care Excellence 
(NICE). After a cost-effectiveness analysis NICE recommended that from 
January 2016, SNB is offered to UK patients with T1-T2 OSCC with clinically N0 
necks who do not require microvascular reconstruction[42].  
 
1.3  Salivary gland cancer 
 
Malignant neoplasms of the salivary glands are a heterogeneous group. In 2005 
the World Health Organisation (WHO) classified salivary gland malignancy into 
23 different entities[12], the most common of which are listed in Table 1.1. 
These tumours can be classified according to which gland they arise in (parotid, 
submandibular, sublingual, minor), and also by cell origin.  
There are geographical variations in the prevalence of histological subtypes[43, 
44], but the anatomical distribution always favours the parotid gland, which is 
the location of 60-80% of a salivary tumours[12, 19, 43]. A further 7-11% occur 
in the submandibular gland, 9-23% in the minor salivary gland and 1% in the 
sublingual gland. 
 
Histopathologically primary salivary malignancy can derive from epithelial cells 
(Mucoepidermoid carcinoma, acinic cell, adenoid cystic, adenocarcinoma), 
mesenchymal cells (sarcomas, histiocytomas), and haematolymphoid cells 
(lymphomas) [45].  
 
As well as being a histologically diverse group, salivary gland malignancies are 
rare. The combined global incidence of benign and malignant salivary tumours 
is 0.4-2.6 cases per 100,000, just 6% of all head and neck tumours [43, 46, 47]. 
The majority of salivary tumours are benign although this varies by gland, as 
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demonstrated by the ‘25:50:75 rule’ which although historical gives a rough 
guide to the propensity of malignancy in tumours of the parotid, submandibular 
and sublingual glands respectively [18]. In total salivary gland malignancy 
represents 0.3% of all cancer types. Because of the diversity and scarcity of 
salivary tumours there is a deficit of high level evidence regarding treatment, a 
fact recognised by recently published UK management guidelines[48]. 
 
Surgery is the primary treatment modality, with wide excision of the tumour and 
therapeutic neck dissection in the case of lymph node metastasis. The extent of 
margin is debatable, particularly in relation to adenoid cystic carcinoma, which 
has an indistinct tumour edge with beads of tumour cells permeating the 
surrounding tissue. Post-operative radiotherapy is indicated in patients with 
radiosensitive tumours over 4cm in size or with high-grade features, 
extraparenchymal or nodal extracapsular spread, or multiple nodal metastases. 
The case for elective neck dissection is not clear. Most clinicians would perform 
END in the case of T3-4 and high grade tumours. Nevertheless, Nobis et al. 
showed that up to 30% of patients with low-grade malignancies harboured 
cervical metastasis. Furthermore several case series looking at END in relation 
to parotid malignancies found that many of the metastatic nodes were outside 
the traditional neck dissection fields.  Stenner et al[49] found that up to three 
quarters of the positive lymph nodes were intra- or periparotid. This has 
important implications in parotid surgery. In the case of a small <4cm (T1-2) 
tumour, a subtotal superficial parotidectomy may be sufficient to clear the 
primary disease so minimising the risk of morbidity to the facial nerve.   But if 
one is concerned about positive intraparotid lymph nodes then an argument 
could be made for a total parotidectomy. The risk versus benefit of removing the 
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deep lobe is uncertain as cadaveric studies have shown that the deep lobe 
does not contain any lymph nodes in up to 93% of patients[50, 51].  
 
Consequently the same question arises as in managing early SCC:  “what is the 
optimum method of identifying and removing occult lymph node metastasis?” 
 
1.4  Thyroid cancer 
 
Thyroid tumours are classified by the World Health Organisation as endocrine 
tumours rather than head and neck tumours [52].  In many countries surgery for 
thyroid malignancy is centralised but can fall under the care of head and neck 
surgeons, ENT surgeons, endocrine and general surgeons. In the UK surgeons 
operating on thyroid malignancies are required to provide consultant level 
outcome data and interrogation of the UK Registry of Endocrine and Thyroid 
Surgery (UKRETS) found that there are 147 surgeons fully registered in the UK, 
sixteen of whom identify as head and neck surgeons[53]. 
 
 Thyroid tumours are epithelial in origin; commonly follicular cells which give rise 
to differentiated follicular and papillary carcinoma (Table 1.1). Poorly 
differentiated and anaplastic tumours also arise from follicular cells and may 
represent progression of differentiated thyroid cancer (DTC), whereas medullary 
carcinomas arise from parafollicular ‘C’ cells. 
Thyroid cancer is the most common type of endocrine malignancy, and 
constitutes 1.7% of all malignancies worldwide. There is considerable 
geographic variation with higher incidence in the developed world, although 
there is a consistently higher incidence in females. The incidence of thyroid 
cancer has increased over the last 3 decades but cure rate for DTC remains 
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high with an 80-90% ten year survival rate, even in patients with regional 
metastatic disease.  
 
Fine needle aspiration cytology (FNAC) guided by ultrasound scan is the 
investigation of choice but it is not always possible to differentiate between 
benign and malignant disease (particularly follicular adenoma or carcinoma). It 
is not uncommon for patients to undergo a diagnostic thyroid lobectomy, which 
may be converted to a staged completion thryroidectomy once the pathology 
has been reviewed.  Staging is according to TMN (Table 1.2). 
 
Occult lymph node metastasis are thought to occur in 20-50% of DTC[54], 
however the significance of this spread is debatable. Most patients will receive 
post-operative radioiodine, which ablates both residual thyroid tissue and 
metastatic disease. This offers excellent tumour control, but there is a small 
subset of patients who relapse. Criteria for these ‘high-risk’ patients include 
male gender, age over 45 years, tumour over 4cm and extra capsular or extra-
thyroid disease. Elective central neck dissection (clearance of level VI and VII) 
is recommended in high-risk patients, although the procedure is associated with 
an increased risk of recurrent laryngeal nerve damage and 
hypoparathyroidism[55, 56]. 
 
On the opposite end of the spectrum there are clinical trials in progress looking 
at whether patients with low risk disease can be spared iodine treatment[57].   
 
There is lack of consensus about the extent of lymph node sampling required to 




1.5  Laryngeal cancer 
 
The larynx extends from the tip of the epiglottis to the cricoid cartilage and is 
divided into the supraglottis, glottis and subglottis each with their own TNM 
staging. Most laryngeal cancers arise in the supraglottic and glottic regions and 
95% are squamous cell in origin (Table 1.4). Men are more commonly affected 
than women and the risk of developing the disease are increased by the 
synergistic effects of alcohol and smoking (Table 1.1). 
Table 1.4. American Joint Committee on Cancer (AJCC) cancer staging manual 7th edition 
(2010)[28]. TNM staging of Laryngeal Cancer. 
 
T- Tumour 
 Supraglottis Glottis Subglottis 
T1 One subsite, normal 
cord mobility 
Limited to vocal cord(s) 
with normal mobility 
Limited to subglottis 
T2 More than one subsite, 
no fixity of larynx 
Extends to supra- or 
subglottis with normal 
(T2a) or impaired (T2b) 
vocal cord mobility 
Extends to vocal cord(s) 
with normal or impaired 
mobility 
T3 Vocal cord fixation 
and/or post cricoid, pre-
epiglottic or paraglottic 
spread with minor 
cartilage invasion 
Invades inner cortex of 
laryngeal cartilage 
Limited to larynx with 
vocal cord fixation 



















The treatment of laryngeal cancer is very much dependent upon tumour size 
with the emphasis upon preserving laryngeal function. Small tumours up to T2 
can be treated by either radiotherapy, transoral laser microsurgery (TLM) or 
transoral robotic surgery. Traditionally more advanced tumours (T2b-3) are 
offered chemoradiotherapy, however certain cases may be suitable for function 
sparing surgery such as vertical partial laryngectomy (VPL).  Laryngectomy is 
recommended when tumour has spread through cartilage and into the soft 
tissues of the neck[58]. In node positive disease, it is recommended[58] that 
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levels II–V should be treated on the involved side. Elective treatment of the N0 
neck is recommend in T3 and T4 disease. Radiotherapy (RT) or surgery ± post-
operative RT is provided to at least lymph node levels II, III and IV bilaterally.  
 
The incidence of occult cervical metastasis in T3/T4 disease is reported as 21-
78%[59-61], although the reported range is wide there is no doubt that some 
patients are undergoing unnecessary treatment with the additional burden of a 
bilateral neck dissection. Additionally there is controversy over the management 
of paratracheal nodes which are found to harbour occult metastasis in 9-27% of 
cases but do not form part of the routine neck dissection[62].  SNB again offers 
the possibility of bespoke treatment for this group of patients.  
 
 
1.6  Development of sentinel node biopsy 
 
In the 18th century the discovery that malignant disease spread via lymphatics 
set the intellectual framework for the move to radical surgical treatments which 
started in the 1930’s with Halstead and radical mastectomy and in the head and 
neck by Butlin and Crile.  Both life and surgery were harsh in this period and the 
significant surgical morbidity this approach engendered was accepted.  It was 
only late in the last century that sentinel node biopsy was adopted as staging 
tool for patients with early cancer.  
 
In the 1960s Ernest Gould, head of surgery at Washington Hospital, described 
for the first time intraoperative node sampling for metastasis by frozen section. 
He would dissect the “angular node” during parotidectomy and based on the 
histology would decide whether to proceed with radical neck dissection or 
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not[63]. Intellectually there was acceptance that lymph node metastasis which 
were not yet clinically apparent could be detected microscopically, but the 
challenge was in sampling the right nodes.  
 
The sentinel node concept was further explored in penile cancer by Cabanas in 
the 1970s[64] when he performed lymphangiograms of the dorsal lymphatics of 
the penis. Cabanas questioned the routine use of bilateral groin 
lymphadenectomy for both clinically suspicious and clinically normal nodes. He 
felt that lymphatic metastasis was an embolic mechanical process, and would 
usually be a late phenomenon in penile tumours due to thick fascial planes 
acting as a natural barrier. At the time there was no consensus about the best 
management of the groin nodes in penile cancer and patients suffered 
considerably from lymphoedema of the lower limbs when groin dissection was 
undertaken. He developed a technique using a radiopaque dye and plain x-ray 
but this was unwieldy and the impact of his reports was limited to targeted nodal 
resection. In 1992 Morton et al [65]published their data on the application of 
sentinel node biopsy in the management of melanoma. They confirmed the 
basic concept that if the SLN contained no cancer cells, then one can reliably 
assume that all the other nodes in the drainage area are cancer-free. They 
reported a 99% sentinel node identification rate with a false negative rate of 
<1%, which was highly persuasive that SNB was safe to use as a staging tool in 
its own right. If their results are calculated by today’s standards in fact their 
sentinel node identification rate was 86% (194/223 patients) and false negative 
rate of 4% (47 true positive and 2 false negative results) but nevertheless these 
impressive results paved the way for the adoption of SNB into routine care. 
Morton et al had introduced important development to the technique – the use 
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of vital blue dye -, which allowed the sentinel node to be identified by colour. 
This optical tracer was better than Cabanas’ x-ray method, but required the 
identification of the fine lymphatic channels draining the dye. This in turn drew 
criticism for the extensive dissection required to expose the channels [66] and 
detection was difficult when there was haemorrhage in the operative field. 
Furthermore the dye quickly flowed through the sentinel node to lower echelon 
nodes and Morton attributed this sampling error for the two false negative 
results, recommending top up injections during the procedure. 
 
The next advance was made by Krag et al who investigated the use of 
technetium labelled sulphur colloid for SNB, a substance already licensed for 
the investigation of lymphatic abnormalities [67, 68]. The radiolabelled colloid 
had two advantages, the general position of the SN could be identified on the 
patient by lymphoscintigraphy (LSG) prior to surgery and secondly the radiation 
could be traced trough the tissues during surgery by means of a hand-held 
gamma probe. This is not the whole answer for without a visual marker it is still 
difficult to identify the sentinel node in situation of low signal to background 
ratio.  
 
The relative advantages of the two tracers  (blue dye & radiolabelled colloid) 
either together or alone have been debated [67, 69-72] but the SNB technique 
has now has been validated through large prospective international studies [73-
75]. Consequently SNB is now widely adopted in the management of breast 
cancer and melanoma with agreed guidelines that include both tracer 
modalities[76, 77] resulting in an average false negative rate in breast cancer of 




Pre-operative sentinel node localisation had been aided by the recent advent of 
Single Positron Emission Computed Tomography/CT (SPECT CT), a fusion of 
gamma radiation images with conventional CT (Figure 1.1). This gives added 
anatomical detail on the position of the radioactive focus (sentinel node) in three 
dimensions and is a useful addition to the SNB protocol in a number of different 
tumour types[80] There is advantage particularly in node localisation in deep 







A. Planar lymphoscintigraphy images of 
anterior floor of mouth tumour. 
B. SPECT/CT images of patient in showing 
improved anatomical localisation of the 
sentinel nodes compared to image A. 
 
Figure 1.1 Lymphoscintigraphy (A) and SPECT/CT (B) images from patient with an anterior floor 




1.7  Physiology of sentinel nodes 
 
The process by which tumour disseminates around the body, and particularly 
the ability form metastatic lymph node deposits is due to a highly complex 
interplay between tumour and host cytokine signals that allows transformation 
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of tumour cells between epithelial and mesenchymal phenotype. The 
mechanisms by which invasion of the lymphatic system and formation of a 
viable growth within the lymph node occurs is the subject of much debate, but 
there is an element of lymph-node ‘preparedness’ to support metastatic growth. 
Much work has looked at the lymph node signalling microenvironment but few 
have related this to changes in the physiological functioning of the metastatic 
and pre-metastatic lymph node. In 2003 a group in Washington university 
cancer research centre investigated E-c-myc transgenic mice that develop a 
highly metastatic strain of lymphoma[85]. They found active lymphatic sinus 
growth within the lymph nodes of the mice before the tumour had 
metastasised[86]. These abnormally enlarged lymphatic channels resulted in a 
23-fold increased flow of subcutaneously injected lymphatic tracer (TRITC-
dextran) through the lymph nodes when compared to wild type littermate 
controls. The investigators proposed that metastasis to draining lymph nodes is 
facilitated by lymph node lymphangeogenesis actively increasing flow, thereby 
promoting dissemination and seeding of tumour cells. Lymph node 
lymphangeogenesis seems to be triggered via c-Myc oncogene overexpression 
stimulating the vascular endothelial growth factor pathway (VEGF-C and VEGF-
D), a mechanism supported by the high levels of c-Myc-expressing B cells 
within the enlarged lymphatic vessels.  
 
Subsequent work was undertaken using a B16-F10 metastatic melanoma 
model which reliably causes metastasis to the draining lymph nodes and lungs 
in mice by two months after injection[87]. Harrell et al[88] injected the hind 
footpads of mice with B16 melanoma cells on one side and sterile saline on the 
opposite side. They investigated the vascular changes around the tumour and 
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draining lymph nodes 13-22 days after inoculation. Findings showed 
significantly increased and enlarged lymphatic sinuses in both the cortex and 
medulla of the popliteal nodes but not the inguinal nodes of the tumour 
containing leg; changes that occurred before metastasis were established. 
Furthermore functional imaging studies of lymphatic flow were undertaken using 
near-infrared fluorescent nanoparticle (quantum dot) preparation injected in 
both footpads. Tracer was detectable in the tumour draining lymph nodes within 
two minutes of injection whereas it took 30 minutes for signal to reach the lymph 
node of the non-tumour side, a more than twenty fold difference in flow rate. In 
this study significant changes in the immune cell population within the tumour 
draining lymph nodes were seen; namely an eightfold increase in the B cell 
population by flow cytometry and histologically these were found in both the 
enlarged lymphatic channels of the cortex and medulla of the lymph node. 
 
The importance of these findings is critical to understanding the reliability of the 
sentinel node procedure. Prior to this information it was felt that lymphatic fluid 
followed a pressure gradient from the high interstitial intratumoural pressure 
driving the flow of cells into the lower pressure lymphatic system[89]. This 
theory did not explain why drainage would be to the same sentinel nodes if for 
example the position of the patient were changed diverting the flow through 
alternative interconnecting lymphatic vessels. However, understanding the 
phenomenon of pre-metastatic sentinel node lymphangiogenesis has explained 
how sentinel node biopsy maps an active process directing lymphatic tracer to 
specific sentinel nodes.  
 




SNB has a sound physiological basis that applies to solid tumours that spread 
via the lymphatic route. The technique is in its infancy in tumours of the head 
and neck but has potential to answer some of the management related 
controversies as outlined above.  The promise of reducing treatment related 
morbidity through harnessing technology to provide individualized treatment 
embodies the ethos of 21st century medicine in the developed world. However, 
there are a number of potential areas where the SNB technique can be 
improved. Presently in oral cancer the false negative rate of SNB is 14%. In 
contrast, the equivalent failure rate of elective neck dissection is reported 
between 6% and18%[37, 40, 90-92]%, with most papers reporting neck 
recurrence after END in the pN0 neck to be 12%[93]. On balance a slightly 
higher failure rate may be accepted for SNB in return for the improved morbidity 
and treatment cost, but ideally it should be explored if it is possible to reduce 
the FNR to a level that is the same or better than the alternative treatment.  The 
first question is therefore – “is there a way to improve the reliability of SNB 
detection in head and neck cancer?” 
 
The second issue is that of accessibility –both accessibility to the tumour and 
accessibility to services to facilitate the SNB procedure. Literature suggests that 
SNB is a test that harnesses the innate physiological behaviour of lymphatic 
spread in cancer, and should be applicable to many tumours.  Currently 
tumours that cannot be accessed for injection until patients are under a general 
anaesthetic are exempted from this procedure as the interruption to surgery 
involved in transferring the patient to the Nuclear Medicine department for 
imaging renders the workflow unmanageable. However, if the imaging process 
which tracks the movement of tracer from tumour to SN could be transferred to 
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the operating theatre, the possibility of using SNB in a range of tumours is 
expanded. Furthermore the wider applicability of SNB in the context of 
worldwide healthcare could be unlocked if the necessity for very expensive fixed 
gantry nuclear medicine imaging equipment is replaced by cheaper portable 
technology. The latter can be transferred between the outpatient and theatre 
setting providing optimum flexibility. The second question to explore is 
therefore; “is there a way to identify the SN in the operating theatre by using 
purely intra-operative techniques?” 
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Chapter 2 Sentinel node biopsy technique  - review of the literature and 
protocol development  
 
 
This chapter is a review of the current guidelines and best practice for SNB, 
which has been undertaken in order to formulate a gold-standard protocol by 
which to test potential improvements. Additionally, a search of literature 
relating to innovative and experimental techniques in SNB has been carried 
out and these data are presented in table form. Information is presented in 
three sections exploring sentinel node tracers, sentinel node imaging, and 
pathological analysis of sentinel nodes. 
 
2.1  Tracers used in sentinel node biopsy 
 
Radiotracers used with or without the addition of an optical tracer form the 
standard for SNB in the head and neck. Blue dye (Patent blue V sodium 
Guebert 2.5%, PVD) is the most commonly used optical tracer[41, 94, 95], 
although there is increasing use of fluorescent optical tracers[96]. Hybrid 
tracers that incorporate more than one modality are not widely used at 
present but may offer an improvement to current practice[97]. 
 
2.1.1  Radiotracers 
 
A radioactive tracer is a compound incorporating a radioisotope (radionuclide) 
that allows localisation of the tracer by detection of emitted radioactive decay. 
The radionuclide is added to a ligand whose structure is dependent upon the 
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function the tracer is expected to perform; in the case of SNB this is a charged 
protein in solution. 
 
In the UK Nanocoll®(GE Healthcare Ltd) is the only currently available tracer 
for use in SNB.  Nanocoll is supplied as 500mcg cold kit for 
radiopharmaceutical preparation. Nanocoll, human serum albumin derived 
from blood donations, is a powder for reconstitution into colloidal suspension. 
It is used clinically when combined with Sodium Pertechnetate (99mTc) to 
form injectable technetium-99m albumin nanocolloid. Sodium Pertechnetate is 
produced separately in a technitium-99m-generator by decay of Molybdenum 
(99Mo)[98].  
 
The radiopharmaceutical product is a heterogeneous suspension of albumin 
particles of which 95% are <80nm in diameter. When introduced 
subcutaneously into connective tissue interstitial fluid 30-40% of the 
administered technetium-99m albumin colloidal particles (less than 100 nm) 
are filtered through the lymphatic capillaries and vessels to lymph nodes. 
Here the particles are trapped within the reticular cells and hence the 
lymphatic drainage can be mapped. At the injection site some of the 
remaining tracer is phagocytosed into local histiocytes and a smaller fraction 
passes into the circulating blood and is broken down via the 






2.1.2  Tracer Injection technique and dose 
 
The dose and method of injection of 99mTc-Nanocoll is dependent upon the 
tumour and for non-skin head and neck tumours the best described 
technique is related to oral squamous cell carcinoma[94].  These 2009 
guidelines provide a step-by-step method for tracer injection, which has 
remained uncontested. In summary, for oral tumours optimal images can be 
obtained by peritumoural submucosal injection using 20-40MBq for the one-
day and 40-80MBq for the two-day protocol. The total injected activity is 
adjusted according to the timing of imaging with respect to surgery. In 
general, higher doses are required for a 2-day protocol, in order to ensure 
the activity exceeds 10 MBq at the time of surgery. Small volumes of 0.1–0.2 
ml per aliquot are recommended to minimize contamination (spilled tracer) 
due to the resistance of the tissue. The injected volume should not exceed 
0.2 - 0.3 ml[94].  
 Tuberculin syringes with minimal dead space are used (Perfektum 
tuberculin syringe 1.0mL capacity, Sigma-Adrich). The tracer is either 
prepared into four separate syringes where the small volume (usually 0.1ml 
Nanocoll) will require a small air bubble to aid expulsion of the tracer through 
the syringe dead space. If a single syringe is used for all injections (usually a 
two day protocol volume of 0.4-0.8ml) then the air bubble is not necessary. 
Radiotracer is injected at 0.1–0.5 cm from the tumour. Tracer is administered 
keeping as a reference the clock face orientation by four separate 
submucosal injections (at 3, 6, 9 and 12 o'clock). Following injection, bleeding 
is controlled with a gauze swab, and the patient asked to rinse the mouth to 
minimize pooling of the radiotracer in the oral cavity. Residual gamma activity 
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in the syringes is measured to accurately calculate the total injected tracer 
activity[94]. 
 
2.1.3  Optical tracers 
 
2.1.3.1  Blue dye (PVD) 
 
Patent blue V sodium Guebert 2.5% (PVD, Guebert, Roissy France) is a 
triarylmethane dye also known as the food additive E131. It is licensed for 
sentinel node biopsy in the UK. The dye is presented in a 2mL clear glass 
ampoule and is suitable for immediate injection (up to 10mls of intravenous 
or 1-2mls for subcutaneous route). The dye has no pharmacological effect 
and is passively excreted in a dose dependent manner in the urine and 
stools in the 24-48 hours following injection. Allergic reaction has been 
noted at a rate of 0.09% in two major studies of SNB in breast cancer[99]. 
Of these, 7% were serious anaphylactic reactions requiring ITU input 
although there were no fatalities.  
 
PVD is rapidly transported via the lymphatic system and is detected by 
discoloration of the lymph node or the lymphatic channels, which can be 
dissected to the lymph node. The tracer can only be seen in contrast to the 
surrounding structures under white light, and will be affected by 




The dye does exhibit some weak autofluorescence when excited at 635nm 
wavelength with emission at 660nm, but the signal is less bright than 
indocyanine green[100].  
PVD will discolour the injection site, which is deterrent to some surgeons 
who believe this hampers their ability to judge the tumour margin. There is 
no evidence to show that that use of PVD increases the risk of a close 
tumour margin[41]. 
During surgery the intention is to inject PVD in the same location and 
method as the radiopharmaceutical. Due the small molecular size of PVD it 
is transported rapidly and not retained within the lymph node, thus the 
timing of injection in relation to surgery is critical in order to capture the dye 
as it passes through the node. 
 
PVD has a proven safety and efficacy record in sentinel node biopsy 
surgery however there are a number of disadvantages to its use. These 
could be avoided by using alternative tracers that are retained within the 




2.1.3.2 Indocyanine Green (ICG) 
 
ICG (PULSION Medical Systems AG, Munich, Germany) is a near infrared 
(NIR) tricarbocyanine fluorescent dye, indocyanine green 









ICG has been used in vascular perfusion studies of the micro and macro 
circulation since the 1970s[102]. ICG is a licensed product for vascular 
studies in the UK[103],and is also used in studies of the lymphatic system in 
patients with lymphoedema[104] but it has not been widely used for sentinel 
node biopsy. The product is dispensed as 25 or 50mg of dark green powder 
stored in an amber glass vial. The powder is reconstituted with 5/10mls of 
sterile water for injection (0.5% w/v, Ranbaxy UK) to give a solution of 
5mg/ml. When injected in vivo (free ICG), the dye binds to plasma proteins 
and remains within the intravascular space without crossing the blood-brain 
barrier. ICG is not metabolized and is excreted into bile without 
enterohepatic circulation.  Subcutaneous injection of ICG leads to its rapid 
drainage into the lymphatic system and the superficial network of lymphatic 
channels can be mapped under near infrared (NIR) light. Free ICG readily 
binds to albumin within the lymphatic fluid and is washed into the lymph 
nodes. ICG retention within the lymph node is dependent upon the size of 
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protein to which it is attached. Unlike PVD, the fluorescent optical signal has 
some penetration of the overlying tissues (up to 1cm)[105] reducing the 
amount of tissue dissection required to identify the sentinel node. Moreover 
the excitation and emission spectra of ICG do not overlap with tissue 






Figure 2.2.Excitation and emission spectra of ICG (Excitation and Emission wavelength are 
drawn by green and red line respectively) and Haemoglobin (blue/red lines), and water (black 
line) absorbance spectra. [106] 
 
Free ICG has been used as sole tracer for sentinel node biopsy with mixed 
results. The optimum dose is uncertain, and there are many imaging devices 
available. Recent studies that have compared free ICG to other tracers or 
investigated the optimum dose of ICG are listed in table 2.1 (Table 2.1. 
Results of Sentinel Node Biopsy using free ICG). It is worth noting that each 
study has used a different near-infared imaging device. Furthermore some of 
the study protocols were such that there may have been some binding of the 
















Study results and conclusion 









All patients had blue dye and free 
ICG by separate injection. ICG had 
99% SLN detection rate, compared 
to detection 91% by blue dye. All 
SN+(35 cases) were detected by 
ICG, 92% by blue dye. ICG is more 
accurate than blue dye. ICG99mTc-
Nanocoll followed by LSG and 
SPECT/CT. 
Stoffels et al. 
JAMA Surgery 
2015[96] 




Concordance of separately injected 
free ICG and 99m Tc labelled 
Nanocolloid was less than 90% 
(p<0.001) and free ICG performed 
particularly poorly in pre-operative 
localisation (21% of basins). 
Accurate SNB requires radiotracer 
as well as fluorescent signal. 
How J et al.  
Gynecol oncol 
2015[108] 








Feasibility of cervical injection in 
patients undergoing hysterectomy 
for endometrial cancer. Three 
tracers injected simultaneously 
(one syringe) but not formally 
mixed. Blue dye performed less 
well than the other tracers (71% 
detection) whereas ICG and 99mTc 
Nanocoll were similar 87% and 88% 
detection rate, but results should 
be interpreted cautiously as there 
may be partial binding of the two 
compounds. 
Samorani et al. 
EJSO 
2015[109] 
301 Breast ICG (0.4-




98.7% concordance between ICG 
and 99m Tc labelled Nanocolloid 
injected up to 18 hours apart. ICG 
detected more SN than 99m Tc 
Nanocolloid 583 vs. 452, and more 
positive sentinel nodes 70 vs. 55. 
Authors suggest that ICG could be 
used to replace nanocolloid tracer 
injection in breast SNB. 
Cloyd et al. J 
Surg Oncol 
2014[110] 





TM, Novadaq  
 
Patients underwent 
lymphoscintigraphy with standard 
radiotracer followed by separate 
injection of blue dye and ICG. 
Sentinel node identification rate 
was 96.2% by radiotracer, 59.6% 
for blue dye, and 88.5% for ICG 
(P<0.05 for ICG vs. blue dye). Radio 
signal is still required to localize the 
sentinel node but blue dye can be 
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safely omitted form the protocol as 















Patient either had SNB by free ICG 
alone (n=2), radioisotope alone 
(n=13) or a both (n=4). Seven 
additional fluorescent sentinel 
nodes were identified in the 4 
patients who had ICG and isotope, 
none were positive for metastasis. 
Poor concordance in combined 
cases, but procedure significantly 
quicker. Free ICG can identify 
additional nodes but clinical 











All patients had intraoperative 
thorascopic injection of free ICG. 
SN identification rate was 80% 
(25/31) but ICG correctly identified 
the position of the positive nodes 
in the one study patient with 
metastatic disease. Adhesions and 
tracer leakage were the cause of 
failure in 6/31 patients. 













SN identification was ICG dose 
dependent with higher rate of 
identification over 1000 mg. All 
positive SNs were fluorescent with 
an average of 3 fluorescent nodes 
compared to 6.5 in completion 
nodal dissection.  
 
These data suggest that free ICG seems to work particularly well in breast 
cancer but is less successful in tumours where the lymph nodes are either 
close to the tumour or buried deep in the tissue. In these cases reliance on 
optical tracer alone is not possible and radiotracer is required to guide the 
surgeon to the local vicinity of the node. Fine dissection can then be 
undertaken guided by the fluorescence signal. Blue dye universally performed 
worse than ICG and many studies concluded that it could be omitted from 









2.1.4 Hybrid Tracers 
 
Hybrid tracers are compounds that harness more than one modality, when 
applied to sentinel node biopsy multimodality usually refers to a combination 
of radio- and optical tracer. Currently there are no commercially produced 
multimodal tracers but they can be assembled from mixing available licensed 
products, namely ICG and 99mTc-Nanocoll. 
 
The multimodal tracer derived from is a mixture of Technetium-99m labelled 
Nanocolloid and indocyanine green (ICG) is referred to as ICG-99mTc-
Nanocoll (Figure 2.3). The major advantage of the hybrid ICG-99mTc-Nanocoll 
tracer over free optical tracer is that the stable compound is trapped within the 
sentinel nodes resulting in high level of concordance of fluorescent and 
gamma signal (>95)[114], reducing the possibility of removing second echelon 
nodes that contain optical tracer only.  
 





Preclinical development of ICG-99mTc-Nanocoll was undertaken at the 
Netherland Cancer Institute[115], where it was shown that the hybrid imaging 
agent allowed combined pre- and intraoperative identification of SNs in mouse 
models for prostate and breast cancer [97, 115]. 
 
 
i) Mouse Breast Cancer Model 
 
Both healthy mice and a mouse mammary tumour model (KEP1-Luc) 
underwent injection of either ICG or Tc99Tc-nanocolloid into tumour or normal 
mammary tissue (10 animals in total).  Following mammary gland injection 
imaging was undertaken with either an IVIS In-vivo camera or SPECT/CT 
before the animals were sacrificed and lymph node dissection performed. 
The fluorescence intensity and radioactivity counts were measured.  
In a second experiment peritumoural injection was undertaken using the 
multimodal tracer ICG-99mTc-Nanocoll. All tumour-bearing mice (n=5) 
showed highly reproducible tracer uptake in the SLN starting around 6 min 
post-injection, with maximum values at 30 minutes. An important additional 
advantage of this multimodal imaging agent was the enhanced signal 
intensity over ‘free’ ICG. Using the same molar amount of dye (7.8 × 10−6 
mmol), free ICG achieved a signal intensity of 30–200%, whereas the 
multimodal imaging agent performed significantly better (1252–8080%; p = 
0.027). Excluding one animal with advanced metastatic spread, this results 
in an average 86- fold increase in signal-to-background ratio. 
 




Male TRAMP mice expressing the SV40 T antigen (TRAMP+) 
spontaneously develop autochthonous prostate tumours with metastases 
occurring at 24 to 28 weeks of age. The lymphatic pathway from the prostate 
gland drains via the lumbar LNs to the renal LNs. In this study, TRAMP+ 
mice between 25 and 30 weeks of age and age-matched nontransgenic 
(TRAMP−) mice were injected intratumorally (TRAMP+) or into the prostate 
(TRAMP−) with cocktail solutions:), NC (99mTc-Nanocoll/ICG), and Human 
serum albumin, HSA (99mTc-Vasculosis/ICG) or dye injection alone (PVD, 
ICG). Distribution of the imaging agents to the lymph nodes was assessed at 
different time points after injection from 15 minutes to 4 hours. The cocktail 
tracer or optical dye injections were given to 30 animals and the combined 
fluorescence and radio signals were detectable in vivo and ex vivo by IVIS 
camera and SPECT/CT. The relative intensities of the fluorescent and 
radioactive signals were measured at different time points (Cocktail 
injections were prepared by diluting 10 μl of ICG solution in 30 μl of the 
respective tracer solution 99mTc-Nanocoll (1.11×10− 7-mmol albumin; 8 MBq 
or 0.21 mCi). Results showed that there was good correlation between the 
fluorescent and radioactive signals in the cocktail group (correlation 
coefficient R ≥ 0.92). The fluorescent signal intensity was higher in the 
cocktail group compared to dye alone, particularly at the later time from 
injection (60 and 240 minutes). 
 
Clinical studies using the multimodal tracer have also been taken forward 
by the Dutch group. The Netherland Cancer Institute have published data 
on its use in head and neck, breast, melanoma, gynaecological and 
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urological cancers (Table 2.2). They estimate to have used the tracer in 
>700 patients, although not all cases have been reported in scientific 
literature. They have not noted any adverse effects related to the use of 
ICG 99mTc-Nanocoll.  
 
In one study they twice irradiated a group of patients to understand if there 
was any difference in the sentinel node labelling abilities of 99mTc-Nanocoll 
if it was combined with ICG or not. They found that the addition of ICG did 
not alter the in vivo behaviour of 99mTc-Nanocoll and in fact the sentinel 
node detection on SPECT/CT was identical after both doses[116]. 
 
Moreover interactions between ICG and Nanocoll prevent self-quenching of 
ICG in these particles, resulting in a high fluorescent intensity, giving an 86-
fold improvement in the signal to background ratios compared to ‘free’ ICG. 
In the ICG– 
99mTc -nanocolloid complex, the ratio of ICG to human serum albumin is 
18:1[117]. While the amount of 99mTc-nanocolloid is identical to that used 
for radiologically guided SNB, the dose of ICG used (<0.05 mg) is 
substantially lower than the amount of ICG allowed for intravenous use. 
 
Table 2.2: Patients studies using ICG-99mTC-Nanocolloid reported in the literature: 




Patient Group Study Protocol Results summary 
Christensen et 
al. Ann surg 
oncol (2016) 
30 oral cancer All patients received 
ICG99mTc-Nanocoll followed 
by LSG and SPECT/CT. 
Intraoperative detection by gamma 
probe and NIR imaging devices 
located 97% of nodes identified pre-
operatively. Fluorescence alone 
identified an additional 11/96 nodes. 










All patients received 
ICG99mTc-Nanocoll followed 
by LSG and SPECT/CT. 
Blue dye injected in non-
facial tumours (n=69) 
Using pre-operative imaging as a 
guide, 96.7%, 93.8% and 61.7% of 
the target nodes were identified 
intraoperatively by fluorescence, 
gamma signal and blue dye 
respectively. In five cases 
fluorescent nodes could be seen 
transcutaneously, in a further five 
fluorescent signal allowed 
identification of nodes not located 
with gamma due to high background 
signal. 
Stoffels et al. 





40 patients with 
cutaneous 
malignancies of 
the head and 
neck 
RCT of hybrid tracer vs. 
radiotracer alone. 
100% intraoperative identification of 
SN with hybrid tracer compared to 
95% with standard tracer. 
Verbeek et al. Int 
J Gynae cancer 
2015[119] 
12 patients with 
vulval cancer  
All study patients received 
CG99mTc-Nanocoll and blue 
dye, results compared to 
historical data using 
ICG:HSA and free ICG. 
100% concordance of ICG and 99m 
Tc signals using the hybrid tracer 
compared to 62% detection rate for 
blue dye. Intraoperative NIR 
fluorescence based SLN detection 
rates were 75%, 83%, and 100% 
for ICG alone, ICG:HSA, and 
ICG99m Tc-nanocolloid, respectively 
(P  = 0.21) 
Bourbon-Arce M 




25 patients with 
head and neck 
tumours (16 
melanoma and 
9 oral cavity) 
All patients injected with 
ICG99mTc-Nanocoll, 
comparison of conventional 
LSG, SPECT/CT, gamma 
imaging and fluorescence 
detection 
26% additional SNs were found 
using the multimodal approach 
Brouwer O.R et 
al, 









9 with penile 
cancer 
All patients had standard 
injection with 99mTc-
Nanocolloid (average dose 
71MBq) followed by 
SPECT/CT. All patients 
were further re-injected with 
ICG-99mTc Nanocoll within 
24 hours (average dose 
74MBq) 
Identical drainage pattern was found 
between the 99mTc-Nanocolloid and 
ICG99mTc-Nanocolloid. All excised 
radioactive lymph nodes were 
fluorescent. 









(RALP) for cN0 
prostate cancer. 
All had pre-operative 
injection with ICG-99mTc 
Nanocoll. Pre-operative 
SPECT/CT was performed. 
Intraoperative SN 
identification undertaken 
with gamma probe and NIR 
laparoscopy combined with 
LN dissection. 
NIR fluorescence intraoperatively 
identified 23/27 SNs found on pre-
operative imaging. Where 
fluorescence did not aid retrieval the 
SN was embedded in fat, which 
attenuated the signal.  
Brouwer OR et 
al. 










All patients had ICG-Tc99m 
Nanocoll injected. 7/11 also 
had blue dye injection. 
100% of sentinel nodes were 
radioactive and fluorescent. 43% of 




AC et al. 
J Biomed Optics 
(2011)[97] 
N=6 patients 
with T2b or 
Gleason >6 
prostate cancer. 
Pilot study in detection of 
fluorescent lymph nodes. 
ICG-99mTc-nanocolloid 
injected into prostate gland 
pre-operatively and 
Sentinella used to detect 
fluorescence ex vivo in the 
pelvic node resection 
specimen. 
Fluorescence was detected in the 
resected tissue. Fluorescence 
correlated with the radioactivity. 
Frontado M et 
al.[123] 
N=20 patients 
with oral cavity, 
melanoma and 
penile tumours 
Patients injected with ICG-
99mTc-nanocolloid and 
blue dye. Correlation of 
blue dye and fluorescence 
n the sentinel nodes. 
97% of the SNs were fluorescent 
while only 39.2% were stained blue 
Van den Berg, N 










All patients injected with 
ICG-99mTc.nanocolloid 
and SPECT/CT prior to 
SNB. 
43 SLN identified, 4 of which were 
close to injection site and identified 
in vivo by fluorescence only. 
Schaafsma et al. 





Patients injected with blue 
dye and two different 
particle density of ICG 
labelled 99mTc-Nanocoll. 
NIR fluorescence aided 
intraoperative identification of 
sentinel nodes. Up to 29 hours post 
injection. There was no difference in 




2.1.5  Selective lymph node tracers 
 
Tilmanocept (Lymphoseek – Norgine Healthcare) is a new sentinel node 
tracer designed for uptake into lymph node via binding to macrophage CD206 
mannose receptor, resulting in preferential uptake into the sentinel node [22]. 
This tracer offers a potential advantage over traditional tracers by clearing the 
injection site rapidly whilst being selectively retained within the sentinel 
nodes[126]. This should reduce the ‘shine-through’ effect in which nodes near 
to the tumour can be missed due to high signal at the injection site. It has 
shown impressive results in reducing the FNR for SNB in oral tumours from 
9%( NEO3-05 [15]) to 2.56% (NEO3-06 [23]). In these successive studies all 
patients underwent concurrent neck dissection and so no there was no control 
group to allow assessment the patient benefit. Lymphoseek has regulatory 
approval in the USA and Europe and but it will not be available for routine 
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clinical use in the UK until late 2017, falling outside the recruitment period of 




2.1.6  Sentinel node tracers – summary 
 
Traditional sentinel node imaging using radionuclide has a long history and a 
reliable outcome, allowing both pre- and intraoperative identification of the 
sentinel nodes. The major disadvantage is if there is shine through effect 
(nodes cannot be discerned from the general radiation blush at the injection 
site), in which case the addition of optical tracer is advantageous.  For this 
reason blue dye is still widely used, but this review has shown the low 
specificity of the dye for the sentinel node. In contrast the literature has shown 
that fluorescence out performs PVD in sentinel node identification, but in its 
free state ICG is not retained within the sentinel node and may lead to 
unnecessary removal of additional non-sentinel nodes. In contrast the hybrid 
tracer ICG99mTc-Nanocoll, incorporating both radionuclide and fluorescent 
modalities combines a gamma and fluorescence signal, which is retained 
within the sentinel node. Head and neck tumours are the ideal anatomical site 
to benefit from this due to the proximity of the injection site and the sentinel 
nodes. Literature review confirms that ICG99mTc-Nanocoll has shown 
promising results in the identification of additional sentinel nodes in oral 
cancer.  The hybrid tracer has not been used in the UK, nor has it been 
applied to non-oral head and neck tumours. Therefore an aim of this work will 
be to introduce the tracer to the UK for the first time, to apply it to non-oral 
cancer head and neck tumours and to develop a protocol for intraoperative 
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imaging, that would allow repeatable testing across different centres and 
different tumours.  
Following injection of the tracer, the next step in the SNB process is the 
imaging protocol, which is discussed in detail in section 2.2. 
 
2.2  Sentinel node imaging 
Sentinel node imaging has evolved from the plain x-rays used in Cabanas’ 
work[64] through to lymphoscintigraphy and subsequently to combination 
modality of single-photon emission computed tomography (SPECT) and x-ray 
computed tomography (CT) resulting in hybrid SPECT/CT[127]. Although x-
rays are no longer used, Lymphoscintigraphy another type of planar (two 
dimensional) imaging is routinely performed and increasingly supplemented 
by SPECT/CT for the additional anatomical detail provided[128]. 
 
 New developments in traditional hybrid imaging such as PET/CT[129], 
PET/MRI[130] as well as novel modality fusion such as 
SPECT/Ultrasound[131] may have a potential role in sentinel node biopsy but 
access to these facilities are at present very limited. Freehand SPECT 
(fhSPECT) is a recently developed mobile imaging system that seems to offer 
a reliable intraoperative 3-D imaging[132].   
 
2.2.1  Lymphoscintigraphy  
 
Lymphoscintigraphy (LSG) comprises both static and dynamic imaging 
phases, allowing collection of complimentary information to distinguish 




The dynamic imaging phase commences immediately following radiotracer 
injection, with frames (images) acquired every 10-20 seconds for 20-30 
minutes. The patient is positioned under the imaging gantry as quickly as 
possible after the tracer has been given, so as not to miss the appearance of 
in-transit nodes and to capture the exact order of appearance of subsequent 
nodes[133, 134]. Once dynamic imaging is completed the static phase follows 
on and collects images at a much longer frame speed (300 seconds) 
recording a summation of the emission of tracer and providing a map of the 
intensity within the field of interest[135]. The images show just the hotspots 
without anatomical reference and therefore require more than one view to 
orientate the reporter. After LSG imaging is complete, SPECT/CT can be 
undertaken but it must be noted that the temporal element of the imaging 
process cannot be captured by SPECT/CT due to the delay between injection 
and imaging. 
 
Although lymphoscintigraphy is a reliable test and much favoured by nuclear 
medicine physicians[136], data does not support a great advantage of this test 
over other modalities in the head and neck. A recent review of sentinel node 
outcomes across 14 European centres found that the false negative rate of 
LSG was 13.5% compared to 10% when SPECT/CT was used although the 
difference did not reach statistical significance (p=0.297)[136].  
 
Flach et al[137] looked at the inter-observer and inter-institution variability in 
reporting sentinel nodes using a series of nine OSCC patient who had 
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undergone LSG and SPECT/CT imaging. They identified a schism in reporting 
which reflected a split in the fundamental ideology of sentinel node mapping. 
On the one hand some teams would label just the first node to appear, others 
would highlight nodes they felt had a direct drainage pathway from the tumour 
(although definition of this introduced further variables) whilst others still would 
label any node that shows tracer activity as a sentinel node. Moreover some 
teams would limit the number of nodes they would consider SN irrespective of 
the images shown by the scans and there was also considerable 
disagreement over the status of hotspots seen in the contralateral neck. 
These disagreements (amongst very experienced practitioners) would seem 
to erode the value of the functional and temporal aspect of 
lymphoscintigraphy perhaps rendering it the preserve of purists. 
 
Certainly there would be no advantage in using a modality that identifies more 
negative nodes than LSG without improving the accuracy of positive node 
identification, and those who favour LSG as a sole imaging tool reference 
recent data showing that LSG identifies fewer nodes than SPECT/CT[138, 
139]. Unfortunately neither of these studies reported sensitivity of each 
modality in detecting positive sentinel nodes.  
 
The major disadvantage of LSG is the lack of anatomical detail and the 
resolution of the images that makes it difficult to distinguish between one hot 
focus and a cluster of closely related nodes. It is unlikely that this is relevant in 
clinical practice as the surgeon will be drawn to the correct region by either 
modality and the number of nodes excised will depend upon a combination of 
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intraoperative gamma counts, anatomy, and operator interpretation. The 
situation of a  ‘missed node’ is the most significant outcome by which to 
assess the reliability of the test but this cannot be measured in the majority of 
cases where all nodes are negative for metastasis and therefore could very 
well be picked by a random choice without detriment to the patient.  
 
2.2.2 SPECT and SPECT/CT 
 
Single-photon emission computed tomography (SPECT) detection is 
undertaken by rotating gamma cameras that allow computation of summated 
radionuclide signal providing excellent spatial resolution and sensitivity[140]. 
Wagner et al.[141] first described the advantages of using the combined 
functional and anatomical information provided by fusion of SPECT and 
conventional CT (SPECT/CT) over planar lymphoscintigraphy for oral cancer. 
They found that SPECT/CT identified 49 draining “sentinel” nodes in 30 
patients. Lymphoscintigraphy identified just 38/49 nodes, although only one 
third of the group went on to have pathological confirmation by biopsy. They 
found the advantage of SPECT/CT over planar imaging was in identifying 
nodes close to the injection site, however it should be noted that the protocol 
did not include immediate imaging by LSG, rather a delay of one hour post 
injection which may account for this discrepancy of higher echelon nodes. 
 
Subsequent studies showed conflicting results of the utility of SPECT/CT over 
planar lymphoscintigraphy[128, 142], and although it is not considered 
essential for accurate SNB [94], it remains a popular investigation allowing 
surgical access planning by anatomical localisation of the SN in relation to 
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critical structures[143]. In many cases SPECT/CT is performed in addition to 
LSG in solely to confirm the anatomical localisation of the nodes already 
identified by planar imaging[137]. 
 
Although SPECT/CT is useful in determining the surgical approach for 
retrieval of the targets, the patient is imaged in standard anatomical positions 
meaning targets can be displaced during the operation particularly when 
tissues are moved or removed.  An ideal imaging tool would be able to update 
during the procedure to reflect the exact status after surgical steps are 
undertaken. Moreover in relation to SNB imaging data that is 
contemporaneously obtained allows the possibility of delivering and tracking 
the radioisotope in real-time during the operation. 
 
The challenge in moving SPECT imaging out of the nuclear medicine 
department is changing from a gantry-based design (whereby the detectors 
are rotated around the patient) to a hand-held detector that can be controlled 
by the operator. There are fully integrated operating theatres which would 
allow for gantry-based detectors AMIGO – Advanced Multimodal Image 
Guided Operating), but these are expensive, require large amounts of space, 
and also interfere with the flow of surgery[144] 
 
2.2.3  Freehand single-photon emission computed tomography (fhSPECT) 
 
The prospect of an intraoperative detector was first reported in 1989 whereby 
a catheter mounted detector was used to locate lung tumours via 
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bronchoscopic approach[145]. The first patent filed for a hand-held detector 
with tomographic capability was in 2001[146] and in 2002 Benlloch et al.[147] 
described a gamma camera able to process stereoscopic images with a 
resolution of 2mm in phantom models. 
 
In 2005 a group based at Technische Universität München in Munich, 
Germany (subsequently forming a commercial operation, SurgicEye GmbH, 
Germany), devised a technique of combining a handheld nuclear detector 
(gamma probe) and a patient position-tracking device that would allow 
generation of 3D nuclear images in a process they christened freehand 
SPECT (fhSPECT)[148].  Although many less measurements points are taken 
by the handheld device (thousands compared to nearly a million in the gantry 
based system), the operator is able to move very close to the region of 
interest thus allowing a comparable level of accuracy. Table 2.3[149] shows 
the relative technical limits of freehand versus gantry-based imaging. 
Table 2.3 Comparison of freehand and gantry based nuclear medicine imaging, taken from 
Chapter 4.Intraopertive 3D nuclear imaging and its hybrid extensions in “Gamma cameras for 






2.2.3.1  DeclipseSPECT System 
 
First introduced in 2007[150] fhSPECT has evolved in the past seven years 
from a prototype to a commercial product, declipseSPECT cart system 
(SurgicEye GmbH, Germany). The set up for the fhSPECT system is shown in 
figures 2.4 – 2.6. The detector comprises a gamma probe (one-pixel gamma 
detector) that provides continuous data collection (updating 20 times per 
second with accuracy of 0.2mm[150]) whilst the position is tracked via infrared 
signal reflected through fiducial markers (navigation i-spheres). To ensure 
accuracy of the equipment calibration is undertaken prior to each procedure, 
confirming the localisation of a known source. Image reconstruction is 
undertaken via iterative algorithms and the image is overlaid on a video image 




Figure 2.4. Components of freehand single-photon emission computed tomography device 
(fhSPECT), declipseSPECT, image provided by SurgicEye GmbH, Germany. 
1) Optical tracking system comprising video camera (centre) and two offset infrared cameras The NDI 
Vicra video camera has resolution of 1032(h) x 778(v) at 30 frames per second and 8 bit colour 
resolution. 
2) Gamma probe (Gamma probe system SG-04, Crystal Photonics GmbH) attached via cord to control 
panel shown in figure 2.2.  
3) Tracking target mounted onto gamma probe. Disposable fiducial markers (navigation i-spheres) on a 
rigid three-pronged frame  
4) Central processing unit (medical PC 4) loaded onto medically certified cart suitable for transfer into 
the operating theatre 








Figure 2.5. Control unit CXS-SG04 (CE 0633) Crystal photonics GmbH Germany for gamma 
probe shown in figure 2.4. 
The control panel selects for nuclide, sample time and pitch of the counts per second. The 
readings undergo linear algorithmic processing by the central processing unit in figure 2.1 to 
produce the 3D image. 
 
 
Figure 2.6. Patient-tracking device. Lightweight sterilisable frame with mounted disposable 
navigation i-spheres (fiducial markers). 
 
The stent is taped to the patient near to the region of interest. The stent can also be placed 
on the patient during SPECT/CT where implanted stainless steel (316) rods allow localisation 
via downloaded images in declipseSPECT central processing unit, allowing comparison of 
the fhSPECT and SPECT/CT images. 
 
2.2.3.2  Augmented reality image fusion 
 
Augmented reality (AR) is the fusion of digital computer-generated information 
with a real-world view to form a composite image. The DeclipseSPECT 
system produces an augmented reality image of the radiation hotspots 
superimposed onto a real-time video image of the patient, which is displayed 
































Figure 2.7 Production of augmented reality images by DeclipseSPECT system  
A) Probe and patient tracking devices  
B) Freehand SPECT translated and rotated to the coordinate system of the camera and 
finally projected on the image plane (image from Chapter 4, Intraoperative 3D nuclear 
imaging and its hybrid extensions, Gamma Cameras for interventional and intraoperative 
imaging, CRC press 2016)[149] 
 
 
The images are created by ‘scanning’ the patient methodically with a hand-
held gamma probe that is passed over the area of interest from several 
different angles, taking care to avoid directing the probe tip towards the 
injection site. The algorithm commences after a 5 second countdown 
instigated by the operator holding the probe close to a gamma source. The 
processed augmented reality image appears on the screen immediately. The 
image is continuously refined as more counts are accumulated, and the 
operator continues the scan until a clear image of the radiation hotspots are 





is 2-3 minutes. If the navigation spheres are obstructed during the scan an 
alarm sounds to warn the operator that tracking of the probe or patient 
position has been interrupted and counts are not taken until the connection is 
re-established. Once the scan has been completed the results are saved 
automatically and used to create a surgical report which includes the exact 
time and length of the scan, the number of hotspots found and a screen shot 
is automatically stored. Once the scan is saved the operator can flip between 
the augmented reality image (figure 2.8A) and a 3D view (2.8B) and the 
distance between the probe tip and the hot spot is shown in the top right hand 




Figure 2.8.A. Augmented reality image of 
fhSPECT scan result 
Figure 2.8B. Three dimensional image view of 
the same patient showing the patient reference 
target and hotspots only. 
Figure 2.8 Augmented reality and ‘3D mode’ images 
 
Automatic screen shots are saved every three minutes during the procedure 
and additional images can be taken by the operator as required. Scans can 
be performed at any point during the procedure, for example once the sentinel 
lymph nodes have been removed to ensure that there are no remaining 
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hotspots, although the previous scans cannot be re-upload when a new scan 
is taken. All scans appear on the operation report. 
 
2.2.4  Utility of fhSPECT localisation of sentinel nodes.  
 
Review of the literature reveal a small number of case reports and pilot 
studies using fhSPECT (with DeclipseSPECT) for SNB detection in breast 
cancer[148, 151-154], melanoma[155, 156] prostate cancer[157, 158] and 
oropharyngeal tumours [159].  
 
There are four publications detailing the utility of fhSPECT in oral cancer. In 
2014 Bluemel et al.[160] based in Marburg, Germany, reported a case report 
of  fhSPECT in a patient with an anterior floor of mouth tumour in which the 
system detected sentinel node identified by pre-operative lymphoscintigraphy 
and SPECT/CT. This led to a case series of twenty-three oral cancer patients 
in whom pre-operative scanning by fhSPECT had a 98% detection rate (out 
performing lymphoscintigraphy but not SPECT/CT) however, the investigators 
were not blinded to the results of the conventional nuclear medicine imaging 
prior to scanning with fhSPECT [161]. Additionally all the patients in these two 
reports had concurrent neck dissection, potentially masking any failings in the 
technique. 
 
Around the same time a Dutch group were exploring the use of the 
DeclipseSPECT system, reporting their first case in 2013[132] progressing 
to a case series of 66 patients with cT1-T2 N0 oral cancer who underwent 
SNB using fhSPECT. In this study fhSPECT identified 94% of the sentinel 
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nodes that had been identified pre-operatively, however it should be noted 
that the position of the nodes had been marked on the neck by the nuclear 
medicine team prior to the surgeon scanning with the DeclipseSPECT 
system. Investigators asked the surgeons to rate on a three-point scale the 
usefulness of the system in identifying and retrieving the nodes during 
surgery, and found that it provided additional useful information in 24% of 
cases. 
 
2.2.5 PET Localisation of sentinel nodes 
 
Images produced by fusion of positron emission tomography (PET) and 
sequential or simultaneous MRI or CT scans are useful not only for staging 
but are increasingly under investigation with respect to biomarkers such as 
hypoxia, angiogenesis and capillary permeability in assessing response to 
treatment and diagnosis of recurrence[130, 162, 163]. Heuveling et al.[164] 
Investigated the possibility of a PET/CT lymphoscintigraphy using a novel 
tracer 89Zr-nanocolloid albumin, for five patients with oral cancer who also 
underwent traditional gamma camera imaging by SPECT/CT using 
99mTc_nanocolloid. They found that PET/CT lymphoscintigraphy not only 
identified the same SN hotspots as SPECT/CT but also located additional SN 
close to the injection site. The authors noted they were able to identify 
lymphatic channels draining into the lymph nodes that could not be seen on 
the SPECT/CT. This advantage however did not translate to the operating 
room as there is currently no appropriate intraoperative detection device for 





2.2.6  Sentinel node imaging – summary 
 
Lymphoscintigraphy and SPECT/CT are widely used together for standard SN 
imaging.  
At the present time there is little evidence to support a move away from these 
modalities, but the development of freehand SPECT may allow an alternative 
method of sentinel node imaging that can be performed in the operating 
theatre. To date this modality has not been tested against the gold standard of 
lymphoscintigraphy and SPECT/CT in a blinded trial. An aim of this project will 
be to test the ability of fhSPECT to reliably detect sentinel nodes in patients 
with oral cancer by a surgeon who is blinded to the results of pre-operative 
nuclear medicine imaging. A further aim is to extend the role of fhSPECT in 
other tumour groups. 
 
2.3  Pathological analysis of sentinel nodes 
 
The key hallmark of the SNB pathology protocol is a highly detailed 
interrogation of the tissue. Excised sentinel nodes undergo an increasingly 
intricate and expensive number of tests to detect metastasis. If no metastases 
are found at the early stages (simple bisection and H&E staining, the same as 
in a neck dissection), this triggers more in-depth analysis with the intention 
that a micro metastasis (defined as viable metastatic cells measuring 0.2 
mm) could not be missed. This means most protocols would serially section 
the nodes at 150-200 mm so that the intervening sections, “curls” which are 
not analysed, are smaller than the minimum size for a micrometastatic 
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deposit. This generates a huge number of slides per node, particularly if the 
node is negative. 
 
2.3.1  Sentinel node pathology protocol 
 
 There is little controversy about the histopathological procedure, it has been 
well described and is highly reliable with little deviation from the protocol 
described for melanoma and breast cancer. Table 2.4 outlines the pathology 
protocol described in studies of SNB in oral cancer. 
Table 2.4 Sentinel node pathology protocols reported in trials. 
 






Stoeckli (2007[165]) 2.5mm slices 
along long axis 
At 150m Stained for H&E and 
pancytokeratin at each 
step. 
Alkureishi([94]2009) 2mm through 
longest axis 




AE1/AE3 or MNF 116 
Civantos (2010[166]) 2-3mm from 
hilum to 
periphery 
Not clear 4 slides from each section 
reviewed by central 
laboratory with 
pancytokeratin AE1/AE3. 
CK8/18, MNF 116 
Chung (2015[167]) 2mm through 
longest axis 
At 250m Six slides at each level 
using AE1/AE3 




Reviewed by central 
laboratory with 
pancytokeratin AE1/AE3. 
CK8/18, MNF 116 
Schilling(2016)[41] Bisection or 
2.5mm slices 
Five slices at 
150m 
AE1/AE3 looking for 
morphologically viable 
immunoreactive cells – 
confirmed by H&E of 
adjacent slice 
 
The general pathology protocol is described in figure 2.8, based upon 
published guidelines[94] as well as ongoing work by the author in formulating 
best practice guidelines in conjunction with the National Institute of health and 
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Care Excellence (NICE). A sentinel node biopsy is reported as positive when 
at least one node on one side of the neck contains viable carcinoma cells.  
 
2.3.2  Pathological reporting of sentinel nodes and TNM staging 
 
During the course of this work, guidance on pathological reporting and staging 
of OSCC was updated by the change from AJCC cancer staging manual 7th 
edition (TNM 7) published in 2010 [28] to the 8th edition (TNM 8)published in 
2017[5]. Pathological sentinel node status is unchanged between the two 
versions with the exception of extranodal extension (ENE)[169] (Table 2.5). 
Table 2.5 Changes in pathological staging of sentinel nodes between AJCC 7th and 8th 
edition. 
Nomenclature; Suffixes are used after the pN stage: 
  (sn) to indicate sentinel node biopsy 
 (mi) to indicate micrometastases 
 (i+) to indicate ITCs 
AJCC Cancer Staging manual 7th edition recognises the following staging: 
 pN0(sn) for no sentinel node metastasis 
 pN1(sn) for no sentinel node metastasis 
 pN1(sn)(mi) for single ipsilateral node with micrometastasis 
 pN2(sn)(mi) for multiple ipsilateral node with micrometastasis 
 pN2c(sn)(mi) for contralateral or bilateral nodes with micrometastasis 
AJCC Cancer Staging manual 8th edition recognises the following staging: 
As above except in the case of extranodal extension (ENE) which will upgrade N status such 
that: 
 pN1(sn) with ENE will become pN2a(sn) 
 pN2(sn) with any node showing ENE will become pN3(sn) 
 pN2c(sn) with any node showing ENE will become pN3 (sn) 
 
2.3.2.1  Isolated Tumour Cells (ITC) 
 
In melanoma and merkel cell cancer the presence of ITC in the sentinel 
nodes, (sn)(i+), are considered a positive result but in breast cancer they 
are not. Due to lack of data there is currently no consensus on the 
significance of ITC in oral cancer, but emerging data indicates that the 
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presence of ITCs impacts on the patient’s prognosis[170]. For this reason 
and until further data is collected a result of (i+) i.e. viable tumour cells is 
followed by a completion neck dissection. 
 
2.3.2.2 Tumour thickness 
 
Up to 2017 tumour (T) staging categorisation was decided by largest 
tumour dimension and invasion of adjacent structures (Table 1.2). The 
TNM 8 introduced a new parameter of tumour depth to additionally stratify 
T stage (Table2.6).  
 





AJCC cancer staging manual 7th 
edition (TNM 7) 
AJCC cancer staging manual 8th 
edition (TNM 8) 
T1 Tumor ≤2 cm Tumor ≤2 cm, ≤5 mm depth of 
invasion (DOI)  
T2 Tumor >2 cm but ≤4 cm Tumor ≤2 cm, DOI >5 mm and ≤10 
mm or tumor >2 cm but ≤4 cm, and 
≤10 mm DOI 
T3 Tumor >4 cm Tumor >4 cm or any tumor >10 mm 
DOI 
 
Patients are considered eligible for SNB if they are clinically staged T1-
2[172], thus the addition of staging by depth will impact on the future 
treatment recommendation for patients upstaged to T3 by this parameter 








2.3.3  “On-Table” diagnosis of sentinel node metastasis 
 
Rigorous pathological examination by serial sectioning outlined above takes 
up to one week to complete, thus the patient and clinician must wait for the 
diagnostic result before decision regarding definitive treatment can be 
established. Ideally the status of the sentinel node would be diagnosed whilst 
the patient remains under anaesthetic for the biopsy, and the decision to 
proceed with neck dissection decided in the same operation, this would also 
allow patients requiring microvascular reconstruction to undergo SNB as there 
would be no second procedure that could threaten the microvascular 
reconstruction. Some early adopters of SNB found they had good sensitivity 
(94%) using on-table frozen section (FS) to diagnose metastasis[173] but 
these results were not replicated in later larger studies[174-176] that showed 
FS had a sensitivity as low as 50% and concerns regarding processing the 
remaining node tissue have seen this approach fall out of favour. 
 
Another possibility is intraoperative molecular sentinel node analysis by rapid 
processing methods including One Step Nucleic acid Amplification (OSNA), 
and quantitative Reverse Transcriptase – Polymerase Chain Reaction (qRT-
PCR). OSNA based on automated isothermal amplification of cytokeratin CK-
19 has been validated by 96% concordance with gold-standard histopathology 
in breast cancer[177], allowing on-table diagnosis within 20 minutes and a 
commercially available system (RD-100i OSNA system (Sysmex UK)) has 
been recommended for on-table diagnosis in breast SNB by NICE[178].  
OSNA based on CK-19 detection in lymph nodes also showed promise in 
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OSCC[179, 180] however a study looking at the prevalence of expression of 
CK-19 within primary OSCC and corresponding metastatic nodes found that 
just 80% of nodal metastasis would be detected by this method[181] . Another 
more specific and sensitive target may be possible, but currently a 
commercial patent held by Sysmex Co. prevents further development of this 
technique. 
 
2.4  Pathological analysis of sentinel nodes – summary 
 
The pathological processing of sentinel nodes by serial sectioning is a 
logical and reliable process with little possibility of error if the correct nodes 
have been supplied to the laboratory. This thesis does not aim to test this 
stage of the sentinel node procedure.  However, some post hoc analysis 
based on the TNM 8 will be considered to understand the effect this may 
have upon future studies.  
 
2.5  Sentinel node biopsy technique and protocol development - 
Summary 
 
Technical aspects of  SNB technique have been appraised and based on this 
literature review  key areas have been identified in which further research is 
required to define and refine sentinel node reliability and  applicability every 




The most impactful potential advancement will be in moving the entire 
procedure into the operating room. Preliminary studies using fhSPECT would 
support this advance, but this innovative modality has only been tested as an 
adjunct to conventional imaging whereas it’s full potential lies in sentinel node 
identification without the need for the patient to undergo lymphoscinctigraphy 
and SPECT/CT. If fhSPECT can be validated against these methods, many 
patients with deep body tumours such as larynx, lung, stomach, and intestine 
would be able to benefit from ‘at risk’ nodal identification and individualised 
staging. The  hybrid  tracer ICG-99mTc-Nanocoll is a simple modification of SN 
technique that can be immediately used in clinical practice. Its optical 
properties are superior for sentinel node identification compared to PVD in a 
number of patients with head and neck malignancy, but so far this advantage 
has not been widely recognised in the UK. Further work is needed to 
ascertain the additional benefit of fluorescence in order to justify the 
investment required to adapt the operating theatre and purchase equipment 
for NIR imaging compared to the low cost (naked-eye) detection of PVD. 
Clearly the ability to pathologically stage the sentinel node in theatre is an 
ultimate aim but the development of this requires huge commercial investment 
and is some years away from use in routine clinical practice. 
 
The first aim of this work is to test fhSPECT against established SNB 
technique in oral cancer, secondly to ascertain the benefit of fluorescence 
imaging in SNB in oral cancer, and finally to investigate the feasibility of 
applying SNB to new tumour groups. 
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Chapter 3 Blinded comparison of sentinel node localization in oral 
cancer by pre-operative lymphoscintigraphy and SPECT/CT with 
intraoperative localisation by freehand SPECT (fhSPECT). 
 
3.1  Introduction  
The complex nature of lymphatic drainage within the head and neck means 
that intraoperative gamma probe localisation of sentinel nodes is always 
informed by pre-operative imaging (lymphoscintigraphy and/or SPECT/CT). 
Freehand SPECT (fhSPECT) offers the possibility of real-time intraoperative 
lymphoscintographic mapping for sentinel node biopsy (SNB). The advantage 
of fhSPECT is the ability to build up a dynamic three-dimensional mapping of 
the radioactive ‘hot-spots’ within the region of interest, which will move with 
changes in the patient’s position during surgery. It also allows for re-scanning 
during the procedure to reflect changes in the anatomy.  
To date fhSPECT has been investigated as an adjunct to traditional sentinel 
node imaging rather than an independent localisation modality for SNB 
procedures. However, if fhSPECT proves accurate enough to localise sentinel 
nodes without the need for gantry-based outpatient imaging, the process 
could be moved to the operating theatre thus reducing the time and cost 
associated with the procedure.  
This also opens up possibility to apply SNB to tumours such as tonsil and 
tongue base which are only accessible for injection with radiotracer once the 
patient is under general anaesthetic. Moreover this system is markedly 
cheaper than the gantry based systems. 
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3.2  Study aim  
This study aims to assess whether fhSPECT guided sentinel node biopsy can 
be accurately undertaken in patients with oral cancer by a surgeon who has 
been blinded to the results of pre-operative lymphoscintigraphy and 
SPECT/CT. The accuracy of the three imaging modalities  (fhSPECT, 
lymphoscintigraphy and SPECT/CT) are measured by sentinel node 
identification rate, identification of positive sentinel nodes, and false negative 
rate. A secondary aim is to understand the optimum post injection window for 
identification of lymphatic drainage by fhSPECT, thus informing any future 
protocol that may rely on the intraoperative delivery of radiotracers.  
 
3.3  Study population 
 
Ethical permission was granted to recruit patients aged between 18 and 90 
with newly diagnosed T1-T2 oral squamous cell carcinoma who were clinically 
staged N0 and were awaiting sentinel node biopsy. Clinical staging was 
undertaken by CT and MRI scan of the neck plus ultrasound fine needle 
aspiration cytology (FNAC) of any nodes that were clinically suspicious. 
Exclusion criterion included any patients who were unable to give informed 
consent, who were pregnant or breast-feeding those who had undergone any 
previous neck surgery or radiotherapy and anyone in whom the use of a 
radiotracer was contraindicated. 
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Patients were identified via the head and neck outpatient clinic and the weekly 
head and neck Multi Disciplinary Meeting (MDM) at Guys Hospital, London. 
Patients deemed appropriate for inclusion by MDM discussion were 
approached by the author during outpatient clinic consultations, at least two 
weeks prior to undergoing surgery. It was at this time that the Patient 
Information Leaflet was discussed and given to the patient (Appendix A – 
Patient information leaflet). 
In accordance with our ethical permission (Ref: 12/LO/1542), all patients were 
given the opportunity for further discussion about the study either in person or 
by telephone at least twenty-four hours after receiving the initial information. If 
following this consultation, patients were willing to enter into the study they 
were asked to sign informed consent documentation (Appendix B – Consent 
form), the recruitment and outcome of patients is shown in figure 3.1 (results 
section 3.6) 
 
3.4 Materials and methods  
Data collected at each stage of the procedure described below were 
contemporaneously recorded on a specifically designed proforma. Paper 
copies were anonymised and stored in the site file, held in a locked office in 
the head and neck department of Guys Hospital London. Data was 
transcribed into a password protected secure online database (Infoflex 
version 5, CIMS, UK) by the author and data was analysed using a 
combination of Infoflex v5 analysis module, Excel for Mac 2008 (version 




Images collected as part of the analysis were downloaded and stored on a 
password protected GSTT Trust PC, or kept on the DeclipseSPECT hard 
drive, along with each operative report. 
 
3.4.1 Pre-operative Imaging 
 
All patients presented first to the nuclear medicine department at Guy’s 
Hospital to undergo imaging prior to surgery. Patients were assigned to 
receive the tracer on the afternoon before their operation (two-day protocol) or 
on the morning of surgery (one-day protocol) based on availability of the 
scanners in the nuclear medicine department. This pragmatic approach to 
scheduling was based on data showing that the success of the biopsy is not 
influenced by the time elapsed between the injection and surgery as long as 
the pathway is completed within 24 hours[136]. A member of the nuclear 
medicine and surgical team reviewed results of the imaging prior to theatre. 
One surgeon remained blinded to the results and was designated to lead the 
subsequent surgical procedure. 
In order to test the ability of fhSPECT to identify immediate drainage, a subset 
of the study group underwent additional fhSPECT imaging following injection 
in the nuclear medicine department. This was only possible if the device was 
not being used in theatre at the time of injection. 
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The pre-operative sentinel node imaging adhered to a widely validated 
protocol[41, 94], which has also been previously reported in the literature by 
this department[182].  
The tumour site was anaesthetised by topical anaesthetic spray (Xylocaine 
pump spray 10%, (Lidocaine 10mg/dose, AstraZeneca). Four submucosal 
injections of 99mTc-Nanocoll (GE Healthcare Ltd) were delivered by a nuclear 
medicine physician (GG) at equidistant points (12, 3, 6 and 9 O’clock position) 
0.5mm from the margin of the tumour. The total effective dose was 40-80Mbq 
for a two day and 10-20 MBq for a one-day protocol.  
Following injection the patient rinsed their mouth with water to prevent artefact 
from swallowed tracer, and proceeded directly to dynamic 
lymphoscintigraphy. Patients were imaged in the supine position with the 
tumour side towards the camera or neutral position if midline.  
Planar imaging was performed using a dual head gamma camera (e.cam, 
Siemens Healthcare, Munich Germany) using a low energy high-resolution 
collimator with 9.1mm resolution[183]. Dynamic images were taken in the 
anterior or oblique view (20 x 60s, 128 x128 matrix). Directly after dynamic 
imaging static images (120s or 300s, 256 x 256 matrix) were acquired. The 
position of the sentinel nodes were localised on the skin of the neck using a 
57Cobalt point-source marker and was marked on the skin, based on the static 
images of the head and neck  
 Following dynamic and static lymphoscintigraphy the patients progressed to 
SPECT/CT imaging using a dual-detector gamma camera with a mounted 2-
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row multidetector CT scanner with intrinsic resolution of 3.8mm[184] (Symbia 
T, Siemens Healthcare). SPECT protocol used 128×128 matrix by180° in the 
anterior L-mode rotation with 3° angle step and 20–25 seconds per projection, 
in 8 iterations, using correction for attenuation and scatter.  CT images were 
obtained by 130kV 17mAs 4.42-5mm slices and reconstructed to sagittal, 
axial, and coronal views. Co-registered SPECT/CT images were fused using 
E.soft 2007 application package (Siemens Healthcare) and any mis-
registration was adjusted manually. 
 
Table 3.1 Nuclear medicine imaging protocol 
 
Imaging Modality Imaging parameters 
 
Dynamic Lymphoscintigraphy 30-60 minutes continuous imaging (20 x 
60s, 128 x128 matrix). 
Static Lymphoscintigraphy Anterior and oblique images  (addition flood 
source image) (120s or 300s, 256 x 256 
matrix) 
SPECT-CT   128×128 matrix by180° 
CT: 130kV 17mAs 4.42-5mm slices 
 
If undertaken, a post injection fhSPECT scan (by MM or CS) commenced five 
minutes after the injection had been completed. In these cases, the patient-
tracking device was placed on the patient’s forehead and the position marked 
on the skin using permanent marker pen and covered by a clear occlusive 
dressing (Tegaderm, 3M medical USA), allowing accurate relocation during 
surgery producing directly comparable scans. Both sides of the neck were 
scanned until clear images of radiation hotspots were seen or at least 2000 
counts were obtained. The fhSPECT was completed within five minutes but if 
unsuccessful, no further delay was permitted and the patient proceeded with 
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standard lymphoscintigraphy and SPECT/CT protocol described above, to 
minimize disruption to the standard care pathway. 
Following review by the non-blinded surgeon, the position of all the identified 
sentinel nodes was recorded on a proforma. 
3.4.2  Surgery 
All surgery was undertaken at Guys Hospital, London by both MM and CS. 
One took the role of lead surgeon and was blinded to pre-operative imaging. 
Patients were admitted on the morning of surgery and consent reconfirmed. 
Intubation was via the nasotracheal approach. After photographing, all 
markings on the neck were removed by the non-blinded surgeon before the 
patient entered the operating room. 
Anaesthetised patients were positioned supine, with head ring support and 
the 3D patient-tracking device secured to the forehead. The lead surgeon 
undertook an fhSPECT scan and the position of the identified sentinel nodes 
was marked on the neck with indelible pen, photographed, and recorded on 
the data collection sheet. An augmented reality image of the patient and 3D 
mode showing depth of the node from the probe tip was automatically 
recorded by the DeclipseSPECT and stored in the hard drive of the device. 
 The position of the nodes identified by fhSPECT informed the surgical 
approach and the results of the lymphoscintigraphy and SPECT/CT were 
withheld until the sentinel node procedure was completed to the satisfaction of 
the lead surgeon. The only planned exception to this was in the case of no 
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nodes being found by fhSPECT in which case the pre-operative imaging 
results were revealed at the beginning of the invasive procedure. 
The tumour periphery was injected with Patent V blue dye (Guerin, Paris) 
0.1mls by the same technique as the radiotracer. 
Incision(s) in the neck were planned according to the established sentinel 
node position.  Local anaesthetic was not used. Generally a 2-3cm incision 
was placed in a skin crease closest to the node, or placed in a location 
convenient to access more than one nodal basin if required. The neck was 
opened in layers taking care to preserve neurovascular structures and to 
minimise bleeding. Once the target nodal basin was accessed the lead 
surgeon looked for blue staining. If no blue dye was seen the surgeon used 
the hand-held gamma probe to isolated the correct node. If the hot node could 
not be found in the basin using the gamma probe without navigation function 
a repeat fhSPECT scan was undertaken at this stage. All nodes were 
removed with a cuff of surrounding fat and the following information was 
recorded on a designated whiteboard in the operating room; 
 Neck level from which the node was retrieved - When more than one 
node was removed from a neck level each was numbered according to 
the order in which they were removed e.g. left level IIa node 1 (L2a.1), 
left level IIa node 2. 
 Size – maximum dimension measured in millimetres 
 Colour  - presence of optical tracer (Patent V Blue dye)  
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 Node scintigraphic count – the average gamma count obtained over 
ten seconds of recording once the node was excised and moved away 
from the patient.  
 Bed scintigraphic count – average gamma count obtained over ten 
seconds with the probe tip placed within in the position that the node 
was excised. If the bed count remained high after all anticipated 
sentinel nodes were removed (based on fhSPECT) then another 
fhSPECT scan was undertaken 
 Background count – the probe was held on the patients chest pointing 
away from the injection site and mean gamma count obtained over ten 
seconds recorded.  
 
All excised nodes were placed in separate pots containing 10% buffered 
formaldehyde solution and labelled according to neck level, number and 
gamma count. In accordance with convention[185], to be considered a 
sentinel node, the gamma count was a minimum of 10 times the background 
radiation and more than 10% of the count of the hottest node excised.  Nodes 
that did not meet these criteria were labelled ‘non-sentinel lymph node’ and 
were submitted for routine H&E examination rather than serial sectioning.  
Once this process was completed and before the neck incisions were closed, 
the results of the lymphoscintigraphy and SPECT/CT were revealed by the 
non-blinded surgeon. If there was discrepancy between the pre-operative 
imaging and the fhSPECT result (nodes not detected by fhSPECT) then the 
images were reviewed in full by both surgeons on a screen in theatre and a 
joint decision was made if further nodes required retrieval. Once all targeted 
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sentinel nodes had been removed, the neck was closed and the primary 
tumour was excised, aiming for a pathologically confirmed clear margin of 
over 5mm. Sentinel nodes were transported to the histopathology laboratory 
at Guys Hospital on the same day as surgery and processed according to the 
protocol outlined in chapter 2. 
 
3.4.3 Follow –up 
 
Patients were reviewed on the ward, one day following surgery, to assess for 
any complications associated with the procedure. Complications were graded 
according the Clavien-Dindo classification[186]. Patients were reviewed in 
clinic one week after surgery to discuss the results of the sentinel node 
biopsy. If the biopsy proved positive for metastasis, a completion neck 
dissection was scheduled. The final nodal staging was based on combination 
of the SNB and the completion neck dissection. In accordance with UK 
guidelines post-operative radiotherapy was recommended to patients who 
had extracapsular spread or metastasis in more than one lymph node[187]. 
For this study patients were followed up in the head and neck clinic at Guy’s 




3.5 Recruitment and analysis plan 
Descriptive statistics were used and as the study group underwent paired 
investigations, patients acted as their own control group. Sample size 
calculations showed that it would not be feasible to recruit enough patients in 
a single centre to show a statistical difference between the modalities. Based 
on previous unit activity and allowing for adequate follow up period it was 
decided to aim to recruit fifty patients into the study.  
The primary outcome measure was the number of sentinel nodes correctly 
identified by fhSPECT, SPECT/CT and lymphoscintigraphy. The performance 
of each technique was compared using one-way repeated measures analysis 
of variance (ANOVA) analysis.  
If an imaging modality showed a single hotspot where other modalities 
showed two or more separate areas this was considered to be a missed node 
by the modality. If two or more hot nodes were removed from an area that 
showed a single hotspot on all modalities (clustering) this was not considered 
a missed node.  
The second outcome was the detection of positive sentinel nodes. The 
expected true positive rate in T1-T2 oral SCC is 23-34%.[41, 166, 188] In this 
group we expected 12-17 positive biopsies.  To consider fhSPECT a safe 
option it should be able to detect all the positive nodes (SN+) that had been 
found by other methods i.e. 100% concordance between LSG or SPECT/CT 




A false negative result was defined as any patient who developed an isolated 
recurrence in the neck after a negative SNB. The mean time to diagnosis of 
missed metastasis is 6 months following surgery[41], and all study patients 
were followed up for at least one year. The SENT multicentre trial showed that 
the false negative rate for SNB in oral cancer is 14%[41].  On this basis we 
would expect to find 2 -3 false negative cases in the study group cohort. 
Univariate survival analysis models were built using Kaplan-Meier product-
limit estimator for disease free survival (DFS). Table analysis on outcomes 
was performed using either chi-square or Fisher’ exact to test significance, 
depending upon the distribution of the variable in question.  
 
3.6  Results  
Between November 2012 and November 2015 fifty patients were recruited to 
the study. Three patients undergoing SNB declined to enter the study and did 







Figure 3.1. Patient recruitment and flow diagram. 
 
A total of 144 sentinel nodes were retrieved, an average of 2.88(+/-2.05) node 
per patient (range 1-8). The sentinel node biopsy was positive for metastasis 
in 19 patients (38%), in three cases two positive sentinel nodes were 
identified therefore 22 positive nodes were excised. Patient and tumour 
characteristics are shown in table 3.2  
Six patients had midline tumours of which half drained to bilateral sentinel 
lymph nodes. Of the remaining patients with lateralised tumours, seven had 
bilateral sentinel nodes identified (7/44, 16%). In two cases positive sentinel 
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nodes were contralateral to the tumour (2/19) 10% of positive cases, both 
level 1b. None of the sentinel nodes were found below level III. 
Table 3.2 Characteristics of patient and tumour. 
 
Ten lymph nodes were excised during the SNB that contained weak gamma 
signal which did not meet the ex-vivo count criteria to be considered sentinel 
nodes. A further eight nodes were excised during the SNB procedure that 
contained no gamma signal. These non-sentinel nodes were examined 
histopathologically and all 18 were negative for metastasis. 
 All patients 
(n=50) 
Positive Sentinel 
node biopsy  
(n=19) 
Effect of variable 
on sentinel node 
status  
Male (28/50) 56% (10/28) 36% p=0.7 




61.5   ± 12.08 
(range 24-87) 
 p=0.61 
Positive SNB (19/50) 38%  
Negative SNB (31/50) 62% 
Tumour location 
Tongue (33/50) 66% (15/33)  45% p=0.3 
Floor of mouth  (8/50) 16% (2/8)  25% 
Lower alveolus (3/50) 6% (0/3) 0% 
Lower lip (2/50) 4% (1/2) 50% 
Retro-molar (1/50) 2% (1/1) 100% 
Buccal (2/50) 4% (0/2) 0% 
T stage (AJCC 7th Edition, 2010) 
T1 40 (80%) 12/40 (30%) p=0.02 
T2 10 (20%) 7/10 (70%) 
T stage (AJCC 8th Edition, 2016) 
T1 38 (76%) 9/38 (24%) p=0.001 
T2 9 (18%) 7/9 (78%) 
T3 3(6%) 3/3 (100%) 
N (sn) stage 
N1 (16/19) 84%  
N2b (3/19) 16% 
Extracapsular spread 
Yes (3/19) 16%  
No (16/19) 84% 
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Completion neck dissection was undertaken in all 19 patients with positive 
SNB. In two cases further positive nodes were found in the completion neck. 
Post hoc analysis using the 2016 AJCC 8th edition cancer staging 
guidelines[189] upstaged three patients to T3, two that had been staged T1  
and one T2 by the 2010 guidelines[28] . Table 3.2 shows the 8th edition 
guideline has a statistically significant correlation with sentinel node status (p-
0.001), and that all the T3 cases were positive for metastasis. 
3.6.1  Excised sentinel nodes 
 
The location and pathological status of sentinel nodes that were excised are 
divided by anatomical site and represented in figures 3.2-3.7. These figures 
represent the total nodes submitted for serial sectioning having met 
intraopertive criteria (gamma count with/without blue dye) to be designated 
sentinel nodes. Review of all imaging modalities (fhSPECT, SPECT/CT, 
lymphoscintigraphy) was undertaken prior to submission to pathology 
ensuring no further hotspots remained in the neck, thus these nodes are 






Number and location of sentinel nodes excised from 
primary tongue tumours (red= positive for 
metastasis, green = negative for metastasis) 
 Negative Node 
 
Positive Node 
Facial 0 0 
Level 1a 3 0 
Level 1b 9 2 
Level IIa 33 11 
Level IIb 4 0 
Level III 32 4 
Level IV 0 0 
Level V 0 0 
Total 81 17 
 
Figure 3.2. Tongue tumours 
 
Number and location of sentinel nodes excised from 
primary floor of mouth tumours. 
 
 Negative Node Positive Node 
Facial 2 0 
Level 1a 1 0 
Level 1b 9 2 
Level IIa 1 0 
Level IIb 0 0 
Level III 8 1 
Level IV 0 0 
Level V 0 0 
Total 21 3 
Figure 3.3 Floor of mouth 
Figure 3.4 Lower alveolus 
 
Number and location of sentinel nodes excised from 
primary tumours of the lower alveolus. 
 Negative Node Positive Node 
Facial 3 0 
Level 1a 0 0 
Level 1b 5 0 
Level IIa 0 0 
Level IIb 0 0 
Level III 0 0 
Level IV 0 0 
Level V 0 0 
Total 8 0 
 
Tongue tumours 





Number and location of sentinel nodes excised from 
primary tumours of the lower lip. 
 
 
 Negative Node Positive Node 
Facial 2 0 
Level 1a 0 0 
Level 1b 4 1 
Level IIa 0 0 
Level IIb 0 0 
Level III 0 0 
Level IV 0 0 
Level V 0 0 
Total 6 1 
Figure 3.5 Lower lip 





Number and location of sentinel nodes excised from 
primary tumour of the retromolar region. 
 Negative Node Positive Node 
Facial 0 0 
Level 1a 0 0 
Level 1b 1 0 
Level IIa 1 1 
Level IIb 0 0 
Level III 0 0 
Level IV 0 0 
Level V 0 0 







Number and location of sentinel nodes excised from 
primary buccal tumours. 
 
 
 Negative Node Positive Node 
Facial 1 0 
Level 1a 0 0 
Level 1b 0 0 
Level IIa 2 0 
Level IIb 0 0 
Level III 1 0 
Level IV 0 0 
Level V 0 0 
Total 4 0 
Figure 3.7 Buccal mucosa 
 
Figures 3.2 -3.5 Location of positive and negative sentinel nodes from all tumour sites. 
 
 
3.6.2  Immediate fhSPECT scan 
Fifteen patients underwent fhSPECT scan five minutes following injection of 
the radiotracer. The results of these were compared to the pre-operative 
fhSPECT scans which were taken in theatre just prior to the surgical 
procedure (range 3.5-18 hours post injection depending on if a one or two day 
protocol had been used).  
In three cases the immediate fhSPECT scan showed no clear drainage to the 
neck. In a further two cases there was drainage seen to the neck but the 
signal could not be isolated to a discrete area. The remaining ten cases had 







Table 3.3 Cases that underwent immediate freehandSPECT (fhSPECT) scan following 
injection of radiotracer. 
FOM= Floor of mouth. * denotes sentinel node that was found to contain metastasis. 
 
 
Nine of the fifteen patients proved to have positive sentinel nodes by 
histopathological analysis (60%).  The positive sentinel node was located by 
immediate fhSPECT in only three of these cases, thus the sensitivity for 
detection of positive sentinel nodes was 33% and the false negative rate 40%.  
Examples of cases are shown below (figures 3.8-3.10) these demonstrate 
characteristic high signal and scatter which is found at the tumour site 
immediately post injection and illustrate three scenarios that typically arise; 
i) No discernable drainage is found on immediate fhSPECT scan with clear 
drainage shown on subsequent (pre-operative) fhSPECT scan. (5/15 cases) 
ii) Clear drainage seen on immediate fhSPECT scan, but additional drainage 
found on subsequent scans. (7/15 cases) 
iii) Clear drainage seen on immediate scan with no additional hotspots found 









One or two 
day 
protocol Immediate fhSPECT result 
SNB 
Result 
1 Left Tongue 20 One Indeterminate drainage left neck  Positive 
2 Left FOM 20 One Left and right submental and right IIa Negative 
3 Right Tongue 20 One Right level IIa Negative 
4 Right Tongue 85 Two Right level IIa and Right level III Negative 
5 Right Tongue 20 One Right level IIa Positive 
6 Left Lower lip 20 One Right and left Ib and left facial Negative 
7 Left Tongue 33 One Left level IIa * Positive 
8 Right Tongue 19 One Right level II/III* Positive 
9 Left Tongue 17 One No nodes found Positive 
10 Left Tongue 20 One Left Ib*  Left IIa Right IIa Positive 
11 Left FOM 20 One No nodes found Negative 
12 Right Lower lip 20 One Left and right facial, Left IIa Positive 
13 Midline FOM 54 Two R submental, right facial, Right III Negative 
14 Midline FOM 53 Two 
Indeterminate drainage right and left 
neck Positive 





Case 14. Immediate fhSPECT scan (left) from midline floor of mouth tumour showing indeterminate drainage in both 
sides of the neck with high signal at the injection site. Pre-operative fhSPECT (right) at 17 hours post injection shows 
clear drainage to level I lymph nodes of which one contained metastatic deposits. 
 
Figure 3.8 Pattern one: No discernable drainage found on immediate fhSPECT scan with 




Figure.3.9 Pattern two; Clear drainage seen on immediate fhSPECT scan, but further 




Case 7: Immediate fhSPECT (left) showing clear drainage from left lateral tongue (yellow box) to a single left level 2a 
node (black box) subsequently positive on pathological analysis. However pre-operative fhSPECT at five hours post 




Figure 3.10. Pattern three: Clear drainage seen on immediate scan with no additional 
hotspots found on subsequent scan 
 




3.6.3 Blinded fhSPECT compared to lymphoscintigraphy and SPECT/CT 
 
Of the 144 sentinel nodes excised 95 were identified by lymphoscintigraphy, 
122 by SPECT/CT and 125 by fhSPECT (Table 3.4).  A sample case is shown 
in figure 3.11. 
 
A one-way repeated measured analysis of variance (ANOVA) was conducted 
to evaluate the null hypothesis that there is no difference in the number of 
sentinel nodes localised by each modality. The results of the ANOVA indicate 
  
Case 8. Immediate fhSPECT scan (left) showing drainage to right level 2a/3 lymph node. Pre-operative fhSPECT scan 
(right) at four hours post injection shows reduced signal at the injection site with increased signal at the level 2a/3 
sentinel node but no additional hotspots. 
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a significant effect, Wilks’ Lambda p<0.001. Follow up comparisons indicated 
that pair-wise difference between lymphoscintigraphy and both SPECT/CT 
and fhSPECT were significant (p=0.002) but comparison between SPECT/CT 




Figure 3.11 Sentinel node identification by SPECT/CT and lymphoscintigraphy versus 
fhSPECT. All modalities found three sentinel nodes. Neck markings by nuclear medicine (left) 
and surgeon (right) can be compared (Nb. anterior mark 'x' by surgeon denotes the tumour 



















Lymphoscintigraphy failed to show any drainage in four patients. SPECT/CT 
showed no drainage in one patient and fhSPECT showed drainage in all 
patients. In two cases the surgical plan was changed after revealing the 
results of the SPECT/CT. In both cases the patient was rescanned by 
fhSPECT and further nodes were localised and excised. These nodes were 
negative for metastasis thus they are no considered a false negative result. 
All modalities missed positive nodes in at least one patient (Table 3.5). The 
false negative rate for lymphoscintigraphy, SPECT/CT and fhSPECT was 
26.3%, 15.8% and 5.3% respectively. If we consider the hypothetical situation 
that all the positive nodes missed were left until clinically apparent the overall 
neck control rate (NCR) for each modality in this cohort (fifty patients, three 


















LSG 95 1.9 .149 1.5-2.2 4 (8%) 
SPECT/CT 122 2.4 .184 2.3-3.0 1 (2%) 




Table 3.5 Number of positive nodes found by each modality 
 





Neck control rate 
 
LSG 5  
 
26.3%  84% 
SPECT/CT 3  
 
15.8% 88% 
fhSPECT 1  
 
5.3% 92% 
Total (all modalities) 0 0% 94% 
 
Freehand SPECT failed in to identify a positive node in one patient with a 
tongue tumour. The pre-operative fhSPECT scan identified a facial node and 
a level IIb node. Both pre-operative SPECT/CT and LSG found two hot areas 
in the left neck - level IIa and level III - of which the level IIa node was positive 
for metastasis.  
 
3.6.4  Blue dye 
 
At least one blue lymph node was found in 41/50 patients (82%), mean 
number of blue nodes was 1.8 (range 1-3). All blue nodes met gamma count 
criteria for sentinel nodes. Blue dye did not drain to the node containing 










There were minimal complications encountered following SNB. Only one 
patient had to return to theatre, the remaining six patients with complications 
had no change in their clinical course. Complications related to the sentinel 
node procedure are shown in table 3.6 
Table 3.6 Complications related to Sentinel Node Biopsy 
 
Complication Management/outcome Clavien-Dindo Score 
Wound infection Responded to oral antibiotics Grade 2 - Mild 
Sialocoele Aspirated in clinic twice Grade 1 - Mild 
Sialocoele Aspirated once in clinic Grade 1 - Mild 
Sialocoele Managed conservatively but re-admitted for 
observation at patient’s request 




Residual weakness (House-Brackmann 
score 2/5) at 18 months. 
Grade 1 - Mild 
Haematoma Return to theatre for drainage Grade 3b – Moderate 




Median follow up was 65 months (range 21-119 months). No false negative 
results were encountered in the follow up period. Five patients died from 
disease recurrence (three in the neck, two with distant metastasis), all were in 
the sentinel node positive group. Disease free survival for sentinel node 
positive versus sentinel node negative was significant (p<0.005, log-rank test 





Figure 3.12 Kaplan-Meier life table analysis showing disease free survival analysis for 
positive and negative sentinel node biopsy result 
 
3.7  Discussion  
The study group showed a slightly higher than expected rate of positive 
sentinel nodes (38%), of which a statistically significant proportion occurred in 
the T2 tumours (n=10, p<0.05). This increased the number of positive cases 
with which to test our hypothesis, but one could argue that T2 patients with a 
70% risk of metastasis were disadvantaged by undergoing two procedures 
(SNB followed by END).  These results are further accentuated by restaging 
using 2016 AJCC 8th edition cancer staging guidelines[189] in which three 




offered SNB according to the eligibility criteria. All three of these cases had 
positive sentinel nodes.  
Immediate fhSPECT was performed in 30% of the study group and provided 
new information in this field of investigation. The reason that not all patients 
could be scanned immediately post-injection was due to clashing scheduling 
of both surgery and injection. Often, more than one SNB cases would be 
scheduled per day therefore the DesclipseSPECT was in use in theatre at the 
time that the second patient was undergoing injection.  
Nevertheless the experiences gained showed that immediate fhSPECT is not 
reliable, with a false negative rate of 40%. This can be explained by the high 
level of signal at the injection site immediately after injection resulting in signal 
scatter and shine through effect masking signal tracking to the sentinel nodes.  
This study protocol did not allow delay of more than ten minutes between 
injection of the tracer and commencement of lymphoscintigraphy. This is due 
to historical concern about the risk of missing in-transit sentinel nodes. These 
are defined as nodes which the tracer completely passes through en-route to 
second echelon nodes, and can escape detection if only late images are 
taken.  In-transit nodes are recognised as rare occurrences and have been 
reported in melanoma but there are no reports of this situation occurring in 
oral cancer.  
In this study the performance of fhSPECT, particularly in the immediate post 
injection period was unknown and so the study was designed to alter the 
standard imaging pathway as little as possible. 
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What has been shown clearly by these results is that lymphoscintigraphy 
performs poorly compared to both SPECT/CT and fhSPECT in the detection 
of positive and negative sentinel nodes (p<0.005). There was no additional 
benefit to performing LSG (i.e. it did not identify nodes missed by other 
modalities) thus opening up the possibility that LSG could be omitted allowing 
serial fhSPECT scans to be taken in the immediate period following injection. 
SPECT/CT is normally performed after the LSG protocol is finished, usually 
90 minutes following injection. A future protocol could therefore be devised 
where patients are scanned every 10-15 minutes post injection followed by 
SPECT/CT at 90 minutes in order to assess the real-time tracking capabilities 
of fhSPECT. 
 
Freehand SPECT showed excellent sentinel node identification when used 
pre-operatively, however it did miss a positive sentinel node in one case. In 
this patient two hotspots had been identified in the left neck by all three 
modalities, LSG and SPECT/CT localised to level IIa and III whereas 
fhSPECT showed a facial node and a level IIB node.  When the gamma probe 
was used independently of the navigation mode during the procedure, 
sentinel nodes were retrieved from level IIb and III. This suggests that there 
was a co-registration problem between the gamma probe and patient tracking 
device, leading to incorrect reconstruction of the gamma signal in three-
dimensions. The DeclispeSPECT has two mechanisms to prevent errors of 
registration; 1) a simple calibration procedure of the gamma probe tracking 
device prior to the procedure and 2) a projected virtual reality image of the 
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collimated beam which should coincide with video image of the probe tip 
during data collection. 
In this case a potential explanation is that the head position (and thus the 
patient tracking device) was moved during the data collection. The tracking 
device is attached to the forehead and will map accurately when the head is 
rotated in a neutral position however if any lateral flexion of the neck is 
introduced the relationship between the nodal hotspots and patient tracking 
device is changed and could explain why the nodes appeared to have been 
shifted superiorly in relation to the actual position. 
 
3.8 Conclusion  
These data show that a surgeon who is naïve to the results of pre-operative 
sentinel node imaging can use freehand SPECT in the operating theatre to 
accurately locate sentinel lymph nodes. Freehand SPECT showed excellent 
sensitivity and a low false negative rate, but a higher detection of negative 
(possibly non-sentinel nodes). Data collected from immediate post injection 
fhSPECT is unreliable for SN node detection, suggesting that there is an as 
yet undefined optimum imaging window for this modality. It remains to be 
established if this imaging window coincides with a time frame that is 
compatible with intraoperative injection and sentinel node retrieval. 
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Chapter 4  Additional benefit of ICG-99mTc-Nanocoll in sentinel node 




4.1  Introduction  
 
Optical tracers are used in sentinel node biopsy to improve the ease of 
localisation of sentinel nodes during tissue dissection. In surgery a collimated 
gamma probe can direct the surgeon to the area of highest signal intensity in 
the region identified by pre-operative imaging, but because of signal 
penetration and scatter in-vivo, the probe cannot determine which is the hot 
node in a cluster, nor when there are overlying nodes. This may lead to 
additional unnecessary tissue dissection (with subsequent scarring) and 
inadvertent removal of non-sentinel nodes. The current standard optical tracer 
is blue dye[94] which is injected separately to the radiotracer. The dye has 
different physical properties to the radiotracer and therefore the flow rate and 
retention within the node is not identical. Moreover the dye stains the injection 
(tumour) site affecting the appreciation of tumour margins during surgery. 
Some surgeons avoid using blue dye for these reasons[41]. 
Indocyanine green (ICG) is a fluorescent green dye that can be non-
covalently bound to preparations of albumin. This allows the formation of a 
multimodal tracer comprising a colloidal particle labelled with both nuclide 
(technetium-99) and fluorescent dye (ICG)[118]. Because the optical tracer is 
bound to the conventional tracer, the flow is theoretically identical. There is no 
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staining at the injection site as the fluorescent signal is not apparent unless 
tissues are viewed with a near infrared (NIR) camera. There is a risk of 
allergic reaction with ICG but it appears to be lower than with blue dye 
(0.0001% vs. 0.09% [99, 103]). The major disadvantage of ICG is that the 
detection of the signal can be attenuated by ambient light, which can be 
difficult to exclude in the operating theatre. 
4.2  Study aim  
 
This exploratory phase II study aimed to establish the additional benefit of the 
fluorescent signal in the multimodal tracer ICG-99mTc-Nanocoll in identifying 
sentinel nodes in patients with early oral cancer using a newly developed 
clinical spectral imager (CSI)[190].  
The tracer was judged to have aided the SNB procedure in cases where: 
 
i) Intraoperative fluorescence is detected through overlying tissue 
aiding localisation of sentinel nodes already identified by pre-
operative imaging. 
ii) Intraoperative fluorescence allows identification of sentinel nodes 
close to the injection site not detectable by gamma signal due to 
shine-through effect. 
 
This study aimed to develop a reliable and repeatable intraoperative imaging 
protocol using the clinical spectral imaging device.  
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If an additional benefit of fluorescence guided SNB was established this would 
add to evidence supporting the use of fluorescence as the optical tracer of 
choice for SNB.  
 
4.3  Endpoints and outcomes 
 
The primary endpoint was the number of lymph nodes successfully identified 
by multimodal detection in a series of patients with cT1-2 NO oral cancer. We 
expected to find at least one hot and fluorescent node in each patient.  
Secondary endpoints were the additional benefit of the fluorescent component 
of the multimodal tracer. These were defined as: 
 
i) identification of fluorescent sentinel node at an early stage of the 
procedure as defined in section 4.7.6  
ii) sentinel node identified by fluorescence alone (failure of gamma 
camera due to shine through effect)  
iii) sentinel node localised on deeper dissection using fluorescence 
alone 
 
Tumour identified on fluorescence because of low/absent gamma signal  








4.4  Study set up and pre-clinical work 
 
4.4.1  Regulatory approval 
 
Ethical approval was granted for use of the blue dye +/- multimodal tracer as 
a non-CTIMP study (Clinical Trial of Investigational Medicinal Product) but 
second opinion was sought from the medicine health regulation authority 
(MHRA) as to whether this investigation should be registered as a drug trial. 
Because the multimodal tracer involved simple mixing of two licensed 
products with no pharmacological activity that are both excreted 
unmetabolised, it was advised that this study is considered equivalent to other 
trials using Nanocoll +/- blue dye and therefore not subject to regulations 
associated with CTIMP.   
 
The multimodal tracer was new to Guy’s and St Thomas’ (GSTT) NHS trust 
therefore Trust approval was sought for its use. Evidence was presented to 
both the GSTT formulary committee and the Trust Risk and Quality (TRAQ) 
committee in November 2014. Both committees granted provisional approval 
for use of the multimodal tracer, ICG-99mTc-Nanocoll, for all patients 
undergoing sentinel node biopsy pending review of the first ten cases. A trust 
approved new procedure patient information leaflet was produced (Appendix 
C – PIS Multimodal tracer). Results of the first ten cases were presented to 
the TRAQ committee and subsequently full approval was granted to use ICG-





4.4.2  Risk assessment and training 
 
The clinical spectral imager (CSI) was developed by collaboration between 
two CRUK Cancer Imaging centres, one based at Kings College London and 
the other at the University of Oxford. The design and development as well as 
pre-clinical and clinical validation of the system was published in 2014[190]. 
The CSI was assembled in-house thus exempt from CE marking requirements 
but underwent risk assessment by the Guy’s and St Thomas’ NHS trust 
clinical engineering and medical physics departments. Recommendations 
were made to reduce the risk of retinal damage from the emitted laser; 
patient’s eyes to be covered during the procedure and staff working within 
30cm of the device were advised to wear laser safety glasses.  
The research team carried out additional steps to further improve safety; both 
MM and CS undertook a certified training course on the core knowledge of 
use of lasers. “Laser in use” signs were placed on the doors of the operating 
theatre when the CSI was in use. CS also ran a training session for the 
theatre staff to explain the use of the CSI. 
 
4.4.3 Optimisation of fluorescence imaging 
 
4.4.3.1 Pre-clinical optimisation of fluorescence imaging 
 
Unpublished pre-clinical work was undertaken within the research group[191] 
to establish optimal preparation of the tracer, and optimal imaging conditions 
by the clinical spectral imager (CSI) in an animal tissue model. This work by 
Byrne et al. was based on publications describing the ‘self-assembly’ nature 
of the multimodal tracer[115].  A different method of assembly of the 
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compound by repeated cycles of heating was also investigated to ascertain if 
this increased the number of ICG molecules bound to Nanocoll, leading to 
improved intensity of the fluorescent signal. Results showed that there was no 
improvement in the fluorescence when the compound was heated compared 
to the self-assembly method.  
The CSI allows six different settings for level of gain (amplification of signal) 
and eight for integration time (summation of signal over a specified period of 
time), resulting in 48 possible combinations.  Changes in the settings affect 
camera sensitivity as well as image definition and brightness. Byrne 
conducted image optimisation studies using cuboids of porcine muscle 
injected with ICG, finding that optimal images were obtained by setting gain 
between x4 and x10 (possible range x2-10) and integration time between 0.4s 
and 0.5s (possible range 0.2s -4s).  These data suggest a range that can be 
applied to the clinical setting, assuring a standardised quality of imaging. As 
porcine muscle has different light absorbance and auto fluorescence 
properties to human tissue, it was planned to confirm this image optimisation 
using tissue from the first case recruited into the study. 
 
4.4.3.2 . Assessment of tumour autoflourescence  
 
Baseline human tumour and non-tumour tissue was collected and imaged 
using the CSI as part of a separate and ongoing parallel study (Intra-operative 
GE-137 fluorescence imaging in breast cancer and oral cancer EudraCT 
Number: 2014-003554-13). The excitation and emission wavelengths of the 
CSI were set to optimal fluorescence characteristics of ICG  (784 nm and 
>800 nm respectively). The maximum possible sensitivity to fluorescence 
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signal was achieved by adjusting the control unit settings to gain of x10 and 
integration time of 4 seconds. This confirmed that human OSCC tissue 
imaging by CSI with ambient light excluded at a distance of 20-30cm elicited 




Figure 4.1 Neck dissection tissue from EudraCT study 2014-003554-13 viewed under white 
light (WL) 
Image A tissue viewed with near infrared light at 790nm wavelength at a variety of settings 
showing no tissue autofluorescence.  
Image B - gain x4 integration time 40ms.  
Image C - gain x8 integration time 0.5s.  
Image D - gain x10 integration time 2.0s. 
 
 
4.4.3.3  Quality assurance of fluoresence imaging  
 
A reference phantom was constructed to calibrate the camera prior to each 
case. The phantom contained ICG solution diluted with water for injection, 
producing three different concentrations (Figure 4.2). The SBR was calculated 
under optimised conditions described in section 4.6.2  (distance 20cm, gain x 
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8, integration 0.5s, ambient light excluded), allowing detection of any drift in 




Figure 4.2 Reference phantom of ICG solution- from left to right; 5.0, 10, 25 µM /ml 
 
 
4.4.3.4  Blue dye fluorescence imaging 
 
Patent V blue (PVB) dye (Guerin, Paris) exhibits fluorescence when excited 
by light just inside the visible spectrum (630-690nm). To confirm that there 
was no overlap between the fluorescent signals of ICG and PVB, luminance 
measurements were taken (as outlined in 4.5.2) from a node stained blue in a 
patient that had not received ICG. The CSI was set to excite at 630nm and 
then 784nm. This confirmed that there was weak fluorescence at 630nm and 
none at 784nm. The maximum luminance achieved by PVB at 630nm was 
40% of that shown by ICG at 784nm under the same conditions (Fig 4.3 C). 
As expected, there was no conflict between the fluorescence spectra of PVD 
and ICG. However, given that an endpoint of this study is the surgeon’s 
subjective interpretation of the stage of surgery at which ICG emission was 
clinically useful, it was decided to omit blue dye to avoid influencing the 




4.5  Material and methods 
 
4.5.1 Study group and recruitment 
 
 
Patients with newly diagnosed cT1-T2 N0 oral SCC were considered for this 
study. The eligibility criteria and the process of recruitment was identical to the 
process outlined in section 3.3. Additionally patients received a trust approved 
information leaflet about the multimodal tracer (Appendix C). 
 
 
4.5.2  Preparation and injection of multimodal tracer 
 
ICG powder (PULSION Medical Systems AG, Munich, Germany) was mixed 
with sterile water for injection (0.5% w/v, Ranbaxy UK) to achieve a 
concentration of 5mg/ml. From this solution 0.05 mL was taken (containing 
0.25 mg of ICG) and added to 2 mL 99mTc-Nanocoll, giving a final 
concentration of ICG in the hybrid agent of 0.125 mg/mL.  The mixed 99mTc-
Nanocoll and ICG was gently agitated by hand and then left at room 
temperature for 30 minutes to allow association to take place.  Once ready the 
tracer was drawn up into four separate tuberculin syringes each containing a 
volume of 0.1-0.2ml depending on if a one or two-day protocol was being 
undertaken.  The final dose total of ICG was 0.05-0.1mg.  
The tumour site was anaesthetised by topical spray (Xylocaine pump spray 
10%, (Lidocaine 10mg/dose, AstraZeneca). Four submucosal injections of the 
light-green coloured multimodal tracer ICG-99mTc-Nanocoll were delivered by 
a nuclear medicine physician (GG) at equidistant points 0.5mm from the 
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margin of the tumour. The total effective dose of technitum-99m was 40-
80Mbq for a two day and 10-20 MBq for a one-day protocol. 
 
4.5.3  Pre-operative sentinel node localisation 
 
 
Sentinel node imaging was undertaken by static and dynamic 
lymphoscintigraphy as well as SPECT/CT and fhSPECT. Prior to the 
operation the targeted sentinel nodes had been decided and location was 
marked on the neck. There was no blinding during this study. During surgery 
a hand held gamma probe (Crystal photonics GmBH, Germany) integrated 
into the declipseSPECT was used to locate the sentinel nodes. 
 
4.5.4  Intraoperative set up of clinical spectral imager 
 
 
The CSI unit was placed on a portable trolley and the camera head mounted 
on a custom-built clamp attached to a post elevated from the trolley. This 
ensured the camera could be easily moved in an out of the surgical field 
during the operation and eliminated position variation and movement artefact 
during image acquisition. The control panel and camera head tubing was 
covered by a transparent sterile drape (P3 medical, Bristol, UK) allowing the 
surgeon to adjust focus without decontamination of the surgical field. The CSI 
was connected to a laptop via the S-video out of the control unit. An analog to 
digital convertor USB Video & Audio Grabber (Winstars Technology Ltd), 
provided S-video to USB 2.0 interface linkage. Digital images were captured 
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using BlazeVideo HDAV Grabber software and stored in bitmap (.BMP) 
format. Images were analysed using ImageJ software (Fiji, National Institutes 
of Health, USA). 
At the beginning of the procedure a white balance was taken with a surgical 
swab. A calibration image was taken using the reference phantom. Images 
then were recorded at pre-specified points during the operation. The image 
was first focused manually using the white light to obtain a crisp image. 
Ambient light in the theatre was minimized by using blackout blinds. Theatre 
lights were switched off during NIR image acquisition. Any LED screens that 
could not be switched off were covered temporarily with a reinforced surgical 




All surgery was undertaken at Guys Hospital, London by MM. Capture of 
intraoperative images and ex-vivo fluorescence analysis using the CSI was 
undertaken by CS.  
 
A standard approach to sentinel node biopsy was undertaken without blinding. 
Nodes were marked on the neck and a convenient incision was made. If more 
than one non-adjacent nodal area was explored separate incisions were 
made. No local anaesthetic was used. Near-infrared images were taken at 




Stage 0. Through skin prior to incision 
 
Stage 1. After skin had been raised by subplatysmal dissection 
 
Stage 2. After unwrapping and retraction of adjacent muscle (e.g. digastric, 
sternocleidomastoid muscle) but prior to identification of the sentinel node by 
the naked eye. 
 
Stage 3. After node localised by gamma count but prior to dissection from 
surrounding tissue (node may be visible to the naked eye). 
 
Stage 4. Ex-vivo after excision (node visualised in black box to exclude 
ambient light) 
 
Stage 5. Imaging of the bed from which the node has been excised to assess 
if fluorescent nodes remained. 
After baseline (stage 0) imaging by the CSI, the incision was opened in layers 
down to the immediate subplatysmal plane. Following meticulous 
haemostasis the surgical field was again viewed using the CSI. If no 
fluorescence was detected images were not recorded. Further dissection was 
directed according to gamma signal. This procedure was repeated for each 
plane of dissection until fluorescence detected or the node was excised. After 
excision all nodes were placed in a light excluding box on a background of 
blackened aluminum to allow calculation of  maximum luminance. 
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If the fluorescent nodes were identified at an early stage of the procedure (0-
3) no further images were taken to prevent unnecessary delay to the 
operation.  
Data collected at each stage of the procedure were contemporaneously 
recorded on a specifically designed proforma. Paper copies were anonymised 
and stored in the site file, held in a locked office in the head and neck 
department of Guys Hospital London. The surgeon also dictated a report of 
the operation immediately following the procedure specifically referring to the 
helpfulness of the fluorescence. Data was transcribed into a password 
protected secure online database (Infoflex version 5) by CS and data was 
analysed using a combination of Infoflex v5 analysis module, Excel for Mac 
2008 (version 12.3.2) and Statistical Package for the Social Sciences  (SPSS 
IBM, version 24). 
Images collected as part of the analysis were downloaded in bitmap format 
and stored in on a password protected external hard drive.  
 
4.5.6 Optimisation of Intra-operative fluorescence imaging 
 
Image optimisation analysis was undertaken on tissue from the first study 
case. Images were taken using all 48 setting combinations at a distance of 
20cm inside a black box that completely excluded ambient light. Mean 
luminance was calculated by drawing region of interest boundary around the 
fluorescent sentinel lymph node as well as a similarly sized piece of 
surrounding adipose tissue. Signal to background ratio (SBR) was calculated 
by dividing the mean nodal luminance by the background mean (adipose 
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tissue) giving a value in arbitrary units. Sample images are shown in Figure 
4.3 where optimal imaging (SBR 1.4) is shown in image 4.3C using gain 
amplification x8 and an integration time of 0.5 seconds. Figure 4.3B 
demonstrates under exposure (SBR 1.2) whereas in 4.3D (SBR 1.080) the 






Figure 4.3(A-D) Fluorescently labelled sentinel node (left,)  designated as signal region of 
interest (ROI) and surrounding fat tissue (right) designated background ROI. 
Tissues viewed under different light settings by the near infrared clinical spectral imager.  
A. White light only 
B. Excitation at 784nm gain setting x4, integration 40ms. Signal to background ratio (SBR) 
1.2. 
C. Excitation at  784nm gain setting x 8, integration of 0.5 s. SBR 1.4.  





4.5.7  Follow up 
 
Patients were reviewed on the ward one day following surgery to assess for 
any complications associated with the procedure. Complications were graded 
according the Clavien-Dindo classification[186]. Patients were reviewed in 
clinic one week after surgery to discuss the results of the sentinel node 
biopsy. If the biopsy proved positive for metastasis a completion neck 
dissection was scheduled. The final nodal staging was based on combination 
of the SNB and the completion neck dissection. Post-operative radiotherapy 
was offered to patients who had extracapsular spread or metastasis in more 
than one lymph node. 
 
 
4.6  Results 
 
 
Between November 2014 and June 2016 twenty-seven patients were enrolled 
in this study. Characteristics are shown in table 4.1. In the group 41% had 
positive sentinel nodes, of whom 40% had T1 tumours. Two patients had 
metastasis with extracapsular spread. At a mean 13 months follow up (range 
4-23) all but one of the patients were alive and free of disease. One patient 
with a pT2N1(sn) tumour of the tongue died from lung metastasis without local 






Table 4.1 Characteristics of patients in the tumour group 
 
Variable All patients (n=27) Positive Sentinel node biopsy  
(n= 11) 
Male 16 5/15 (33.3%) 
Female 11 6/11 (55%) 
Age (years median, 
standard deviation) 
63 (range 24-87)  
Positive SNB 11 (41%)  
Negative SNB 16 (59%)  
T1 20 (74%) 8/20 (40%) 
T2 7 (26%) 3/7 (43%) 
Tumour location 
Tongue 19 (70%) 7/19 (37%) 
Floor of mouth 5 (18.5%) 2/5 (40%) 
Lower alveolus 1 (3.7%) 0/1 
Lower lip 1 (3.7%) 1/1 (100%) 
Buccal mucosa 1 (3.7%) 1/1 (100%) 
 
 
4.6.1 Fluorescence detection of sentinel nodes – primary endpoint 
 
 
A total of 84 sentinel nodes were removed giving an average of 3.11 nodes 
per patient (range 1-7). Thirteen positive sentinel nodes were removed from 
eleven patients. The primary endpoint was met in all patients with least one 
fluorescent node detected. All positive sentinel nodes were fluorescent. An 
average of 2.61 fluorescent nodes were identified per patient (range 1-6). A 
total of twelve non-sentinel nodes were excised, five of these were hot but did 
not meet cut-off criteria to be judged a sentinel node. Only two non-sentinel 
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nodes were fluorescent, in both cases (Number 6 and 7 in table 4.2) there 
was one unusually hot sentinel node with counts per second (CPS) >3000 
causing some of the excised but still high CPS nodes to be down-graded to 
second echelon by the 10% rule.  
 
 
4.6.2  Near infrared imaging results - secondary endpoints 
 
 
No transcutaneous fluorescent signal was found prior to incision (Stage 0 
imaging) Figure 4.4 shows different intraoperative stages at which 

















Stage 1. After skin flaps raised in subplatysmal plane. Image shows weak fluorescent signal anterior 
to muscle. 
  
Stage 2. After unwrapping and retraction of adjacent muscle. Image shows moderate fluorescent 
signal deep to the retracted muscle. 
 
 
Stage 3. After node localised by gamma count but prior to dissection from surrounding tissue. Left 
image shows a node visible to the naked eye. Middle image demonstrate excellent signal, with 





Stage 4. Ex-vivo. Left image shows excised node under white light only, imaged in a black box 




Stage 5. Imaging of resection bed. Left and right images show region from which a fluorescent node 
was removed (indicated by tip of forceps). No further signal is seen. 
  
 
Figure 4.3. Fluorescence imaging results obtained at stage 1-5. Findings in each case are 






Table 4.2 Results of multimodal SNB using ICG-Tc99m Nanocoll. 
Colour identifies the status of the nodes: red = positive for metastasis, orange  = non-sentinel 
nodes, green = only identified by fluorescence in-vivo. Maximum luminance is given in 





Case  Tumour 
location 
Sentinel nodes by gamma 
signal (neck level, node 




(neck level, node 
number (maximum 
luminance) 
Stage of operation fluorescence detectable 













2 Right (R) 
Oral tongue 
R3.1 (263) R3.2(144), R2a 
(130) 
 








L3.1 (208), L3.2( 84), L3.3 
(148), L1b (232)  


















R3 (528), L3 (413), 
R2a.1(58), R1b (415), 
Submental (279),L1b(154), 
L2a (187) 
R3 (111), L3 (79), R2a 
(12), r1b.1 
(55)submental (14), L1b 
(10) L2a (10) 
Stage 3 






L2a.2 (250) L2.a.2(93) 
L1b (80) R1b (80) 
 
Stage 3 &4 
Brightest node was hottest node but other 




Floor of mouth 
L1b(3810) R1b(117) 
 
R1b (80) L1b (65) 
 
Stage 3 

















9 Oral tongue R3.1 (876), R3.2(496), 
R3.3(286) 
 
R3.1 (196) R3.2  (201) 
R3.3 (160) 
Stage 2 
Excellent signal, fluoresced through 
overlying fat 
Yes 
10 Oral tongue R2a.1(835), R2a.2(1087) 
R2a.3(1605), R2a.4(901) 
R2a.1 (202) R2a.2 (260) 
R2a.3 (240) 
Stage 2 
Good signal 3/4 hot nodes 
Yes 
11 Lower lip R Prefacial(578)R post facial 
(82), R3 (297), L1b(772), 
L2a(575) L3(618) 




Reasonable signal  
 
No 
12 Oral tongue L2b.1(449) L2b.2(170), 
L3(148) 
 









L2a.1 ( 56) R1b (260) 
R3.1 (34) R3.2 (59) 
 
Stage 5 
Fluorescence very bright in level 1b right 
side, subsequently hot ex-vivo two other 
level 1 node not very fluorescent but hot ex-
vivo 
Yes 
14 Floor of mouth L3(120), L1b.1 (23), 
L1b.2(49)  
 
Need to check 143 Stage 3 
Reasonable signal  
No 
15 Floor of mouth R1b.1(123), R1b.2(130)  
 
R1b.1 (89) R1b.2 (114) 
 
Stage 4 
Fluorescent signal mainly ex-vivo 
No 
16 Oral tongue R2a.1(171) R2a.2(59) 
 










Very strong signal from one node 
(subsequently positive) 
Yes 
18 Oral tongue L2a.1(219) L2a.2(2054) 
L2a.3(365) 










Good signal helping node localisation 
Yes 
20 Buccal mucosa R2b(-), Facial 1 (-) Facial 2 (-
), !a(-) 
 




Vey low gamma signal making node 







fluorescence helped because the gamma 
signal did not help in finding nodes seen on 
scans. 
21 Lower alveolus R facial (35) R1b(41) 1a(-) 
 
R facial R1b (55) 
 
Stage 4 
No comment made 
No 





Hottest node fluorescent 
No 
23 Floor of mouth 1a(48) L1b(321) R1b(89) 
L3(-) 
 




Fluorescence ex-vivo only 
No 
24 Oral tongue R2a.1(176) R2a.2(100), 
R2a.3(-) 1a(114)  
R2a.1 (166) R2a.2 (55) 
 
Stage 4  
No comment made 
 
25 Floor of mouth 1a(-) R1b(36) L1b(471)R2a(-
) L2a.1(287) L2a.2(205) 
 
R1b  L1b  L2a.1 L2a.2 




Submental nodes only in vivo but remainder 
week fluorescence out of body 
No 




1a (134) R1b(280)) 
R2a(88) 
 
Stage 2 &3 
Differential signal highest from submental 
and right 1b 
Yes 
27 Oral tongue L2.1 L2.2 L3  
(gamma signal not legible) 








4.6.3 Additional benefit of ICG 
 
Table 4.2 shows that fluorescent signal was of additional benefit over and 
above conventional gamma imaging and met the secondary end points in ten 
cases (37%). In just one case the fluorescent signal was detected at stage 1 
imaging, but fluorescence mostly helped in localizing the sentinel nodes 
during deeper dissection (stage 2 imaging in 7 out of ten). In one case 
fluorescence detected a node that had been missed due to shine through 
effect (Case 13) and in another (Case 20) fluorescence guided the surgery 
because the gamma signal was unusually low. 
These data show that cases in which fluorescence helped in locating the node 
during surgery had a maximum luminance of  >200, these cases also showed 
the strongest gamma signal. To investigate this further univariate analysis 
was undertaken using Pearson’s correlation which showed a significant 
relationship (p=0.351). Scatter graph plot of gamma signal against luminance 
was constructed and simple regression analysis produced a correlation 
coefficient (R2) of 0.301.  When fluorescent nodes with gamma signal above 
1000 CPS were excluded (10/63, 16%), the R2 increased to 0.4 (Fig. 4.4). The 
true estimation of correlation may be limited by the boundaries of 16-bit grey 
scale of PNG images. 
 
4.7 Discussion  
 
We have demonstrated that all patients recruited in this study had tumour 
draining nodes identified using fluorescent labeling, and importantly that all 
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metastatic nodes were fluorescent. Furthermore, fluorescence provided 
additional benefit in over one-third of patients (37%), where nodes were not 
identified accurately on gamma detection alone.   Fluorescence guided SNB 
has the potential to improve intraoperative identification of sentinel nodes. By 
highlighting the position of nodes before they become visible under white light, 
operating time and tissue dissection could both be reduced. However, in open 
surgery the interference of ambient light can significantly interfere with intra 
operative appreciation of the signal thus adding a level of complexity to the 
use of this technique. Consideration was given to measuring the variability of 
the luminance between patients and the correlation with the intensity of the 
gamma signal in order to optimise the fluorescence signal. There is however, 
huge variability between the gamma signal intensity between patients 
presumably as a result of minor changes in injection technique, fluid 
compartment pressures and flow as well as tissue mobility and patient activity 
following injection. 
 
PVB was not used in this study because of the possibility that it would 
influence the operators appreciation of the fluorescent signal, thus we have no 
direct comparison of the performance of the blue dye. However, chapter three 
in this thesis describes a study using the same edibility criteria in which PVB 
was used as the optical tracer. These data showed that at least one blue 
lymph node was found in 41/50 patients (82%), but in six of the nineteen SNB 
positive cases the sentinel node was not blue.  Thus the sensitivity and FNR 
of PVB compared to ICG-99mTc-Nanocoll in these two studies is 32% vs. 0%, 
and 68% vs. 100%.  These figures would support the hypothesis that 
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fluorescence imaging by hybrid tracer is superior to optical imaging with PVB. 
However, we have also shown that there is no interference between the 
optical properties of the two dyes and they could be used together, although 
aside from the ability to see blue staining without special equipment it is 
difficult to see the advantage of PVB.  
Following these results, all further work was undertaken with the multimodal 




Chapter 5 Feasibility study for the development of sentinel node biopsy 
in salivary gland cancer 
 
5.1 Introduction  
 
Surgical management of early stage salivary gland malignancy, especially of 
the parotid gland, is complex with a variety of options for the both the primary 
site and the neck. A number of factors are considered prior to surgery; tumour 
size, histological subtype, and grade. These parameters give some indication 
about the propensity of the tumour to metastasise (occult metastasis are 
reported in 17% of low grade compared to 25% of high grade T1/2 parotid 
tumours[49]), but the pattern of lymphatic flow particularly in relation to intra- 
and periglandular nodes has not been well characterized. Thus the extent of 
both gland excision and cervical nodal resection is not clear. Such decisions 
have significant implication for the patient, for example the incidence of facial 
nerve paresis and paralysis following total parotidectomy compared to 
superficial lobectomy is 15%vs. 6.8% and 4.4% vs. 0.08%[192] respectively.  
Despite Ernest Gould’s 1960 report of sentinel node biopsy in salivary gland 
disease[63] there has been little advance in the topic over the last 50 years. 
Gould’s series consisted of 28 patients with parotid tumours in whom he sent 
the ‘angular node’ for frozen section analysis in order to decide if radical neck 
dissection was necessary. There were major limitations to his approach - 
Gould did not use any tracer to map the lymphatic flow but assumed the 
sentinel node would be the same in each case, and on final histopathology 20 
of the 28 cases were found to be benign tumours. In total three of the 
malignant cases had positive sentinel nodes. Despite these flaws his 
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approach served as the foundation for the development of SNB in other areas 
of the body but use in salivary malignancy stalled. 
In 2006 a case series of six patients with parotid carcinoma was 
reported[193]. The authors used 99mTc- labelled nanocolloid (50MBq) 
injected at 8 sites around the tumour. A sentinel node was identified on static 
lymphoscintigraphy within ten minutes of injection in all patients. All 
underwent SNB and concomitant level II-IV or V neck dissection depending 
upon the location of the sentinel node. Positive sentinel nodes were found in 
two patients and in one there was a false negative result. In this case the false 
negative result was attributed to an intra glandular metastatic node disrupting 
drainage. Lymphoscintigraphy images from this study show that the entire 
gland was hot (Figure 5.1), presumably due the large number of peri-tumoral 
injections given. This combined with the poor anatomical detail gleaned from 
static lymphoscintigraphy would certainly preclude the identification of intra- 




Figure 5.1 Right anterior oblique lymphoscintigram 10 minutes post injection in a patient with 
salivary duct carcinoma in the right parotid gland. 




Currently there is only one other publication that describes the use of SNB for 
primary salivary malignancy [194]. This case report describes use of SNB in a 
minor salivary gland tumour but the injection and imaging technique is not 
reported. 
There is clearly a need to be able to map the at-risk lymph nodes from 
salivary tumours both in the gland itself and the neck and tailor surgery 
accordingly. There is a real prospect that the extent of surgery can be 
reduced with a significant reduction in risk of surgical morbidity to the patient. 
Recent developments in sentinel node biopsy technology should allow 
improved localization of intra- and extraglandular nodes, allowing wider 
introduction of SNB in the management of salivary gland malignancy. 
 
5.2 Study aim  
This study aims to develop a modern SNB protocol for use in salivary gland 
malignancy. The developed protocol should be able to reliably identify both 
intra and extra-glandular lymphatic drainage. The result of the SNB will be 
validated against concurrent resection +/- nodal dissection, the extent of 
which has been decided by MDT consensus. In this validation study the SNB 
is not used to decide if neck dissection is necessary, in contrast to studies 
presented in chapters 3 and 4 of this thesis. 
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5.2.1 Endpoints and outcomes 
Salivary gland malignancies are rare tumours but this study aims to recruit the 
largest series of salivary patients to undergo SNB to date. For initial validation 
it was felt recruitment of ten patients would be feasible. 
The primary endpoint is identification of a sentinel node in all cases. 
Furthermore we would expect to be able to preoperatively identify intra- and 
periglandular sentinel nodes. 
The secondary endpoint is the false negative rate compared to concurrent 
nodal resection if undertaken.  
Information generated from this study should allow development of a protocol 
for a prospective multicentre study of SNB in salivary tumours. 
 
5.3 Study population and recruitment 
 
Ethical approval was obtained to recruit patients aged between 18 and 90 with 
newly diagnosed T1-T2 primary malignancy of salivary origin who were 
clinically staged N0 were approached for consent. Eligible patients presented 
with a lump and no associated complaint such as pain, numbness, tumour 
fixity or muscle weakness. Tumour diagnosis was confirmed by ultrasound 
fine needle aspiration cytology (FNAC) or punch biopsy and reviewed by a 
specialist head and neck pathologist. Clinical staging was undertaken by CT 




Exclusion criterion included patients who were unable to give informed 
consent, pregnant or breast-feeding, those whom had undergone any 
previous neck surgery or radiotherapy and anyone whom had a history of 
allergy to contrast agents. 
 
Patients were identified via the head and neck outpatient clinic and the weekly 
head and neck Multi Disciplinary Team Meeting (MDM) at Guys Hospital, 
London. Patients deemed appropriate for inclusion by MDM discussion were 
approached by the author during outpatient clinic consultations at least two 
weeks prior to undergoing surgery. It was at this time that the Patient 
Information Leaflet specifically explaining the role of sentinel node biopsy in 
salivary gland cancer was discussed and given to the patient (Appendix D – 
Patient information leaflet salivary cancer), in addition from 2014 patients 
were given the information leaflet about the multimodal tracer (Appendix C). 
 
All patients were given the opportunity for further discussion about the study 
either in person or by telephone at least twenty-four hours after receiving the 
initial information. If following this consultation, patients were interested in 
entering into the study they were asked to sign a consent form (Appendix B), 
Three copies of the consent form were completed: one for the patient; one for 







5.4 Materials and methods  
 
5.4.1 Radiotracer injection technique 
 
The initial protocol was based on the two-day technique successfully 
employed in oral squamous cell carcinoma, where four peritumoural injections 
of Tc99m-nanocoll are delivered at a dose of 40-80Mbq. From November 
2014 patients received the multimodal tracer ICG-Tc99m-Nanocoll.  
In the case of parotid tumours, the injections were given under ultrasound 
scan (USS) guidance. The overlying skin was prepared using a topical alcohol 
wipe (Steret, Medlock Medical) and allowed to dry. The tumour was reviewed 
by ultrasound imaging and the overlying skin was marked with pen at the 
intended site(s) of injection. A 23G (blue) needle 25mm in length was inserted 
under ultrasound visualisation so that the tip was lying within the gland 
adjacent to the tumour. The needle was connected to a pre-filled syringe 
containing the radiotracer in which an air bubble had been deliberately 
incorporated to ensure the tracer passed through the dead-space of the 
needle. Injection was undertaken under ultrasound visualisation as assurance 
that the needle position had not moved outside the gland. Pressure was 
placed on the area with a clean swab whilst the needle was withdrawn to 
prevent backflow of the tracer through the needle tract. 
 The imaging protocol was reviewed after every two cases by the research 
team to decide if improvements could be made. It was agreed that there 
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would be no increase in the tracer dose above 80MBq nor any additional 
scanning undertaken.  
5.4.2 Pre-operative imaging 
 
Immediately following injection of the radiotracer patients underwent static 
and dynamic lymphoscintigraphy followed by SPECT/CT as described in 
section 3.4.1. Lymph node position was marked on the neck using indelible 




All surgery was at performed by MM at Guys Hospital, London. Node position 
was confirmed in the operating theatre by fhSPECT scan using the 
DeclipseSPECT system (Surgiceye, GmBH Germany), there was no blinding 
in this study. If the multimodal tracer (ICG99mTc-Nanocoll) was used the near 
infrared imaging system was used when the surgeon needed help in locating 
the sentinel nodes during surgery. 
 
5.4.3.1 Parotid gland surgery 
 
Surgery was performed under general anaesthetic with nerve monitoring 
(NIM-Response® 3.0, Medtronic, USA). Procedures performed ranged from 
partial superficial to radical parotidectomy. If intraparotid sentinel nodes were 






5.4.3.2 Sublingual gland surgery 
 
Sublingual tumours were excised by wide excision the gland with removal of 
the lingual plate of the mandible en-bloc. The primary site was reconstructed 
with a free flap based on the radial artery of the non-dominant hand. 
 
5.4.3.3 Minor salivary gland surgery 
 
Minor gland tumours were excised by wide excision and reconstructed with 
free flap if required. 
 
5.4.3.4 Sentinel Node Biopsy surgery 
 
Sentinel node excision was undertaken alongside the planned surgery. When 
neck dissection was performed the sentinel node(s) were identified within the 
specimen ex-vivo by fhSPECT +/- fluorescence imaging. These sentinel 
nodes were marked with a stitched plastic ring and sent along with fhSPECT 
or fluorescence images to the pathologist to ensure that serial sectioning was 
performed on the correct nodes.  
 
If sentinel nodes were located in an area outside the planned operative field, 




If the sentinel nodes were located in regions that were difficult to access or 
located outside the usual surgical field then the nodes were not removed to 
avoid additional surgical morbidity to the patient. 
 
5.4.3.5 Neck dissection surgery 
 
The requirement and extent of neck dissection was decided during the MDM. 
If neck dissection was not recommended the patient was still considered 





Sentinel nodes underwent serial sectioning according to the protocol 
described in section (2.3). However at stage 3 anti-pan cytokeratin antibody 
(AE1/AE3) was supplemented by further immunostaining if indicated by the 
tumour subtype.  
If a node could not be macroscopically identified and dissected from within an 
area of tissue that was registering a high gamma signal ex-vivo then the entire 






5.5 Results  
 
Between 2012 and 2016 ten patients with primary salivary malignancy were 
recruited, of which eight were parotid tumours. The characteristics of the 
patient and tumours are shown in table 5.1. 
 
Table 5.1 Characteristics of patients/and tumours with primary salivary malignancy recruited 
































T2N0M0 Yes  
 

























































































































One patient was upstaged to T3 intraoperatively due to gross extension through the gland 
capsule. Frozen sections of the facial nerve were also sent intraoperatively showing extensive 
perinueral spread. All but one of the patients were offered post operative radiotherapy 
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(PORT).  In two cases this was because the tumour excision margins were close and in the 
remainder recommendation was based on histological tumour character or node positivity.  
 
5.5.1 Imaging results and protocol development 
 
All patients had sentinel nodes identified and in two cases these contained 
metastatic deposits. There were no false negative results. Table 5.2 describes 
the injection technique and imaging findings for each case. 
 
Table 5.2. Sentinel node biopsy findings in salivary gland tumours.  
LSG = lymphoscintigraphy, SPECT/CT = single-photon emission computed tomography, 
fhSPECT = freehand SPECT, ICG = Indocyanine green. Y/N indicated if the sentinel node 
was identified by the method 
Case Injection 
method 







1.Parotid 4 x 
peritum
oural 
SN1 RIIb N Y Y 12 N/A 195 Negative 
SN2 RIIb N N Y 20 N/A 20 Negative 
SN3 Periglandular 
(preauricular) 
N Y Y 8 N/A 135 Negative 


















SN1 LIIa Y Y Y 25 Yes 91 Positive 







SN1 LIII N Y Y 18 Yes 45 Negative 
SN2 LIb N Y Y 8 Yes 51 Negative 







SN1 R Ib Y Y Y 11 No 185 Positive 
SN2 L Ib N Y Y 8 No 349 Negative 
SN3 L Ib N Y Y 8 No 138 Negative 
SN4 LIb N Y Y 12 No 110 Negative 






N N Y 20 Very 
weak 
5 Negative 







The first two cases were injected by peritumoural method (4 separate 
injections) under ultrasound guidance. In both cases immediate 
lymphoscintigraphy showed that the entire gland was hot and no sentinel 
nodes could be identified. SPECT/CT proved more useful than LSG in the first 
case, identifying a level IIb sentinel node, which was confirmed the following 
day by preoperative fhSPECT and excised (Fig.5.1).  An additional node in 
the same neck level as well as a small node on the superio-posterior facial 
surface of the gland (pre-auricular periglandular) was identified by gamma 
count intraoperatively. 
 
In the second case however both LSG and SPECT/CT failed to show any 
drainage. At surgery the next day however, when the total gamma signal 
within the gland had decreased, fhSPECT was able to clearly identify an 
intraparotid hotspot (Fig 5.2).  This area was excised separately to the 
tumour, guided by a strong gamma signal, but it was not possible to identify a 
discrete lymph node within the surrounding parotid tissue (no optical tracer 




SN1 RIIa Y Y Y 19 Yes 74 Negative 






N N Y 10 No 27 Negative 














Y Y Y 10 Y 45 Negative 
SN2 LIIa Y Y Y 10 N 5 Negative 




N Y N Not sampled 
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was submitted for serial sectioning.  Within the specimen two lymph nodes 
were found measuring just 2mm and 4mm in maximum dimension, both 




A. Surface marking of peritumoural injection. 
B. Ultrasound scan showing injection of tracer around the tumour within the parotid 
gland. 
C. Rendered reconstruction of SPECT/CT scan showing sentinel node in level IIb 
D. Intraoperative fhSPECT locating level IIb nodes. 
 



















Figure 5.3. (A-D) Sentinel node biopsy parotid tumour case 2. 
 
 
Following review of these cases it was decided that the very high signal seen 
within the entirety of the gland immediately after injection was likely to affect 
the ability to identify sentinel nodes on lymphoscintigraphy especially 
intraglandular sentinel nodes. Thus a change in protocol was instituted to see 
if reliable drainage could be found by single intra-tumoural injection.  The total 
tracer dose was injected under ultrasound guidance with the needle placed 
into the centre of the tumour. This change in protocol allowed first 
identification of a sentinel node by lymphoscintigraphy (Fig 5.3). In addition 




A. Lateral and  
B. Anterior-posterior (AP) rendered SPECT/CT image showing complete filling of the parotid gland. 
C. Lateral (left) and AP (right) lymphoscintigraphy showing complete filling of the gland and no drainage. 
D. Pre-operative freehand SPECT (fhSPECT) one day post injection showing tumour (inferior) and 
intraparotid sentinel node (superior, contained two small lymph nodes) 
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sentinel node and the procedure was more comfortable for the patient. 




Figure 5.4 Intratumoral injection of Tc99m-Nanocoll, showing drainage to a level IIa lymph 
node on lymphoscintigraphy(left) and SPECT/CT (right) 
 
 
5.5.2  Parotid drainage 
 
Fifiteen sentinel nodes were located in the eight patients with parotid tumours.  
Seven of the sentinel nodes were found in a peri- or intraglandular location.  
Periglandular nodes were found in the pre-auricular tissue overlying the gland 
capsule. All the intraglandular nodes were within the superficial lobe of the 





Figure 5.5 Drainage pattern from parotid tumours 
 
Lymphoscintigraphy performed poorly in localising sentinel nodes from parotid 
tumours, identifying just three of fifteen nodes. SPECT/CT found eight of 
fifteen nodes pre-operatively but neither SPECT/CT nor LSG were able to 
show peri- or intraglandular nodes. Fluorescence was used in four patients 
and fluorescent nodes were identified in all these cases although in half the 
signal was low and the fluorescence was only appreciated once the tissue 
had been excised. Freehand SPECT seemed performed well, however it had 
the advantage that it was the only imaging modality used on day two of the 
protocol, and therefore shine through effect was reduced. It is possible that 
SPECT/CT or LSG performed on the second day would perform better than 
on day one  
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Just one patient had metastatic disease; the positive node was detected by 
SNB at level IIa. In this case no additional intraparotid metastatic nodes were 
found during routine histopathology. 
 
5.5.3 Sublingual gland drainage 
 
Two patients with sublingual tumours underwent SNB. In both cases injection 
was delivered under direct vision into palpable tumours of the floor of mouth. 
Level Ib was the most common location for sentinel nodes (figure 5.6). One 










5.5.4 Minor salivary gland drainage 
 
Just one patient with a minor salivary gland tumour was included in this study. 
The tumour was located in the left posterior palate and was injection under 
direct vision. Sentinel nodes were localised to left post facial and 
parapharyngeal as well as bilateral level IIa. Figure 5.7 shows the location of 
the parapharyngeal node on SPECT/CT. It was not possible to locate this 
node by fhSPECT because of limitations in obtaining multidimensional 
gamma counts, this was the only node in the series that fhSPECT failed to 
localize. This parapharyngeal node was outside the normal field of dissection 






Figure 5.7 SPECT/CT of left palate tumour showing injection site anteriorly and left 








5.6 Pathology Results 
All ten patients were correctly diagnosed with salivary malignancy by pre-
operative fine needle aspiration but the histopathological subtype was 
changed by definitive pathology in five cases, reflecting the difficulty of 
characterising these tumours by cellular pathology. Two metastatic sentinel 
nodes were found with no additional metastatic nodes in the nodal dissection. 
The immunostain used in stage three of the serial sectioning protocol (chapter 
2), are shown in table 5.4 




Immunostain Imunohistochemical target 
Acinic cell AE1/AE3 “Pancytokeratin” marker for 
CK types  
1 - 8, 10, 14 - 16 and 19 
Adenoid cystic CK-7 Cytokeratin 7 
Epithelial myoepithelial P63 “Myoepithelial marker “ 
Mucoepidermoid carcinoma AE1/AE3 “Pancytokeratin” marker for 
CK types  
1 - 8, 10, 14 - 16 and 19 
 
Seven patients had contiguous neck dissection with an average of 23 nodes 
removed per patient (range 15-66). These specimens were assessed by 








These data show that sentinel node biopsy is a viable procedure in salivary 
gland malignancy. The study aim of 100% sentinel node identification rate as 
well as localisation of intra-and periglandular lymph nodes was achieved.  
The advantage is the introduction of personalised care with management 
tailored to the individual.  This is important particularly in parotid cancer for 
there is the prospect that total parotidectomy with its attendant risk of injury to 
the facial nerve can be replaced with a more minimally invasive procedure. 
Futhermore sentinel node biopsy can direct the need and extent of neck 
dissection, as with oral cancer.  
However, this is early work and represents the largest cohort of salivary gland 
cancer patients to undergo SNB to date. Further validation studies are 
required, and due to the rarity of these cancers this will need mutlicentre if not 
multinational collaboration.  This work has refined a protocol that can be 
immediately transferred into subsequent phase II/III trials. 
Further aim of this work is to use the refinements test here to extend the role 
of SNB into other tumour groups. 
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Chapter 6 First experiences in extending the role of SNB in the head and 




This thesis aimed to improve the SNB technique and extend its role. Two new 
technologies have been evaluated with good results, and a new tumour group 
investigated. To finish this work and open up new channels of research, these 
techniques were applied to more challenging tumours. For the first time in the 
UK SNB in thyroid, laryngeal and prostatic cancer have been performed. This 








Sentinel node biopsy has the potential to accurately stage the neck in thyroid 
tumours, thereby ending the uncertainty surgeons currently face in deciding 
the extent of neck dissection required. The test has promise with meta-
analysis of 24 studies showing the technique found an occult metastasis rate 
of 42.9% in differentiated thyroid tumours[195]. The false negative rate was 0-
16% depending upon the protocol used, and the best method of performing 
SNB is not agreed. 
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Wiseman et al. reviewed the protocol of ten published studies[196]. Seven out 
of ten studies used blue dye alone whilst the other three used radiotracer +/- 
blue dye. It was noted that the blue dye had a propensity to stain the 
parathyroid glands, which are similar in appearance to nodes and in some 
cases leading to their inadvertent removal and subsequent hypocalcaemia in 
12%. This result is not surprising if you consider that injection of blue dye is a 
well-known technique for the intraoperative localisation of aberrant 
parathyroid glands[197-199]. 
Le et al. performed a prospective study of SNB in 39 patients with thyroid 
cancer[200].  Sentinel nodes could be detected ten minutes after 
intratumoural injection with 20MBq of radiotracer in 38 cases. The sensitivity 
of SNB when compared to the neck dissection specimen was 88%. The 
incidence of permanent hypoparathyroidism was 3.1% suggesting that the 
radiotracer is more accurate in differentiating lymph nodes from parathyroid 
glands than blue dye alone.  
The use of SPECT/CT in these cases seems to improve the detection of 
nodes in the lateral compartment of the neck, showing drainage in up to 50% 
of patients in two recent studies[201, 202].  
The aim of this pilot study was to trial the use of multimodal tracer ICG-Tc99m 
Nanocoll and fhSPECT imaging in thyroid cancer SNB in order to develop 
techniques that could be applied to a validation study. 
 




Ethical approval was granted to recruit patients with differentiated thyroid 
cancer who were due to undergo total or partial thyroidectomy with removal of 
the central or lateral lymph nodes. Patients were offered SNB alongside their 
surgery (patient information sheet – Appendix E). 
 Up to 24 hours prior to surgery consented patients underwent single intra-
tumoural ultrasound guided injection of 10-40Mbq ICG-99mTc-Nanocoll 
followed by lymphoscintigraphy and SPECT/CT as described in section 3.4.1. 
If possible immediate fhSPECT was undertaken prior to nuclear medicine 
imaging.  
During surgery the sentinel nodes were identified using a combination of 
fhSPECT (declipseSPECT) and NIR fluorescence imaging (section 4.5.6). 
The tumour excision and planned nodal resection completed the operation. 




Four patients with FNA proven differentiated thyroid tumours undertook SNB 
alongside standard surgery. Three had a two-day protocol and received 
40MBq ICG-99mTc-Nanocoll with one undergoing same day injection at a dose 
of 14MBq.  Imaging and pathology results are reported in table 6.1. 
Two patients underwent immediate fhSPECT which yielded no useful results. 
SPECT/CT did identify sentinel nodes in all patients, although unexpectedly 
this did not tally with the intraoperatively identified nodes in all cases. In two 
cases hot and fluorescent sentinel nodes were identified lying on the surface 
of the thyroid gland (periglandular node example shown in image 6.2) close to 
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the injection site. Neither had been found on pre-operative imaging and in one 
case the node contained a metastatic deposit.  
 













































Not done Left level 
IV node 






























Left level IIa Periglandular 
(negative) 
Level IIa (negative) 
Bilateral neck 
dissection, positive 
node level IV 
 
A total of nine sentinel nodes were excised, two of which were positive for 
metastasis. In both cases additional positive nodes were removed during 
concurrent neck dissection. Two cases with negative sentinel nodes were 
found to have multiple positive nodes in the neck dissection, giving a false 






Figure 6.33. Lymphoscintigraphy (left) and SPECT/CT images (right) from injection of 40MBq 
ICG-99mTc-Nanocoll into tumour of the left lobe of thyroid. 





Figure 6.34. Intraoperative white light/NIR imaging showing periglandular fluorescent node 







Figure 6.1. Excised specimen  (right hemithryroidectomy, right lateral neck dissection, left 
level IV sentinel node and intrathoracic metastatic deposit orientated anatomically. 
 
 
All patients received post–operative radioiodine therapy and were alive and 
free of disease at latest follow up. No patients had permanent hypocalcaemia.  
 
6.2.4 Discussion - sentinel node biopsy in thyroid cancer 
 
These preliminary results show that more refinement is needed before SNB 
can be applied to thyroid cancer. In this small series the drainage was fickle 
and appeared to change between the nuclear medicine scans and surgery. 
The reliability of the technique may have been affected by the patient 
selection. SNB is a test for patients that are clinically N0, but in this study 
validation against concurrent nodal resection was planned. Surgeons were 
reluctant to recruit patients without at least borderline suspicion of involved 
nodes. All four recruited patients had radiologically suspicious nodes pre-
operatively but equivocal FNA.  In the final pathology all patients has multiple 
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metastatic nodes in the neck.  Sentinel nodes were found in every case but 
were falsely negative in two patients, both had multiple highly cystic 
metastasis. It is possible that the metastatic process being well underway 
undermined the validity of the SNB test. 
Our imaging did show clearly in two patients a node on the surface of the 
gland (Figure 6.2) close to the injection site, which has not been previously 
reported in the sentinel node literature. In one patient this node contained 
metastasis but in the other the sentinel node was falsely negative suggesting 
that it is not a constant first echelon node, but certainly this warrants further 
attention in any future work. 
 




The usefulness of SNB in laryngeal tumours is extremely pertinent as there is 
little consensus on the management of the N0 neck[203, 204]. Because the 
larynx is a midline anatomical structure some surgeons elect to clear nodes 
from both sides of the neck even if the tumours is lateralised[58, 203, 205]. 
Some however will clear just one side, but only for the smallest of tumours 
because laryngeal cancers appear to have the highest occult metastasis rate 
(over 30%) out of all the head and neck tumours[206]. SNB has two major 
advantages at this site. Firstly, advances in surgical techniques now allow for 
some primary laryngeal tumours to be resected via a minimally invasive 
transoral approach (e.g. TORS, Trans Oral Robotic Surgery)[207, 208], but 
the advantage of minimal surgery is lost where concomitant neck dissection 
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increases the surgical morbidity. Secondly uni- or bilateral elective neck 
dissection is common with advanced laryngeal tumours or those failed cases 
first treated by chemo-radiotherapy[209, 210]. In such circumstances the 
potential reduction in morbidity if neck dissection can be avoided are even 
greater than in the virgin neck[209]. 
There are published data on the feasibility of SNB in laryngeal tumours, which 
show excellent sensitivity of the technique with both open or transoral 
resection of the tumour. Lawson et al [211]published a prospective case 
series of 29 patients with supraglottic tumours staged by SNB and 
concomitant neck dissection. Radiolabelled nanocolloid was injected 
peripherally and also into the tumour under direct vision at the start of surgery. 
The tracer was allowed a short time to flow into the lymphatic system before 
the primary tumour was resected. This reduced the intense radioactive shine 
from the primary tumour that could obscure the much weaker accumulation of 
the tracer in the SNs of the neck.  The sentinel nodes were then located via 
hand held gamma probe and excised before the neck dissection was under 
taken. When compared to the completed neck dissections the sensitivity of 
SNB was 100%, specificity was 78% (there was one further positive node 
found in one patient although this case also had +ve SNB) and negative 
predictive value 100%. 
A retrospective analysis of 20 patients with laryngopharyngeal tumours staged 
by SNB as part of a larger case series of combined head and neck 
tumours[212] also showed that in 100% of patients the SNs were identifiable. 
When the SN analysis (by either frozen section of H&E staining) was 
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compared to the neck dissection or subsequent nodal recurrence, the false 
negative rate was 6.9%. 
 
The technique was further expanded to include patients that had undergone 
previous treatment (surgery/radiotherapy) for a neck malignancy. In 2013 
Flach et al.[213] reported their findings in 13 patients with primary laryngeal 
tumours compared to 6 patients with previously treated head and neck 
squamous cell carcinoma. They found that sentinel nodes were identifiable in 
92.3% of primary tumour patients compared to just 16.7% of those that had 
been previously treated. The sensitivity and NPV were 80% and 87.5% 
respectively. 
Data would suggest that SNB in primary laryngeal tumours is a reliable 
technique. There is however a range of sensitivity reported (80-100%) and we 
believe that a combination of intraoperative fhSPECT and multimodal tracer 





Ethical permission was granted to recruit patients with laryngeal cancer who 
were undergoing partial or total laryngectomy alongside unilateral or bilateral 
elective nodal clearance. Eligible patients were offered SNB alongside their 
surgery (Appendix F –PIS Laryngeal cancer).  
As these tumours are not amenable to injection in the outpatient setting the 
tracer was injected peritumourally by laryngoscopy at the beginning of the 
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surgical procedure. No nuclear medicine scans were undertaken and the 
sentinel nodes were solely located by intraoperative fhSPECT and NIR 




One patient with a midline cT4aN0M0 laryngeal SCC consented to undergo 
SNB alongside primary surgical management by laryngectomy and bilateral 
neck dissection. A total of 40 MBq of ICG-99mTc-Nanocoll was injected in four 
divided doses (Figure 6.4a). Immediate fhSPECT scan showed drainage to 
two left sided sentinel nodes (Figure 6.4 b, left IIa and III). The specimen was 
resected en-bloc and re-scanned ex-vivo by fhSPECT  (Figure 6.4c) and NIR 
imaging showing the same hotspots.  
   
 
Figure 6.36. UK first Laryngeal SNB. 
A. Injection of tracer during laryngoscopy.  
B. B immediate fhSPECT scan showing two hotspots in the left neck (shown by two red 
arrows).  
C. C Laryngectomy and bilateral neck dissection specimen by fhSPECT showing two 
hot spots in the left neck. 
 
Final staging was pT4aN1M0 with a single positive node found in the right 
neck, thus the SNB was falsely negative. This patient went on to have post-
operative chemoradiotherapy and was alive and disease free at last follow up. 
 





Here we present initial experience with SNB in laryngeal cancer.  For the first 
time sentinel node imaging was undertaken solely in theatre. In this instance 
the tracer did not flow to the sentinel node. This was a large tumour and it was 
difficult to identify the margins to target the peritumoural injections. This may 
have resulted in uneven distribution of the tracer and non-representative 
drainage. It is not clear if it necessary to inject the tracer peritumourally, and it 
would be advantageous if reliable drainage could be traced following single 
intratumoural injection. Further work is needed to validate this proposed 
technique.  
What has been shown in this case is that tumour drainage can be mapped in 
real time intraoperatively by fhSPECT.  This encouraging finding supports the 
move of the procedure from the nuclear medicine department and into the 
theatre, opening up the potential applications of SNB. 
 
6.4 Sentinel node biopsy in Prostate cancer 
 
In order to challenge the reliability of the techniques we have explored, and to 
test the general applicability to new tumour groups we found a non- head and 




The European Association of Urology guidelines[214] suggest that pelvic 
lymph node dissection (PLND) should be undertaken alongside radical 
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prostatectomy if the risk of metastasis is >7%.  Pelvic nodal dissection 
(PLND) remains the gold standard staging tool but increases surgical time 
and morbidity [215, 216].  Furthermore there is debate about the extent of the 
nodal dissection.  The dilemma stands between a higher false negative rate 
with limited PLND (where up to 50% of metastasis would be missed[217, 
218]) compared to an increased morbidity from extended PLND[215]. It is into 
this gap that sentinel lymph node biopsy neatly fits by directing the surgeon 
just to the at-risk lymph nodes, and this is reflected in the fact that there are 
good published data series of over 2000 prostate cancer patients that have 
been staged by SNB[219, 220] 
 
 
6.4.2 Method   
 
Ethical approval was obtained prior to recruiting a high-risk patient (Gleason 
3+3) with informed consent. The patient was offered SNB alongside robotic 
assisted prostatectomy and pelvic lymph node dissection. On the morning of 
surgery the patient underwent transanal ultrasound guided injection of 
radiotracer. 100MBq of Tc99m labelled nanocolloid was delivered into each 
lobe of the prostate. The patient underwent static as well as dynamic 
lymphoscintigraphy followed by SPECT/CT. During surgery sentinel nodes 
were identified by fhSPECT, dissected from the rest of the lymph node 
specimen and sent for separate histopathological assessment according to a 




6.4.3 Results  
 
Two sentinel nodes were identified on lymphoscintigraphy within 20 minutes 
of tracer injection (Figure 6.5a). Sentinel nodes were located in the left 
obdurator and internal iliac lymph nodes. Second echelon nodes were seen in 
the pre-sacral and para-aortic region (Figure 6.5b and 6.5c).  
 
   
 
Figure 6.5.  
A: Planar lymphoscintigraphy anterior view showing injection site with two sentinel nodes 
superiorly and a small amount of tracer in the bladder below. 
B SPECT/CT showing left oburator node 
C Internal iliac node. 
 
Sentinel nodes were subsequently identified within the lymph node resected 
lymph node packets and imaged ex-vivo by fhSPCT (Figure 6.6). Pathological 
examination of the sentinel nodes revealed no metastasis and the rest of the 
nodal resection was also pN0. There were no complications associated with 
the procedure. 
 





Figure 6.6. A. Pelvic node dissection packets divided by anatomical region, sentinel nodes 
were dissected separately and shown in the two squared outlines. B same tissue viewed by 
fhSPECT showing both sentinel nodes have radioactivity (blue). 




Our technique demonstrates the feasibility of providing SNB for patients with 
high-risk disease. Draining sentinel nodes were identified within a timely 
fashion, and with validation could allow for one step intraoperative 
radionuclide injection and sentinel node identification.  
Although this is the first reported case in the UK the technique is well 
described in the literature. In 2009 Holl et al[219] published a validation study 
of 2020 patients that underwent SNB and showed an SN detection rate of 
98% and a false negative rate of just 6%.  Sixty-nine percent of men in this 
trial had SNB as the sole staging tool, and in 7.2% positive SNs were found 
outside the field that would normally be dissected even for ePLND. In 2013 
Winter et al. [220]published their series on 1229 patients that underwent SNB 
as part of an open radical prostatectomy. They compared the detection of 
metastatic nodes by SNB to expected levels based on the EAU predictive 
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nomogram. They found that 15% of metastasis would have been missed if 
treatment had been given according to the EAU guidelines. The SNB 
technique has been validated in robot assisted laparoscopic prostatectomy 
(RALP)[221] and is complimentary to this minimally invasive and patient 
tailored surgical approach. 
 
6.5 Chapter Summary  
 
The cases discussed in this chapter represent the first step in translating the 
validated SNB technique into new areas. These results highlight some of the 
technical difficulties that will be encountered in establishing SNB in new 
tumour groups. They also bolster evidence that SNB can be tweaked to suit 
the physiology and anatomy of the tumour. Once the optimum protocol has 
been elucidated for each tumour group, the technique can be more widely 
established. 





Chapter 7 Final conclusions and plan for future work 
 
This body of work has delved into a number of new areas in sentinel node 
biopsy in head and neck cancer. Traditional sentinel node imaging 
(lymphoscintigraphy and SPECT/CT) has been directly tested against 
intraoperative imaging by freehandSPECT, the first time that this has been done 
in any tumour group. The intraoperative system worked well, with an excellent 
false negative rate of just 5.3%.  This study showed that lymphoscintigraphy 
performs particularly poorly in sentinel node detection, and SPECT/CT although 
more accurate than LSG does not appear to give an advantage over fhSPECT. 
This has huge implications for the future standard for SNB. If the imaging can 
be transferred to theatre then much of the cost and time associated with the 
procedure can be reduced. The culmination of this project did look at one case 
where solely intraoperative imaging was used. In this patient with laryngeal 
cancer sentinel nodes were identified but proved to be falsely negative. This 
was probably because of difficulty in accurately injecting the tracer.  
Furthermore our data looking at the accuracy of immediate fhSPECT in oral 
cancer showed that the optimum timing of injection and scanning are not yet 
fully understood. The next area of work will be to look at refining the injection 
and scanning technique in patients without nuclear medicine scans. Ideally 
deep and difficult to access tumours could be mapped using a single 
intratumoural injection as we demonstrated with salivary gland SNB. An ideal 
model would be tonsil tumours where the patient could undergo injection on two 
separate occasions - one by peritumoural and one by intratumoural method. 
Scans (SPECT/CT and fhSPCET) should be taken both times to see if the 
drainage by both methods is identical. To assess the optimum imaging window 
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serial fhSPECT scans could be undertaken. For fhSPECT to be most useful, 
accurate mapping would need to be possible within 10 minutes of injection in 
order to minimise disruption in the surgical flow, whether this is possible is yet to 
be confirmed. 
Multimodal detection of sentinel nodes using ICG-99mTc-Nanocoll was 
successfully performed. In this series of oral cancer patients the fluorescence 
aided detection in over one-third of cases. The specificity of ICG was vastly 
superior to control data looking at reliability of patent blue dye (PVB).  Thus 
confirming that PVB can be dispensed with as an optical tracer. Most of the 
fluorescent nodes however were discovered at a later stage of the surgery, 
once a significant amount of tissue dissection had been performed. Ideally the 
fluorescence would be visible through the skin, which was reported in other 
case series. This may be due to patient selection, tracer formulation and 
imaging protocol/equipment. There are a number of commercially available 
fluorescence imaging systems that could be investigated in the future. Ideally 
the development of multimodal probe that could incorporate gamma and 
fluoresence detection would be advantageous. 
Salivary tumours are a new area for SNB, particularly with these improved 
methods. Here we have shown that SNB is feasible and reliable. This protocol 
will pave the way for future work in salivary malignancy in the form of 
prospective multicentre studies. 
Our finding have been extrapolated to other new tumour groups – thryoid, 
layrnx and prostate with promising initial results. 
On critical reflection this body of work has fulfilled its aim to investigate novel 
techniques in sentinel node biopsy and to provide evidence to support their 
incorporation into day-to-day clinical practice. The hope is that following this 
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work, the possibilities for SNB have been truly expanded meaning that many 
patients around the world will be able to benefit from personalised staging in the 
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Appendix A. Patient information sheet 
 
 
Short title of project  
 
New Intra Operative Sentinel Node Biopsy Procedure (Mouth) 
 
Full title 
Adaption and validation of a 3D navigation system that tracks the intraoperative 




The commonest way cancer cells spread are by tiny lymphatic channels that drain fluid from the cancer to 
lymph nodes around the tumour. The lymph nodes act as a form of filter and catch the tumour cells. The 
spread is not random but goes first to a single node then later on to other nodes. This first node is called 
the SENTINEL NODE. If the SENTINEL NODE is free of tumour you can safely assume all the other 
surrounding lymph nodes are also free of tumour.   The spread of cancer cells to the local lymph nodes is 
so important that it is customary when removing the main cancer to remove the surrounding lymph nodes 
at the same time. This can greatly increase the magnitude of surgery and the side effects that come from 
this surgery.  
 
This situation has now changed and in some tumours (breast and skin), lymph nodes are sampled for 
cancer rather than all the lymph nodes being removed. At the moment this type of surgery is limited to 
certain cancers, as the technology had not been developed for other types of cancer. We believe there is a 
reliable technique to identify the SENTINEL NODE in the type of cancer that you have been diagnosed 
with.  
 
We now have at Guy’s an intra operative 3D tracking system that will allow us to identify the SENTINEL 
NODE in the operating theatre. The node can then be removed and checked for cancer.  
At present the accepted standard of care in the UK for your disease is to remove the mouth tumour and 
the surrounding lymph nodes. But at Guy’s Head and Neck cancer centre we lead a European Trial where 
is was established that the sentinel node biopsy was safe when used in the management of early mouth 
cancer and in addition saved about 75% of patients a neck dissection. This is not going to change; you are 
going to be offered the choice of adopting the conventional UK approach (tumour removal and neck 
dissection ) or the current standard of care at Guy’s ( tumour removal and sentinel node biopsy). Once 
you have made your choice, what we propose is at the time of your surgery we identify the SENTINEL 
NODE draining your tumour by using both conventional imaging by camera and CT scan before surgery 
and again by the new 3D sentinel node imaging system during the operation. We use the same radiotracer 
as is used in breast cancer, which has been safely given to hundreds of thousands of patients. This is 
injected around the tumour just before surgery. The tracer will then flow to the SENTINEL NODE . We 
will check where the sentinel nodes are by using our normal test which involves a gamma camera to 
watch for the appearance of radioactive tracer as it flows in the sentinel node and then perform a 
SPECTCT (the camera will move around your body in the nuclear medicine department) which will 
ensure that the site of the sentinel node is found prior to surgery. We can detect the sentinel node at 
surgery using our 3D navigation system. Your SENTINEL NODE will then be removed before carrying 
on with the standard operation.  
 
 
Approximately 150 patients with a similar disease as you will be involved in this study.  Before you 
decide to participate, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the information carefully and discuss it with friends, relatives and your 
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GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. This leaflet will explain the procedure, tell you how it 
is performed and will answer some of the questions you may have. 
 
 
What is the purpose of the Study? 
The aim of the study is to see if a new 3d Navigation technique can help us to reliably identify the 
SENTINEL NODE in people with early cancers.  
 
Why Have I been chosen? 
You have been recently diagnosed with an early mouth cancer and are due to undergo surgery for this 
disease. Your surgery will entail removal of the tumour and in addition either all the lymph nodes around 
the tumour or just the sentinel nodes depending on which approach you choose. The surgery you receive 
will not be changed, however during the operation we would like to identify the SENTINEL NODE using 
the technology we have described above. We are asking only suitable patients with early cancer to take 
part in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be asked to sign 
a consent form. If you do decide to take part you are still free to withdraw at any time and without giving 
a reason. If you decide not to take part it will in no way affect the care you receive. 
 
What will happen to me if I take part? 
The injection of a very low dose of  radiotracer around the tumour will be undertaken after the mouth has 
been numbed with anaesthetic spray. The amount of radioactivity from this tracer is lower than is used in 
routine CT scans and is completely removed by the body. Less than 1ml of tracer is injected. You will 
then be laid on a bed and a camera will watch the spread of tracer from your mouth into your neck. You 
do not have to do anything. Once we know in which direction the tracer is draining we can get a much 
more accurate image by using a SPECT/CT. Again there is nothing for you to do but lie on a bed while 
the picture is captured.  
 
 
 You will then move to the operating theatre where you will be put to sleep in the normal way. When you 
are asleep some blue dye is injected around the tumour once again and this also travels to the sentinel 
node and helps the surgeon identify the right sentinel node which ideally is both radioactive and blue. In 
addition we will use the 3D tracking system before we start surgery to identify the position of the sentinel 
node with a third imaging system. All sentinel nodes identified will be removed for carefully examined by 
our pathologists. The rest of your operation will be completed in the standard way. The sentinel node 
biopsy will not affect the success of your operation in any way. 
 
What do I have to do? 
You do not need to do anything special as part of this study. You will recover from your operation in the 
normal way. 
 
What is the procedure that is being tested? 
The procedure is a 3d Navigation tool called Surgiceye, which allows us to visualise the SENTINEL 
NODE through the skin. It can be used alongside other equipment that may be used during your 
operation. Surgiceye has been validated for use in other parts of the world but we are the first NHS 
Hospital in the UK to be able to use it. 
 
 
What are the side effects of taking part? 
Sentinel node biopsy has been performed for several years, and there are very few side effects associated 
with it. These are: 
1. Blue dye may stain the urine. We inject blue dye into the tissues around your tumour, and since the dye 
is removed by your kidneys, for about one day after your operation, your urine will be stained blue. 
2. Hypersensitivity. There have been a few reports of people being allergic to the blue dye and very 
occasionally to the nanocoll. This is more common in people who suffer allergies to other things. If you 
tend to suffer from allergies, please let us know. 
 
3. There is radiation used during the procedure. The dose is low and equivalent to 2 months of natural 
background radiation or a lifetime cancer risk of 1 in 50,000 (compare this to a natural cancer risk of 1 in 





What are the possible disadvantages and risks of taking part? 
Sentinel node biopsy has been shown to be very safe and has a very low complication rate. Because we 
are using a new technique the operation may take slightly longer but this will only be a short time 
compared to the total surgery. If the SENTINEL NODE is not found within a short time we will not 
continue to look for it but we will proceed directly with your planned operation. 
 
What are the possible benefits to taking part? 
If you agree to take part in this research project it may not help you directly. You are planned to receive 
the current standard of care for your tumour.  
 
We expect most of the SENTINEL NODES will be found in the area that your surgeon already plans to 
operate in, however we know from some published data that about 10% of the time the SENTINEL 
NODES are found in another area of the neck. If this happens to you then you may have another small 
incision on the side of the neck to remove the SENTINEL NODE. The benefit of this is that we can detect 
cancer spread, which would have been missed by the standard treatment.  
 
Because the cure rate for your type of cancer is extremely good our overall aim is to eventually reduce the 
amount of surgery patients such as yourself will need. We are trying to refine our treatment regimes so 
that patients will get exactly the treatment needed to eradicate the cancer and nothing more or less. In that 
respect your participation in this study will be helping future generations of cancer sufferers 
 
What happens when the research study stops? 
After you have undergone the surgery you will get your results in the normal way. This will be to decide 
about further treatment for the cancer (e.g radiotherapy treatment). All cancer patients are followed-up in 
the outpatient clinic for a few years. Your participation in this study will not change the treatment you 
receive nor the follow up in clinic. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to the results of the research study? 
We intend to publish our results in the medical literature and if we do so your anonymity will be 
maintained throughout.  
 
Who is organising and funding the research? 
The research is being undertaken Guys Hospital and its affiliated centres as part of its Academic Health 
Sciences Centre status. 
 
Who has reviewed the study? 
 
The study protocol has been reviewed and approved by the local research ethics committee, which is 
made up of both doctors and lay members. 
 
What if there is a problem? 
  
Questions and Concerns – If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. Please contact: Principle 
Investigator Professor Mark McGurk: mark.mcgurk@kcl.ac.uk : 02071884348 
 
Complaints – If you have a complaint, you should talk to your research doctor who will do their best to 
answer your questions. If you remain unhappy, you may be able to make a formal complaint through the 
NHS complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient Advisory 
Liaison Service (PALS) on 0207 1888188, address: PALS, KIC, Ground floor, north wing, St Thomas’ 
Hospital, Westminster Bridge Road, London, SE1 7EH . 
 
Harm – This trial is co-sponsored by King’s College London and Guy’s and St Thomas’ NHS Foundation 
Trust. The sponsors will at all times maintain adequate insurance in relation to the study 
independently. Kings College London, through its own professional indemnity (Clinical Trials) and no 
fault compensation and the Trust having a duty of care to patients via NHS indemnity cover, in respect of 
179 
 





If you or your family have any questions or require any further information, please contact  
Professor McGurk 02071884348 
 







Appendix B. Consent Form 
 
Study number:________ 




Validation of 3D navigation during intra operative Sentinel Node Biopsy in respect to head and neck, 
urological, breast and gynaecological cancers. An Observational Guy’s Study 
 
1. I confirm that I have read and understood the information sheet dated 14/9/12 Version 2.1 for the 
above study and have had the opportunity to ask questions.  
 
2. I understand that my participation is entirely voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
3. I understand that sections of any medical notes may be looked at by responsible individuals 
undertaking and supervising the study where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
4. I consent to all the specimens removed at surgery to be used by the teams involved in the study 
for research on sentinel nodes and other related genetic/laboratory investigations.   
 
5. I consent to take part in the study.   
 
 
_________________________     ____________        ________________________ 
Name of Patient   Date   Signature 
 
 
_________________________     ____________        ________________________ 
Name of Researcher   Date   Signature 
 
 
_________________________     ____________        ________________________ 
Name of person taking consent  Date   Signature 




Appendix C. Patient information sheet multimodal tracer 
 
 
PATIENT INFORMATION SHEET 
 
New Intra Operative Sentinel Node Biopsy Procedure 
 
Adaption of a tracer for identification of sentinel lymph nodes in early cancer 
 
The commonest way cancer cells spread are by tiny lymphatic channels that drain fluid from the cancer to 
lymph nodes around the tumour. The lymph nodes act as a form of filter and catch the tumour cells. The 
spread is not random but goes first to a single node then later on to other nodes. This first node is called 
the SENTINEL NODE. If the SENTINEL NODE is free of tumour you can safely assume all the other 
surrounding lymph nodes are also free of tumour.  
 
At Guys and St Thomas’ NHS trust we are introducing an innovative type of tracer to identify the 
SENTINEL NODE. This tracer can be used to highlight the SENTINEL NODE which can then be 
removed during your operation. 
 
The new tracer is a mixture of a standard radiotracer (which is routinely used for sentinel node biopsy) 
and a fluorescent green dye (called indocyanine green, ICG). The radiotracer has been safely given to 
hundreds of thousands of patients with only a tiny risk of an allergic reaction to the protein (nanocoll) 
injected. The new technique we are introducing is the addition of fluorescent green dye to the tracer, 
which means that the SENTINEL NODE will glow green under certain lights. This will make it easier to 
find the correct SENTINEL NODE at surgery.  
 
The combination of fluorescent green dye and radiotracer has been used in this country in a very small 
number of cases only, but it has been used in other parts of Europe in over 500 patients and the results 
have been good. The fluorescent dye has been used for other medical conditions (such as assessment of 
blood flow through parts of the body) since the 1950s and has a very good safety record. The mixture of 
radiotracer and green dye has been carefully examined by chemists in the laboratory as well as in animal 
studies to make sure that there are no undesirable effects when these two compounds are given together. 
 
The addition of the fluorescent dye to the tracer does not alter the operation you will be having, but 
because this is a relatively new technique we would like to ask your permission to use the fluorescence 
alongside the standard treatment you will receive. 
 
 
Do I have to have the new tracer? 
 
It is up to you to decide whether or not to have the new tracer. If you do decide not to you will have the 
standard tracer and this will in no way affect the care you receive. 
 
What will happen to me if I have the new tracer? 
 
The radiotracer and fluorescent dye will be mixed together and injected in exactly the same way as the 
standard tracer. Normally patients have four very tiny injections around the tumour. Less than 1ml of 
tracer is injected. Following this there may be some scans required but this depends on the type of tumour 
you are having surgery for – this will be exactly the same no matter which tracer is used. The only 
difference is during your operation. If you have the new tracer the surgeon can use a special light (near 
infrared wavelength) which will cause the fluorescent tracer to glow brightly and should make it more 




What do I have to do? 
 
You do not need to do anything special. You will recover from your operation in the normal way. We will 
check with you the day following the surgery if you have noticed any side effects that could be related to 
the tracer 
 
What are the possible side effects of the new tracer? 
 
1. The green dye that we inject fluoresces under certain lights. This means that if the injection is given in 
a visible part of the body that this will glow under near-infrared light. Similarly small amounts are passed 
in the urine and this can glow also. All these changes are temporary as the dye is removed from the body 
completely within a couple of days. 
 
2.Hypersensitivity. There have been a few reports of people being allergic to the fluorescent dye. This is 
more common in people who suffer allergies to other things and people. If you tend to suffer from 
allergies, please let us know. The risk of an allergic reaction has been estimated as less than one in ten 
thousand. 
 
Who has approved this tracer? 
 
The new tracer has been reviewed and approved by Guys and St Thomas’ NHS trust formulary committee 
as well as by the trust Clinical Governance Committee.  
 
 










New Intra Operative Sentinel Node Biopsy Procedure (Salivary) 
 
Full title 
Adaption and validation of a 3D navigation system that tracks the intraoperative 




The commonest way cancer cells spread are by tiny lymphatic channels that drain fluid from the cancer to 
lymph nodes around the tumour. The lymph nodes act as a form of filter and catch the tumour cells. The 
spread is not random but goes first to a single node then later on to other nodes. This first node is called 
the SENTINEL NODE. If the SENTINEL NODE is free of tumour you can safely assume all the other 
surrounding lymph nodes are also free of tumour.   The spread of cancer cells to the local lymph nodes is 
so important that it is customary when removing the main cancer to remove the surrounding lymph nodes 
at the same time. This can greatly increase the magnitude of surgery and the side effects that come from 
this surgery.  
 
This situation has now changed and in some tumours (breast and skin), lymph nodes are sampled for 
cancer rather than all the lymph nodes being removed. At the moment this type of surgery is limited to 
certain cancers, as the technology had not been developed for other types of cancer. We believe there is a 
reliable technique to identify the SENTINEL NODE in the type of cancer that you have been diagnosed 
with.  
 
We now have at Guy’s an intra operative 3D tracking system that will allow us to identify the SENTINEL 
NODE in the operating theatre. The node can then be removed and checked for cancer.  
 
At present the accepted standard of care for your disease is to remove the salivary gland tumour and the 
surrounding lymph nodes. This is not going to change; you are going to get standard treatment. What we 
propose is at the time of your surgery we identify the SENTINEL NODE draining your tumour and 
remove it. We use the same radiotracer as is used in breast cancer, which has been safely given to 
hundreds of thousands of patients. This is injected into the tumour. The tracer will then flow to the 
SENTINEL NODE. We will check where the sentinel nodes are using our normal test using a gamma 
camera to watch for the appearance of radioactive tracer in the sentinel node and perform a SPECTCT 
(the camera will move around your body in the nuclear medicine department) this will ensure that the site 
of the sentinel node is found prior to surgery. We can detect the sentinel node at surgery using our 3D 
navigation system. Your SENTINEL NODE will then be removed before carrying on with the standard 
operation.  
 
Approximately 150 patients with a similar disease as you will be involved in this study.  Before you 
decide to participate, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the information carefully and discuss it with friends, relatives and your 
GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
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time to decide whether or not you wish to take part. This leaflet will explain the procedure, tell you how it 
is performed and will answer some of the questions you may have. 
 
What is the purpose of the Study? 
The aim of the study is to see if a new 3d Navigation technique can help us to reliably identify the 
SENTINEL NODE in people with early cancers.  
 
Why Have I been chosen? 
You have been recently diagnosed with an early salivary gland cancer and are due to undergo surgery for 
this. Your surgery will entail removal of the lymph nodes around the tumour. The surgery you receive 
will not be changed, however during the operation we would like to identify the SENTINEL NODE using 
the technology we have described above. We are asking only suitable patients with early cancer to take 
part in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be asked to sign 
a consent form. If you do decide to take part you are still free to withdraw at any time and without giving 
a reason. If you decide not to take part it will in no way affect the care you receive. 
 
What will happen to me if I take part? 
All procedures related to this study will be undertaken whilst you are under general anaesthetic. We 
estimate this will add about ten to fifteen minutes to your operation time. A very low dose of a radioactive 
tracer and a blue dye will be injected around the tumour within 24 hours of your operation. The amount of 
radioactivity from this tracer is lower than is used in routine CT scans and is completely removed by the 
body. Using these methods to guide us we will identify the SENTINEL NODE, which will be removed 
and carefully examined by our pathologists. The rest of your operation will be completed in the standard 
way. The sentinel node biopsy will not affect the success of your operation in any way. 
 
What do I have to do? 
You do not need to do anything special as part of this study. You will recover from your operation in the 
normal way. 
 
What is the procedure that is being tested? 
The procedure is a 3d Navigation tool called Surgiceye, which allows us to visualise the SENTINEL 
NODE through the skin. It can be used alongside other equipment that may be used during your 
operation. Surgiceye has been validated for use in other parts of the world but we are the first NHS 
Hospital in the UK to be able to use it. 
 
 
What are the side effects of taking part? 
Sentinel node biopsy has been performed for several years, and there are very few side effects associated 
with it. These are: 
1. Blue dye may stain the urine. We inject blue dye into the tissues around your tumour, and since the 
dye is removed by your kidneys, for about one day after your operation, your urine will be stained 
blue. 
2. Hypersensitivity. There have been a few reports of people being allergic to the blue dye and nanocoll. 
This is more common in people who suffer allergies to other things. If you tend to suffer from 
allergies, please let us know. 
3. There is radiation used during the procedure. The dose is low and equivalent to 1 year of natural 
background radiation or a lifetime cancer risk of 1 in 7000 (compare this to a natural cancer risk of 1 
in 4).  This additional risk is low.   
 
What are the possible disadvantages and risks of taking part? 
Sentinel node biopsy has been shown to be very safe and has a very low complication rate. Because we 
are using a new technique the operation may take slightly longer but this will only be a short time 
compared to the total surgery. If the SENTINEL NODE is not found within a short time we will not 
continue to look for it but we will proceed directly with your planned operation. 
 
What are the possible benefits to taking part? 
If you agree to take part in this research project it may not help you directly. You are planned to receive 
the current standard of care for your tumour.  
We expect most of the SENTINEL NODES will be found in the area that your surgeon already plans to 
operate in, however we know from some published data that about 10% of the time the SENTINEL 
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NODES are found in another area of the neck. If this happens to you then you may have another small 
incision on the side of the neck to remove the SENTINEL NODE. The benefit of this is that we can detect 
cancer spread, which would have been missed by the standard treatment.  
Because the cure rate for your type of cancer is extremely good our overall aim is to eventually reduce the 
amount of surgery patients such as yourself will need. We are trying to refine our treatment regimes so 
that patients will get exactly the treatment needed to eradicate the cancer and nothing more or less. In that 
respect your participation in this study will be helping future generations of cancer sufferers 
 
What happens when the research study stops? 
After you have undergone the surgery you will get your results in the normal way. This will be to decide 
about further treatment for the cancer (e.g radiotherapy treatment). All cancer patients are followed-up in 
the outpatient clinic for a few years. Your participation in this study will not change the treatment you 
receive nor the follow up in clinic. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to the results of the research study? 
We intend to publish our results in the medical literature and if we do so your anonymity will be 
maintained throughout.  
 
Who is organising and funding the research? 
The research is being undertaken Guys Hospital and its affiliated centres as part of its Academic Health 
Sciences Centre status. 
 
Who has reviewed the study? 
The study protocol has been reviewed and approved by the local research ethics committee, which is 
made up of both doctors and lay members. 
 
What if there is a problem? 
  
Questions and Concerns – If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. Please contact: Principle 
Investigator Professor Mark McGurk: mark.mcgurk@kcl.ac.uk : 02071884348 
 
Complaints – If you have a complaint, you should talk to your research doctor who will do their best to 
answer your questions. If you remain unhappy, you may be able to make a formal complaint through the 
NHS complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient Advisory 
Liaison Service (PALS) on 0207 1888188, address: PALS, KIC, Ground floor, north wing, St Thomas’ 
Hospital, Westminster Bridge Road, London, SE1 7EH . 
 
Harm – This trial is co-sponsored by King’s College London and Guy’s and St Thomas’ NHS Foundation 
Trust. The sponsors will at all times maintain adequate insurance in relation to the study 
independently. Kings College London, through its own professional indemnity (Clinical Trials) and no 
fault compensation and the Trust having a duty of care to patients via NHS indemnity cover, in respect of 






If you or your family have any questions or require any further information, please contact  
Professor McGurk 02071884348 
 
 




Appendix E. Patient information sheet thyroid cancer 
 
Short title of project 
 
New Intra Operative Sentinel Node Biopsy Procedure (Thyroid) 
 
Full title 
Adaption and validation of a 3D navigation system that tracks the intraoperative 





The commonest way cancer cells spread are by tiny lymphatic channels that drain fluid from the cancer to 
lymph nodes around the tumour. The lymph nodes act as a form of filter and catch the tumour cells. The 
spread is not random but goes first to a single node then later on to other nodes. This first node is called 
the SENTINEL NODE. If the SENTINEL NODE is free of tumour you can safely assume all the other 
surrounding lymph nodes are also free of tumour.   The spread of cancer cells to the local lymph nodes is 
so important that it is customary when removing the main cancer to remove the surrounding lymph nodes 
at the same time. This can greatly increase the magnitude of surgery and the side effects that come from 
this surgery.  
 
This situation has now changed and in some tumours (breast and skin), lymph nodes are sampled for 
cancer rather than all the lymph nodes being removed. At the moment this type of surgery is limited to 
certain cancers, as the technology had not been developed for other types of cancer. We believe there is a 
reliable technique to identify the SENTINEL NODE in the type of cancer that you have been diagnosed 
with.  
 
We now have at Guy’s an intra operative 3D tracking system that will allow us to identify the SENTINEL 
NODE in the operating theatre. The node can then be removed and checked for cancer.  
 
At present the accepted standard of care for your disease is to remove the thyroid tumour and the 
surrounding lymph nodes. This is not going to change; you are going to get standard treatment. What we 
propose is at the time of your surgery we identify the SENTINEL NODE draining your tumour and 
remove it. We use the same radiotracer as is used in breast cancer, which has been safely given to 
hundreds of thousands of patients. This is injected into the tumour. The tracer will then flow to the 
SENTINEL NODE.  We will check where the sentinel nodes are using our normal test using a gamma 
camera to watch for the appearance of radioactive tracer in the sentinel node and perform a SPECTCT 
(the camera will move around your body in the nuclear medicine department) this will ensure that the site 
of the sentinel node is found prior to surgery. We can detect the sentinel node at surgery using our 3D 
navigation system. Your SENTINEL NODE will then be removed before carrying on with the standard 
operation.   
 
Approximately 150 patients with a similar disease as you will be involved in this study.  Before you 
decide to participate, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the information carefully and discuss it with friends, relatives and your 
GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. This leaflet will explain the procedure, tell you how it 
is performed and will answer some of the questions you may have. 
 
What is the purpose of the Study? 
The aim of the study is to see if a new 3d Navigation technique can help us to reliably identify the 




Why Have I been chosen? 
You have been recently diagnosed with an early thyroid cancer and are due to undergo surgery for this. 
Your surgery will entail removal of the lymph nodes around the tumour. The surgery you receive will not 
be changed, however during the operation we would like to identify the SENTINEL NODE using the 
technology we have described above. We are asking only suitable patients with early cancer to take part 
in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be asked to sign 
a consent form. If you do decide to take part you are still free to withdraw at any time and without giving 
a reason. If you decide not to take part it will in no way affect the care you receive. 
 
What will happen to me if I take part? 
All procedures related to this study will be undertaken whilst you are under general anaesthetic. We 
estimate this will add about ten to fifteen minutes to your operation time. A very low dose of a radioactive 
tracer and a blue dye will be injected around the tumour during your operation. The amount of 
radioactivity from this tracer is lower than is used in routine CT scans and is completely removed by the 
body. Using these methods to guide us we will identify the SENTINEL NODE, which will be removed 
and carefully examined by our pathologists. The rest of your operation will be completed in the standard 
way. The sentinel node biopsy will not affect the success of your operation in any way. 
 
What do I have to do? 
You do not need to do anything special as part of this study. You will recover from your operation in the 
normal way. 
 
What is the procedure that is being tested? 
The procedure is a 3d Navigation tool called Surgiceye, which allows us to visualise the SENTINEL 
NODE through the skin. It can be used alongside other equipment that may be used during your 
operation. Surgiceye has been validated for use in other parts of the world but we are the first NHS 
Hospital in the UK to be able to use it. 
 
What are the side effects of taking part? 
Sentinel node biopsy has been performed for several years, and there are very few side effects associated 
with it. These are: 
4. Blue dye may stain the urine. We inject blue dye into the tissues around your tumour, and since the 
dye is removed by your kidneys, for about one day after your operation, your urine will be stained 
blue. 
5. Hypersensitivity. There have been a few reports of people being allergic to the blue dye and very 
rarely with nanocoll. This is more common in people who suffer allergies to other things. If you tend 
to suffer from allergies, please let us know. 
6. There is radiation used during the procedure. The dose is low and equivalent to 1 year of natural 
background radiation or a lifetime cancer risk of 1 in 7000 (compare this to a natural cancer risk of 1 
in 4).  This additional risk is low.  
.  
 
What are the possible disadvantages and risks of taking part? 
Sentinel node biopsy has been shown to be very safe and has a very low complication rate. Because we 
are using a new technique the operation may take slightly longer but this will only be a short time 
compared to the total surgery. If the SENTINEL NODE is not found within a short time we will not 
continue to look for it but we will proceed directly with your planned operation. 
 
What are the possible benefits to taking part? 
If you agree to take part in this research project it may not help you directly. You are planned to receive 
the current standard of care for your tumour.  
 
We expect most of the SENTINEL NODES will be found in the area that your surgeon already plans to 
operate in, however we know from some published data that about 10% of the time the SENTINEL 
NODES are found in another area of the neck. If this happens to you then you may have another small 
incision on the side of the neck to remove the SENTINEL NODE. The benefit of this is that we can detect 
cancer spread, which would have been missed by the standard treatment.  
 
Because the cure rate for your type of cancer is extremely good our overall aim is to eventually reduce the 
amount of surgery patients such as yourself will need. We are trying to refine our treatment regimes so 
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that patients will get exactly the treatment needed to eradicate the cancer and nothing more or less. In that 
respect your participation in this study will be helping future generations of cancer sufferers 
 
What happens when the research study stops? 
After you have undergone the surgery you will get your results in the normal way. This will be to decide 
about further treatment for the cancer (e.g iodine treatment). All cancer patients are followed-up in the 
outpatient clinic for a few years. Your participation in this study will not change the treatment you receive 
nor the follow up in clinic. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to the results of the research study? 
We intend to publish our results in the medical literature and if we do so your anonymity will be 
maintained throughout.  
 
Who is organising and funding the research? 
The research is being undertaken Guys Hospital and its affiliated centres as part of its Academic Health 
Sciences Centre status. 
 
Who has reviewed the study? 
 
The study protocol has been reviewed and approved by the local research ethics committee, which is 
made up of both doctors and lay members. 
 
What if there is a problem? 
  
Questions and Concerns – If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. Please contact: Principle 
Investigator Professor Mark McGurk: mark.mcgurk@kcl.ac.uk : 02071884348 
 
Complaints – If you have a complaint, you should talk to your research doctor who will do their best to 
answer your questions. If you remain unhappy, you may be able to make a formal complaint through the 
NHS complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient Advisory 
Liaison Service (PALS) on 0207 1888188, address: PALS, KIC, Ground floor, north wing, St Thomas’ 
Hospital, Westminster Bridge Road, London, SE1 7EH . 
 
Harm – This trial is co-sponsored by King’s College London and Guy’s and St Thomas’ NHS Foundation 
Trust. The sponsors will at all times maintain adequate insurance in relation to the study 
independently. Kings College London, through its own professional indemnity (Clinical Trials) and no 
fault compensation and the Trust having a duty of care to patients via NHS indemnity cover, in respect of 






If you or your family have any questions or require any further information, please contact  
Professor McGurk 02071884348 
 
 








Appendix F. Patient information sheet larynx cancer 
 
 
                              
Short title of project 
 
New Intra Operative Sentinel Node Biopsy Procedure (Larynx) 
 
Full title 
Adaption and validation of a 3D navigation system that tracks the intraoperative 




The commonest way cancer cells spread are by tiny lymphatic channels that drain fluid from the cancer to 
lymph nodes around the tumour. The lymph nodes act as a form of filter and catch the tumour cells. The 
spread is not random but goes first to a single node then later on to other nodes. This first node is called 
the SENTINEL NODE. If the SENTINEL NODE is free of tumour you can safely assume all the other 
surrounding lymph nodes are also free of tumour.   The spread of cancer cells to the local lymph nodes is 
so important that it is customary when removing the main cancer to remove the surrounding lymph nodes 
at the same time. This can greatly increase the magnitude of surgery and the side effects that come from 
this surgery.  
 
This situation has now changed and in some tumours (breast and skin), lymph nodes are sampled for 
cancer rather than all the lymph nodes being removed. At the moment this type of surgery is limited to 
certain cancers, as the technology had not been developed for other types of cancer. We believe there is a 
reliable technique to identify the SENTINEL NODE in the type of cancer that you have been diagnosed 
with.  
 
We now have at Guy’s an intra operative 3D tracking system that will allow us to identify the SENTINEL 
NODE in the operating theatre. The node can then be removed and checked for cancer.  
 
At present the accepted standard of care for your disease is to remove the larynx tumour and the 
surrounding lymph nodes. This is not going to change; you are going to get standard treatment. What we 
propose is at the time of your surgery we identify the SENTINEL NODE draining your tumour and 
remove it. We use the same radiotracer as is used in breast cancer, which has been safely given to 
hundreds of thousands of patients. This is injected into the tumour whilst your are asleep. The tracer will 
then flow to the SENTINEL NODE and we can detect it using our 3D navigation system. Your 
SENTINEL NODE will then be removed before carrying on with the standard operation.  
 
Approximately 150 patients with a similar disease as you will be involved in this study.  Before you 
decide to participate, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the information carefully and discuss it with friends, relatives and your 
GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
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time to decide whether or not you wish to take part. This leaflet will explain the procedure, tell you how it 
is performed and will answer some of the questions you may have. 
 
 
What is the purpose of the Study? 
The aim of the study is to see if a new 3d Navigation technique can help us to reliably identify the 
SENTINEL NODE in people with early cancers.  
 
Why Have I been chosen? 
You have been recently diagnosed with an early larynx cancer and are due to undergo surgery for this. 
Your surgery will entail removal of the lymph nodes around the tumour. The surgery you receive will not 
be changed, however during the operation we would like to identify the SENTINEL NODE using the 
technology we have described above. We are asking only suitable patients with early cancer to take part 
in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be asked to sign 
a consent form. If you do decide to take part you are still free to withdraw at any time and without giving 
a reason. If you decide not to take part it will in no way affect the care you receive. 
 
What will happen to me if I take part? 
All procedures related to this study will be undertaken whilst you are under general anaesthetic. We 
estimate this will add about ten to fifteen minutes to your operation time. A very low dose of a radioactive 
tracer and a blue dye will be injected around the tumour during your operation. The amount of 
radioactivity from this tracer is lower than is used in routine CT scans and is completely removed by the 
body. Using these methods to guide us we will identify the SENTINEL NODE, which will be removed 
and carefully examined by our pathologists. The rest of your operation will be completed in the standard 
way. The sentinel node biopsy will not affect the success of your operation in any way. 
 
What do I have to do? 
You do not need to do anything special as part of this study. You will recover from your operation in the 
normal way. 
 
What is the procedure that is being tested? 
The procedure is a 3d Navigation tool called Surgiceye, which allows us to visualise the SENTINEL 
NODE through the skin. It can be used alongside other equipment that may be used during your 
operation. Surgiceye has been validated for use in other parts of the world but we are the first NHS 
Hospital in the UK to be able to use it. 
 
 
What are the side effects of taking part? 
Sentinel node biopsy has been performed for several years, and there are very few side effects associated 
with it. These are: 
7. Blue dye may stain the urine. We inject blue dye into the tissues around your tumour, and since the 
dye is removed by your kidneys, for about one day after your operation, your urine will be stained 
blue. 
8. Hypersensitivity. There have been a few reports of people being allergic to the blue dye and very 
occasionally to the nanocoll. This is more common in people who suffer allergies to other things. If 
you tend to suffer from allergies, please let us know. 
9. There is radiation used during the procedure. The dose is low and equivalent to 2 months of natural 
background radiation or a lifetime cancer risk of 1 in 50,000 (compare this to a natural cancer risk of 
1 in 4).  This additional risk is low.  
 
What are the possible disadvantages and risks of taking part? 
Sentinel node biopsy has been shown to be very safe and has a very low complication rate. Because we 
are using a new technique the operation may take slightly longer but this will only be a short time 
compared to the total surgery. If the SENTINEL NODE is not found within a short time we will not 
continue to look for it but we will proceed directly with your planned operation. 
 
What are the possible benefits to taking part? 
If you agree to take part in this research project it may not help you directly. You are planned to receive 




We expect most of the SENTINEL NODES will be found in the area that your surgeon already plans to 
operate in, however we know from some published data that about 10% of the time the SENTINEL 
NODES are found in another area of the neck. If this happens to you then you may have another small 
incision on the side of the neck to remove the SENTINEL NODE. The benefit of this is that we can detect 
cancer spread, which would have been missed by the standard treatment.  
 
Because the cure rate for your type of cancer is extremely good our overall aim is to eventually reduce the 
amount of surgery patients such as yourself will need. We are trying to refine our treatment regimes so 
that patients will get exactly the treatment needed to eradicate the cancer and nothing more or less. In that 
respect your participation in this study will be helping future generations of cancer sufferers 
 
What happens when the research study stops? 
After you have undergone the surgery you will get your results in the normal way. This will be to decide 
about further treatment for the cancer (e.g radiotherapy treatment). All cancer patients are followed-up in 
the outpatient clinic for a few years. Your participation in this study will not change the treatment you 
receive nor the follow up in clinic. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to the results of the research study? 
We intend to publish our results in the medical literature and if we do so your anonymity will be 
maintained throughout.  
 
Who is organising and funding the research? 
The research is being undertaken Guys Hospital and its affiliated centres as part of its Academic Health 
Sciences Centre status. 
 
Who has reviewed the study? 
The study protocol has been reviewed and approved by the local research ethics committee, which is 
made up of both doctors and lay members. 
 
What if there is a problem? 
  
Questions and Concerns – If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. Please contact: Principle 
Investigator Professor Mark McGurk: mark.mcgurk@kcl.ac.uk : 02071884348 
 
Complaints – If you have a complaint, you should talk to your research doctor who will do their best to 
answer your questions. If you remain unhappy, you may be able to make a formal complaint through the 
NHS complaints procedure.  Details can be obtained through the Guy’s and St Thomas’ Patient Advisory 
Liaison Service (PALS) on 0207 1888188, address: PALS, KIC, Ground floor, north wing, St Thomas’ 
Hospital, Westminster Bridge Road, London, SE1 7EH . 
 
Harm – This trial is co-sponsored by King’s College London and Guy’s and St Thomas’ NHS Foundation 
Trust. The sponsors will at all times maintain adequate insurance in relation to the study 
independently. Kings College London, through its own professional indemnity (Clinical Trials) and no 
fault compensation and the Trust having a duty of care to patients via NHS indemnity cover, in respect of 






If you or your family have any questions or require any further information, please contact  
Professor McGurk 02071884348 
 
Many thanks for reading this information leaflet. 
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